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ABSTRACT OF THE DISSERTATION
SPECIFIC BINDING OF THE MAMMALIAN HIGH MOBILITY GROUP PROTEIN
AT-HOOK 2 TO THE MINOR GROOVE OF AT-RICH DNAS: THERMODYNAMIC
AND SPECIFICITY STUDIES
by
Tengjiao Cui
Florida International University, 2007
Miami, Florida
Professor Fenfei Leng, Major Professor
The mammalian high mobility group protein AT-hook 2 (HMGA2) is a small
transcriptional factor involved in cell development and oncogenesis. It contains three
"AT-hook" DNA binding domains, which specifically recognize the minor groove of
AT-rich DNA sequences. It also has an acidic C-terminal motif. Previous studies showed
that HMGA2 mediates all its biological effects through interactions with AT-rich DNA
sequences in the promoter regions. In this dissertation, I used a variety of biochemical
and biophysical methods to examine the physical properties of HMGA2 and to further
investigate HMGA2's interactions with AT-rich DNA sequences. The following are
three avenues perused in this study: (1) due to the asymmetrical charge distribution of
HMGA2, I have developed a rapid procedure to purify HMGA2 in the milligram range.
Preparation of large amounts of HMGA2 makes biophysical studies possible; (2) Since
HMGA2 binds to different AT-rich sequences in the promoter regions, I used a
combination of isothermal titration calorimetry (ITC) and DNA UV melting experiment
to characterize interactions of HMGA2 with poly(dA-dT) 2 and poly(dA)poly(dT). My
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results demonstrated that (i) each HMGA2 molecule binds to 15 AT bp; (ii) HMGA2
binds to both AT DNAs with very high affinity. However, the binding reaction of
HMGA2 to poly(dA-dT) 2 is enthalpy-driven and the binding reaction of HMGA2 with
poly(dA)poly(dT) is entropy-driven; (iii) the binding reactions are strongly depended on
salt concentrations; (3) Previous studies showed that HMGA2 may have sequence
specificity. In this study, I used a PCR-based SELEX procedure to examine the DNA
binding specificity of HMGA2. Two consensus sequences for HMGA2 have been
identified: 5'-ATATTCGCGAWWATT-3' and 5'-ATATTGCGCAWWATT-3', where
W represents A or T. These consensus sequences have a unique feature: the first five
base pairs are AT-rich, the middle four to five base pairs are GC-rich, and the last five to
six base pairs are AT-rich. All three segments are critical for high affinity binding.
Replacing either one of the AT-rich sequences to a non-AT-rich sequence causes at least
100-fold decrease in the binding affinity. Intriguingly, if the GC-segment is substituted
by an AT-rich segment, the binding affinity of HMGA2 is reduced approximately 5-fold.
Identification of the consensus sequences for HMGA2 represents an important step
towards finding its binding sites within the genome.
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1. Literature Review
1.1 HMG proteins
Mammalian high mobility group (HMG) proteins are chromatin-associated, non-
histone nucleoproteins, which are essential architectural factors affecting DNA-
dependent processes, like DNA replication, repair and gene transcription, in the context
of chromatin (Reeves, 2003; Bianchi & Agresti, 2005). HMG proteins are grouped into a
superfamily due to their similarity in physical and chemical properties. Based upon their
different structures and recognition of distinct DNA substrates, the HMG superfamily
can be subdivided into three groups: HMGA, HMGB and HMGN (Bustin, 2001). With
respect to their primary structure, all HMG proteins have a similar sequence pattern,
which is characterized by basic DNA binding domains at the N-terminal and an acidic
tail at the C-terminal. However, each HMG protein has its signature DNA-binding motif
and carboxyl end (Goodwin, 1998).
The HMGA family contains three proteins: HMGAla (previously HMGI),
HMGAlb (previously HMGY), and HMGA2 (previously HMGI-C). They bind to AT-
rich sequences in the DNA minor groove via three AT-hook DNA-binding domains
(Reeves & Nissen, 1990). These proteins are accessory factors for the construction of
enhancesomes in the transcription regulation of certain genes (Reeves & Beckerbauer,
2001). By altering of DNA conformation and through specific protein/protein
interactions, they promote the subsequent recruitment of other proteins to the binding
site. The C-terminal function of HMGA proteins is not completely clear, but has been
suggested to be involved in the regulation of DNA binding (Xiao et al., 2000;
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Schwanbeck et al., 2001) and in interactions with other nuclear factors. Dysfunction of
HMGA proteins has been associated with many benign and malignant tumors (Sgarra et
al., 2004).
The HMGB family consists of HMGB 1 (previously HMG-1) and HMGB2
(previously HMG-2) proteins, which are the most abundant HMG proteins in the
nucleus. By modulating chromatin structure, HMGB proteins regulate the activities of
other nuclear proteins, which are involved in transcription, repair and replication
(Thomas, 2001; Widlak et al., 2006). The HMG box is the functional DNA-binding
motif of the HMGB proteins (Read et al., 1993; Weir et al., 1993); it contains
approximately 80 amino acids and has a characteristic L-shaped fold that is formed by
three a-helices. These proteins recognize the DNA by shape, rather than by sequence,
and have a high affinity for bent or distorted DNA (Bruhn et al., 1992; Ferrari et al.,
1992). A hydrophobic surface of the HMG box intercalates into the DNA minor groove,
where it unwinds and bends DNA significantly. The ability of the HMG box domain to
induce DNA conformational change at a specific site is an important aspect of its
biological function. In different DNA-binding models, non-sequence-specific HMGB
proteins can function as a flexible partner with other sequence-specific DNA-binding
proteins in altering the DNA structure at the binding site (Onate et al., 1994; Romine et
al., 1998). Alternatively, certain HMG box-containing proteins first can recognize target
sequences using their sequence-specific binding motifs, and later change the DNA
conformation at the binding site via its HMG box domain (Landsman & Bustin, 1993).
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The HMGN family includes HMGN1 (previously HMG-14) and HMGN2
(previously HMG-17). Both specifically recognize the 146-bp nucleosome core through
the nucleosomal binding motif (Paton et al., 1983; Bustin & Reeves, 1996). When
binding to a nucleosome, two HMGN 1 or HMGN2 cooperatively contact the
nucleosomeal core DNA at the major groove flanking the nucleosomal dyad axis,
whereas no cooperation between one HMGN 1 and one HMGN2 has been discovered
(Alfonso et al., 1994). The nucleosomal binding domain is a positively charged stretch of
approximately 30 amino acids, enriched with arginine residues (Walker et al., 1979). The
C-terminal, called the chromatin unfolding domain, contains a high content of lysine and
proline, which is fundamentally required for changing the architecture of a higher-order
chromatin structure (Trieschmann et al., 1995). HMGN proteins enhance transcription
and replication through their ability to induce decompaction of the nucleosome array on
the chromatin fiber; consequently, they are chromatin-modulating regulators, but not
putative transcription factors. HMGN mutants with a truncated C-terminus do not
activate transcription or de-compact the chromatin, something which appears to be
caused by their deprived interaction with core histones and Hi. It has been observed that
binding of HMGN to chromatin inhibits the acetylation of H3 by PCAF (Herrera et al,
1999), and that HMGN1 competes with Hi binding to the nucleosome (Ding et aL,
1997); this strongly suggests a crucial role of HMGN proteins in relief of histone-
dependent chromatin condensation. By regulating histone activity on chromatin, HMGN
proteins are involved in enhancing diverse DNA-dependent activities at the chromatin
level.
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Based upon the knowledge regarding the multiple functions of the HMG
superfamily in vivo, several models have been proposed for their chromatin binding and
interactions with other proteins: (1) By bending the DNA, as previously shown for
HMGA and HMGB proteins, HMG proteins prevent or facilitate the binding of other
factors to the target site, which usually is located in the vicinity (Whitley et al., 1994;
Das et al., 2004); (2) HMGN proteins alter chromatin structure by regulating the activity
of other chromatin modulating factors (Lim et al., 2006; Postnikov et al., 2006); (3)
HMG proteins are part of the chromatin binding complex; for example, HMGA proteins
observed in the transcriptional enhancesome (Du et al, 1993; Borrmann et al., 2003); (4)
HMG proteins, like HMGA and HMGB, modulate chromatin structure at a specific site,
with the assistance of site-specific binding factors (Bianchi & Agresti, 2005); and (5)
HMG proteins compete with other chromatin regulators, such as histone, in chromatin
binding (Catez et al., 2004). It is noteworthy that, in some cases, more than one
mechanism may be involved at a specific time and under certain circumstances; hence,
HMG proteins may play a dynamic role in DNA-dependent events.
1.2 HMGA proteins
HMGA proteins are high mobility group AT-hook proteins, of which there are
three members: HMGA1a, HMGA b and HMGA2. HMGA1a and HMGA1b
collectively are named HMGA1 protein, since they are encoded by the same gene
Hmgal, but are different mRNA splicing products (Johnson et al, 1988, 1989). HMGA2
is encoded by different gene, Hmga2 (Zhou et al., 1996). In terms of amino acid
sequence, HMGA1 and HMGA2 are 50% homologous. Both proteins have three
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positively charged DNA binding domains, called AT-Hook DNA binding domains, at the
N-terminal, and a negatively charged carboxyl terminus (Goodwin, 1998). The AT-hook
DNA-binding domains of HMGA proteins are highly conserved, consisting of a 9 amino
acid sequence composed of BBXRGRPBB (B=K or R; X=G or P) (Reeves & Nissen,
1990). The C-terminus of HMGA proteins is enriched with glutamic acids, so it is
negatively charged. In addition, there is high content of serine and threonine at the C-
terminal domain, which can be phosphorylated by nuclear kinases (Sgarra et al., 2004).
HMGAla, HMGA1b and HMGA2 contain 107, 96, and 108 amino acids respectively.
HMGA1b has the same sequence as HMGA1a, except for an internal 11 amino acid
deletion between the first and second DNA binding domain. Compared to HMGA 1 a,
HMGA2 has a 12 amino acid shorter sequence between the first and second DNA
binding domains, but contains an extra 9 amino acid linker region between the third
DNA binding domain and the carboxyl C-terminus. In vivo, HMGA proteins are
architectural transcription factors (Reeves & Beckerbauer, 2001). Although they do not
have any transcriptional activity alone, HMGA proteins are important for multiple DNA-
manipulation and protein/protein interactions associated with transcription. By
specifically contacting transcription factors and/or changing DNA conformation at
promoters free of nucleosomes or remodeling nucleosomes in chromatin, HMGA
proteins either promote or prevent the binding of transcription factors and other
chromatin-regulating factors to the promoter/enhancer region (Arlotta et al., 1997;
Mantovani et al., 1998; Fedele et al., 2006). So, by under different mechanisms, HMGA
proteins can either enhance or repress the transcription of target genes.
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Expression of HMGA protein in vivo is stringently regulated, and only is detected
in proliferating and undifferentiated cells (Reeves, 2001). Correlating HMGA expression
with embryogenesis, and observing that HMGA2 knockout mice exhibit a pygmy
phenotype (Zhou et al., 1995), both indicate the functional importance of HMGA protein
in cell growth and development. Moreover, because (1) the induction of HMGA
expression has been shown in rat and human transformed cells (Giancotti et al., 1987,
1989); (2) the rearrangement of chromosome 12q13-15, where the Hmga2 gene is
located, is associated with many benign human tumors (Hess, 1998); and (3) the over-
expression of full-length or C-terminal-truncated HMGA protein has been demonstrated
to be oncogenic in transgenic mice model (Fedele et al., 2002), it is apparent that the
malfunction of HMGA proteins is connected to the genesis of a variety of tumors in vivo.
1.3 HMGA proteins in Transcription regulation
1.3.1 HMGA1 protein in human interferon 8 gene transcription
HMGA proteins are called architectural transcription factors (Grosschedl et al.,
1994), because they do not have transcriptional activity per se, but are important for the
construction of transcription machinery through protein/protein and protein/DNA
interactions (Goodwin, 1998; Reeves, 2000). Specifically, the accessory role of HMGA l
in the transcription regulation of several genes has been described (Reeves &
Beckerbauer, 2001). Among them, the transcription regulation of the human interferon D
(INF P) gene has been most extensively studied.
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The human interferon p gene is virus inducible. Viral induction of the gene is
under the control of four positive regulation domains, which are located approximately
100 bp upstream of the transcription initiation site (Du et al., 1993). The four positive
regulation domains, named PRD I-IV, span 50 bp of the INF f promoter and contain a
specific binding site recognized by transcription factors NF-xB, ATF-2 and IRE
(Visvanathan & Goodboum, 1989; Du & Maniatis, 1992). NF-KB binds to a consensus
sequence in PRD II, which also includes a 5 bp AT-sequence that overlaps with the NF-
KB binding site. Specific binding of NF-KB to PRD II has been proven essential for viral
induction of the human INFp gene. In vivo, inhibition of the p50/p65 NF-KB
heterodimer, by transfecting the cell with an antisense p65 construct, results in a 100-fold
decrease in transcription activity (Thanos & Maniatis, 1992). Even though NF-KB is
needed for transcription activation of the INF gene, it is not the only protein that
interacts with the PRD II element in vivo. In fact, mutations in PRD II, which keep NF-
xB binding intact, decreased the level of viral induction (Visvanathan & Goodbourn,
1989). By screening the nuclear factors against PRD II, HMGA1 later was discovered
binding to PRD II as well. Although the NF-KB and HMGA1 binding sites identified by
DNase I footprinting partially overlap, there is no competition between NF-KB and
HMGA1 when both bind to the INF p promoter. On the contrary, HMGA1 can stimulate
NF-KB binding to PRD IL Methylation interference analysis of PRD II fragment, reveals
how HMGA 1 contacts PRD II at the minor groove of the 5' -AAATT-3' sequence,
whereas NF-KB binds to the major groove at the same time. By changing the DNA
conformation at PRD II, HMGA1 not only enhances the binding of NF-KB, it also
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facilitates cooperation between NF-KB and ATF-2 through its interaction with both of
these transcription factors (Du et al., 1993). In addition to the binding site in PRD II, two
other HMGA1 binding sites have been identified in the flank region of the ATF-2
binding site in PRD IV. Mutation of any of these HMGA binding sites, especially the
one in PRD II, significantly decreases the INF3 promoter activity, which proves that
HMGA1 binding is required for the transcription activation. Furthermore, if an antisense
HMGA1 construct is introduced, the human INF 3 gene is no longer virus inducible
(Thanos & Maniatis, 1992).
More recently, another form of regulation of the human interferon 3 gene has
been described. The formation of the enhanceosome complex at the promoter region
creates a novel activation surface that recruits the CREB-binding protein, CBP/p300
(Merika et al, 1998). CBP is an enormous protein with multiple functional motifs
involved in interactions with different transcription factors, cofactors and basal
transcription machinery (Chan & La Thangue, 2001). Interestingly, CBP has intrinsic
histone acetyltransferase (HAT) activity (Bannister & Kouzarides, 1996). This HAT
activity turns out to be important for both optimum activation and turnoff of the human
INFP gene. Recruiting CBP and the CBP-related cofactor P/CAF to the enhanceosome,
the HMGA1 protein is acetylated by CBP and P/CAF at K 65 and K 71, respectively. In
vitro, acetylation of HMGA1 by CBP, but not P/CAF, decreases HMGA1 binding to
PRD II. This result is consistent with the three-dimensional structure of HMGAl bound
to PRD II, in which K 65, but not K 71, makes backbone contact with the DNA (Munshi
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et al., 1998). To investigate the effect of acetylation of HMGA1 in vivo, COS cells have
been co-transfected with a CAT reporter vector along with either wild-type CBP and
P/CAF or CBP and P/CAF bearing amino acid substitutions in their HAT domains. It
was demonstrated that CAT activity increases two- to three-fold in the presence of wild
type CBP or P/CAF; and that CBP, but not P/CAF, HAT activity is required for the
dissociation of HMGA1 from PRD II, which in turn causes the post-induction turnoff of
the TNFp gene.
Based upon previous research on the transcription of the human INF f gene,
Thanos et al., in 2000, described the details of this canonical model (Agalioti et al.,
2000). They found that the initiation of transcription of the INF 1 gene starts at a
nucleosome-free promoter, followed by recruitment of different transcription factors to
the enhanceosome in a well-defined order. Furthermore, chromatin remodeling, which
removes a nucleosome (nucleosome II) that masks the TATA box, has been proven
important for the recruitment of TFIID to the basal transcription complex. According to
their study, GCN-5, not CBP, acetylates the HMGA protein at lysine 71 in the early
stages of the enhancesome pack, which solves the puzzle of why CBP-mediated
acetylation of HMGA protein seems to be required for both optimal transcription
initiation and posttranscriptional turnoff (Munshi et al., 1998).
1.3.2 HMGA] protein in E-selectin gene transcription
In addition to mediating binding of NF-B to the PRD II element in the human
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interferon p gene promoter, a similar relationship between HMGA1 and NF-KB
regulating transcription of the E-selectin gene also has been observed (Whitley et al.,
1994). E-selectin is a member of the selectin family of transmembrane glycoproteins,
which is important for leukocyte adhesion to vascular endothelium during an
inflammatory response (Pober & Cotran, 1990). Expression of the E-selectin gene is
stringently regulated; it only is expressed in endothelial cells following exposure to
either interleukin-1j (Il-1) or tumor necrosis factor alpha (Ghersa et al., 1992). A careful
analysis of the cis regulatory elements in the E-selectin gene has revealed a striking
similarity in the organization of E-selectin and the human interferon p promoter. Four
positive regulatory domains (designated PDs) were identified in a 150 bp region that is
upstream of the transcription start site. Three of these domains (PD I, PD III and PD IV)
contain NF-KB binding sites, while PD II contains a putative binding site for ATF2
transcription factor. By NF-KB and ATF-2 alone, the promoter cannot be maximally
activated, so other transcription cofactors, which also may be involved in the
transcription complex, were screened. It became evident that the HMGA1 protein was
the cofactor that also specifically binds to the E-selectin promoter. In the transcription
regulation region, four HMGAI binding sites were identified using DNase I footprinting;
three of them were mapped in PD I, PD III and PD IV; the other HMGA1 binding site
was found in PD II, located at the 3' flanking region of the ATF-2 binding site. All these
HMGA1 binding sites featured an AT-rich sequence with a length of 9 bp in PD II and
PD III and 5 bp in PD IV and PD I. Specific binding of HMGA1 to these determined
binding sites was confirmed further by gel mobility shift assay, using a DNA fragment
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containing each PD as a probe. The specific binding of HMGA1 to the positive
regulatory domains indicates that this protein might facilitate the binding of NF-KB and
ATF-2, as observed in the human interferon f promoter (Du et al., 1993).
As expected, by comparing the binding of NF-KB with PD III and PD I in the
presence and absence of HMGA1 protein, HMGA1 was found to be able to significantly
enhance NF-KB binding. This observation has triggered interest in knowing if Il-1-
induced transcription activation is HMGA 1-regulated. In order to answer this question,
the E-selectin gene was put under the control of either wild type or mutated promoters,
and the expression level of the E-selectin gene was monitored in vivo. The mutated
promoter either bears disrupted NF-KB binding sites without affecting HMGA1 binding,
or, conversely, the A/T core in the HMGA1 binding sites is replaced by G/C, which
completely eliminates HMGAI binding but leaves NF-KB binding unaffected. Results
from this in vivo experiment showed that mutation in NF-KB binding almost completely
abolish promoter activity; meanwhile, the promoter containing mutated HMGA1 binding
sites results in at least a 10-fold decrease in 11-1-induced transcription activity. It, thus,
has been proven that both NF-KB and HMGA1 are essential for full activity of the E-
selectin promoter.
Moreover, in vitro, HMGA1 also strongly supports ATF2 binding to PD II on the
E-selectin promoter. The stimulatory effect of HMGA1 on binding of ATF2 with PD II
may be DNA-independent, since the PD II-ATF2 complexes that are formed in the
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presence or absence of HMGA1 exhibit the same mobility during electrophoresis
(Whitley et al., 1994). This is different from what has been observed in HMGAl
interactions with NF-KB and PD III, in which a ternary complex of NF-KB, PD III and
HMGA1 is detected. The presence of HMGAl protein on the NF-KB-PD III complex
suggests that HMGA1 consistently may be required to maintain the DNA conformation
at the NF-KB binding site, or that HMGA1 may be needed for the interaction of other
transcription cofactors with NF-KB in the context of transcription machinery.
1. 3.3 HMGA2 protein in human interferon 13 gene transcription
Since the early 1990s, accumulating results have demonstrated that HMGA1
functions in gene transcription as an architectural transcription factor. However, little is
known about HMGA2, the other member of the HMGA family, in terms of transcription
regulation. Mantovani et al. (1998) first reported that NF-xB mediated activation of the
human interferon promoter can be enhanced by HMGA2. This result implicated all
members of the HMGA family as potential participants in gene transcription. As a
homologue to HMGA1, it was shown that HMGA2 can bind to PRD II as well as
HMGA1, and that it can increase the transcription potential of NF-KB, as HMGA1 does.
Disruption of AT-rich core of PRD II eliminates binding of HMGA2, which also
abolishes HMGA2-dependent transcription enhancement in vivo. Like HMGA1,
HMGA2 also increases the binding affinity of NF-KB for PRD II in vitro. The effect of
HMGA2 binding to PRD II and potentially interacting with NF-KB was studied further in
the differentiated rat epithelial cell line, PC C13. This cell line does not express
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endogenous HMGA 1 protein, a condition that is perfect for studying the transcription
activation of INF 3 gene by HMGA2 alone. By comparing luciferase activity in the
presence of either HMGA1 or HMGA2, Goodwin et al. concluded that HMGA2 has the
same capacity as HMGA 1 as an activator of INF p gene transcription.
Even though it was shown that HMGA2 functions similarly to HMGA1 in
stimulating the binding of NF-xB to PRD II and enhancing the transcription activity of
the human interferon p promoter, this is not true in all instances. First of all, although the
HMGA1 and HMGA2 share highly conserved DNA binding domains, the sequence
outside of the DNA binding domains are distinct (Johnson et al., 1988; Manfioletti et al.,
1991). This difference may affect both their DNA binding specificity and interactions
with other proteins in vivo (Huth et al., 1997). Secondly, in a specific transcription
complex, different protein/protein interactions are involved; HMGA1 and HMGA2 may
recruit different transcription factors, based upon specific protein/protein interactions.
Thirdly, the promoter structure also may determine which protein will be recruited.
Regulatory elements, which contain multiple AT sites, interact with HMGA protein in
different ways (Maher & Nathans, 1996; Piekielko et al., 2001). In this context, the
different lengths of the spacer region between the AT-hooks of the HMGA protein might
be important. A specific arrangement of the AT-rich sequence on the promoter might
recruit only one of these HMGA proteins preferentially.
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1 3.4 HMGA2 protein interferes with the HD binding
An interesting example of HMGA2 in gene transcription regulation has been
demonstrated by its interference with homeodomains (HDs) (Arlotta et al., 1997).
Homeodomains are 61-amino acid-long structures that specifically bind to DNA
sequences with a 5'-TAAT-3' core (Gehring et al., 1994). This DNA binding motif has
been found in a few of the transcription factors that control cell fate decisions (Kaufman
et al., 1990). A simple mechanism that can be involved in the control of HD-containing
transcription factors binding to their response element in the gene promoter could be
realized via regulation of competitors' activity. It has been demonstrated that HMGA2
can interact with some HD-binding sequences and exclude HD from binding to the same
DNA. Using Berenil, a minor-groove binding drug, in the competitive binding of HD to
target sequences, it has been demonstrated that HMGA2 protein competes with HD, not
only by binding to the same sequence, but also through DNA conformational changes. In
vivo, with the expression of HMGA proteins, the transcription activity of the HCR
element, which contains several 5'-TAAT-3' motifs, was 50% inhibited.
1.3.5 HMGA2 protein in cyclin A gene transcription
Cyclin A is a key regulatory protein which, in mammalian cells, is involved in
both the S phase and the G2/M transition of the cell cycle through its association with
distinct cdks. (Rosenblatt et al., 1992). Transcription of the cyclin A gene can be
repressed when p 120E4 F binds to the CRE regulation element on the promoter (Fajas et
al., 2001). Recently, it was shown that HMGA2 protein can counteract pl20E4F-mediated
inhibition (Tessari et al., 2003). In vitro, HMGA2 specifically binds to p 12 0E4F, which
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requires the two N-terminal zinc-fingers of p 12 0E4F, and the second AT-hook with
flanking spacer region between the second and third AT hooks. Similar binding also has
been observed during interactions between HMGA2 and NF-B. As suggested by the
electrophoretic mobility shift assay (EMSA), HMGA2 competes with p1 2 0 E4F in terms
of binding to the promoter of cyclin A. Its relevance to the regulation of the cyclin A
gene in vivo has been demonstrated by chromatin immunoprecipitation experiments
using either purified antibody for HMGA2 or p 1 2 0 E4F. Remarkably, HMGA2 was found
to be associated with the cyclin A gene during the 6 to 24 hours after stimulation of Go
arrested cells, but was not detectable during the Go or G1 phase. HMGA2 binding with
the cyclin A gene peaked 18 hours after stimulation, which corresponded to the S phase,
during which transcription was active. In contrast, no binding of p1 2 0E4F to the cyclin A
gene was detected at 18 hours, and only very weak binding at other times during Go to 24
hours after stimulation. These data reveal the phase-dependent and mutually exclusive
association of HMGA2 and p1 2 0 E4F with the cyclin A promoter, indicating that induction
of the cyclin A gene is mediated by HMGA2 counteracting p120 repression. Previously,
it has been implied that HMGA2 might be involved in cell proliferation and cell
differentiation (Goodwin, 1998); actually, Hmga2_' knock-out mice exhibited a pygmy
phenotype (Zhou et al., 1995). The finding that HMGA2 can regulate the expression of
cyclin A in vivo provides one possible mechanism for this.
L 3.6 HMGA2-mediated E2F activity in pituitary adenomas
It previously has been reported that over-expression of HMGA2 protein in
transgenic mice causes them to develop pituitary adenomas (Fedele et al., 2002). This
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indicates that abnormal expression of HMGA2 is related to pituitary turnorigenesis.
Interestingly, if one mates transgenic mice that over-express HMGA2 with E2F 1
knockout mice, the adenomatous phenotype is almost totally rescued in the double
mutant mice (Field et al., 1996). Such results imply that HMGA2-dependent pituitary
tumorigenesis is mediated through a pathway that requires E2F 1. The E2F family of
transcription factors is crucial for the expression of several genes required to enter the S
phase of the cell cycle (Vigo et al., 1999; Muller et al., 2001). RB (retinoblastoma)
protein, also known as a tumor repressor, controls cell cycle progression by suppressing
the activity of E2F (Chellappan et al, 1991; Seville et al., 2005). In non-proliferating
cells, RB is associated with E2F1 and prevents E2F1 contact with the basal transcription
complex by masking the activation domain of E2F1 (Xiao et al., 2003). Moreover, RB
recruits class I histone deacetylase proteins (HDAC1) to the E2F1 binding site
(Magnaghi-Jaulin et al., 1998). HDACI can repress transcription by removing acetyl
groups from the histone, which causes condensation of the chromatin, thereby blocking
access of transcription factors to the promoter. To better understand the mechanism
behind HMGA2's activation of E2F 1-mediated transcription, a vector containing an
E2F 1 response element was fused to the luciferase report gene. Constructs expressing
RB and HMGA2 were transformed, either individually or simultaneously, to examine for
effects on transcription. Results were that transcription in the cells with an RB plasmid
was suppressed, while transcription in cells containing an HMGA2 plasmid was
increased. When both plasmids were co-transfected, RB-mediated repression was
reversed by increasing the dose of HMGA2. Interestingly, if an HMGA2 plasmid was
transfected alone into a RB-knockout cell, transcription activity was not affected. This
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indicates that HMGA2 does not interact directly with E2F1, but activates transcriptional
activity of E2F 1 by releasing it from RB. In addition to releasing E2F 1 from RB, binding
of HMGA2 to RB simultaneously displaces HDAC 1. Under this circumstance,
acetylation of the E2F 1 binding site opens up chromatin and makes it accessible to
transcription factors.
1. 3.7 Summary
To date, HMGA proteins have been reported to function in the transcription
regulation of approximately 30 genes (Reeves & Beckerbauer, 2001). In most cases,
HMGA proteins exert a positive influence on gene transcription. However, negative
regulation also has been described (Bustin & Reeves, 1996). Because of their divergent
interactions with transcription factors and DNA, different mechanisms have been
proposed to explain HMGA-mediated transcription regulation. In some instances, for
example, in the case of the human interferon p promoter, HMGA proteins bind to AT-
rich sequences in the enhancer, and recruit transcription factors to their specific response
elements. This function of HMGA proteins can be mediated through DNA
conformational changes at the transcription factor-binding site, which increase the
binding affinity between transcription factors and their target sequence. In other
instances, HMGA proteins facilitate the binding of transcription factor without
contacting DNA, as observed in the transcription activation of c-fos and smooth muscle-
specific SM22oc genes (Chin et al., 1998). A possible explanation for this is that HMGA
can associate with target transcription factors, thereby inducing a conformational change
required for binding. This kind of interaction recently was implicated in a study of the
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ETS transcription factor, PU.1, binding to the enhancer of the immunoglobulin heavy
chain gene (Lewis et al., 2001).
In eukaryotic cells, chromatin structure also plays an important role in gene
transcription (Wolffe et al., 1998; Aalfs & Kingston, 2000). The observation that HMGA
proteins directly interact with H1 (Bonnefoy et al., 1999) and nucleosomes (Reeves &
Nissen, 1993) implies that HMGA proteins might execute their transcriptional function
by modulating chromatin structure. Experimental results supporting this proposal
include the finding that HMGA protein can displace H1 from scaffold attachment
regions (SARs) (Zhao et al., 1993) and from HMGA-induced chromatin remodeling in
the transcription activation of the human interleukin-2 receptor ca chain gene (Reeves et
al., 2000). In a quiescent state, the promoter/enhancer regions are protected either by
nucleosomes or inhibitory chromatin proteins, such as histone H1. By replacing the
chromatin repressor and/or via nucleosome remodeling, HMGA proteins play an
important role in opening up the promoter/enhancer region, which makes it much more
accessible to transcription factors and cofactors.
1.4 Hmga2 gene and its Transcription regulation
1.4.1 c-DNA cloning of the Hmga2 gene
In 1991, the c-DNA for mouse HMGA2 was cloned for the first time, using
Lewis lung carcinoma cells, in which HMGA2 is over-expressed (Manfioletti et al,
1991). Earlier, the c-DNA cloning of the HMGAla and HMGA lb revealed that the two
proteins are products of the same gene, but are alternative mRNA splicing products
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(Johnson et al, 1988, 1989). Although HMGA2 is 50% homologous with HMGAl in
terms of its primary structure, it is encoded by a separate gene located on a different
chromosome (Zhou et al., 1996). Figure 1 shows the amino acid sequence derived from
the HMGA2 c-DNA sequence, in which the open reading frame encodes a 108 amino
acid protein with a molecular weight around 12 kDa.
One feature of HMGA2 protein is that it contains high levels of the amino acids
lysine, arginine and glutamic acid. The distribution of these charged amino acids on the
protein is very asymmetrical. The positively charged residues are almost exclusively
concentrated within three 9 amino acid segments called AT-hook DNA binding domains;
while the carboxyl acids largely are located at the C-terminal (Reeves & Beckerbauer,
2001). Each DNA binding domain has a sequence of KR(G/P)RGRP(R/K)(K/G), which
not only is highly conserved between all members of the HMGA family, but also is
homologous among different species (Ashar et al., 1996). In fact, human HMGA2 only
differs from its mouse counterpart in four amino acids (none of the four in the DNA
binding domains), with an extra glutamic acid residue at position 95 (Patel et al., 1994).
NMR structures reveal that the amino and carboxyl groups on the backbone of the AT-
hook peptide form hydrogen bonds with the DNA base in the minor groove; meanwhile,
the positively charged amino groups on the arginine stick out of the minor groove and
form charge-charge interactions with the phosphate groups on the DNA helix
(Geierstanger et al., 1994). The C-terminal of the HMGA2 contains 40% glutamic acid
and about 33% serine and threonine; consequently, it is highly negatively charged and
contains possible phosphorylation target sites for cdc2 kinase (Reeves et al., 1991). It has
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been shown that phosphorylation decreases the DNA binding of HMGA proteins, and the
phosphorylation is cell cycle-dependent. Function of the HMGA proteins during
different stages of cell proliferation and in different cells may be regulated via
phosphorylation at the C-terminal.
With respect to its primary structure, HMGA2 is 100% identical to HMGA1
protein in the first and second DNA binding domains; 66% identical in the third DNA
binding domain, and 60% identical at the acidic C-terminal. Aside from these conserved
regions, little similarity has been observed in the remaining parts of the two proteins
(Goodwin, 1998). Figure 1 shows the sequences of HMGA2 aligned with HMGA1 a and
HMGA1b. Compared to HMGA1a, HMGA1b is characterized by an internal 11-amino
acid deletion between the first and second AT-hook DNA binding domains (Johnson et
al., 1988; Reeves & Nissen, 1995); hence, in terms of the arrangement of the DNA
binding domains, HMGA1b is more closely related to HMGA2 (Ashar et al., 1996).
Different from the HMGA1 proteins, HMGA2 has a featured linker between the third
DNA binding domain and the C-terminal, so that the DNA binding domains of HMGA2
are further separated from the C-terminal. This specific arrangement of the DNA binding
domains in different members of the HMGA family recently has been shown to be
related to the proteins' DNA binding properties (Schwanbeck et al., 2000). DNA with
multiple AT sequences may have a preference for a specific member of the HMGA
family. The most distinct region between HMGA1 and HMGA2 is the 25 amino acids
before the first AT-hook DNA binding domain. The spacer region between every single
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DNA binding domain potentially is involved in DNA binding and in interactions with
other proteins, like different transcription factors (Huth et al., 1997).
10 20 30 40 50 60
HMGA2 MSARGEGAGQPSTSAQGQPAAPVPQKRGRGRPRKQQQ EPTCEPSPKRPRGRPKG
HMGAlb MSESSSKSSQPLASKQEKDGT EKRGRGRPRKQPP KEPSEVPTPKRPRGRPKG
HMGAla MSESSSKSSQPLASKQEKDGT EKRGRGRPRKQPPVSPGTALVGSQKEPSEVPTPKRPRGRPKG
70 80 90 100
HMGA2 SKNKSPSKAAQKKAETIGEKRPRGRPRKWPQQVVQKKPAQETEETSSQESAEED
HMGAlb SKNKGAAKT RKTTTTPGRKPRGRPKK LEK EEEEGISQESSEEEQ
HMGAla SKNKGAAKT RKTTTTPGRKPRGRPKK LEK EEEEGISQESSEEEQ
Figure 1. The amino acid sequence of HMGA2 aligned with HMGAla and
HMGA lb. (*: DNA-binding domain; -: C-terminal)
1.4.2 Genomic structure of the Hmga2 gene
The mouse Hmga2 gene is approximately 150 kb in length, and is composed of
five exons and four introns (Manfioletti et al., 1995; Zhou et al., 1996). Compared with
the c-DNA sequence, Exon I contains the 5'-UTR and amino acids 1-37, which include
the ATG translation start codon and the first DNA-binding domain; Exon II encodes
amino acids 38-66, which contain the second DNA-binding domain; Exon III encodes
amino acids 67-83, which contain the third DNA-binding domain; Exon IV encodes
amino acids 84-94, which contain the linkage region between the third DNA-binding
domain and the C-terminal; and Exon V contains amino acids 95-108 and the 3'-UTR
(Figure 2). In genomic structure, the Hmga2 gene is characterized by a very long Intron 3
(>60 kb) between the coding sequences for the third DNA-binding domain and the linker
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region. Breakpoints in this intron result in a C-terminal truncated protein, which has been
detected frequently in many benign tumors (Hess, 1998).
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
Genomic structure 658bp 2967bp
>110kb
Coding region C
327bp
111bp 87bp 51bp 33bp 45bp
1-37aa 38-66aa 67-83aa 84-94aa 95-108aa
Figure 2. The genomic structure of mouse HMGA2 (DNA-binding domains are
represented by solid boxes)
The c-DNA cloning of the mouse Hmga2 gene reveals an unusually long 3-UTR
(Zhou et al., 1996). The DNA sequence for the 2.8 kb 3'-UTR has been analyzed. Two
polyadenylation signals (AATAAA) have been detected 75 bp apart. The first
polyadenylation signal is located 18 bp downstream from the poly(A) tail, and is
associated with a TGTGTTCA sequence, 35 bp downstream. Since this combination of a
polyadenylation signal and a YGTGTTYY (Y=C or T) element has been described as an
efficient formation for the 3' terminus of mRNA, the first polyadenylation signal, instead
of the second one, may be used as the main transcription termination signal in vivo
(McLauchlan et al., 1985). Compared to the 3'-UTR, the 5'-UTR of the mouse Hmga2
gene is more complicated. In fact, three different transcripts, with lengths between 3.8
and 4.2 kb, have been detected by Northern blot analysis, which indicates the existence
of multiple transcription start sites.
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Characterization of the human Hmga2 gene reveals a structure that is very
homologous with the mouse Hmga2 gene, in which the N-terminal, AT-hook DNA
binding domains, spacer and C-terminal are encoded by five exons (Chau et al., 1995).
However, the 3'-UTR and 5'-UTR are distinct. In human 3'-UTR, three possible
polyadenylation signals associated with a TGTGTTTT sequence have been identified.
The second of these is characterized by a 23 bp space between the two sequences, which
meets the requirement of <50 bp between the signal sequence AATAAA and the
consensus termination sequence YGTGTTYY (Y=C or T) for the efficient termination of
transcription. In an attempt to locate the transcription start site; multiple starting sites
have been identified (Chau et al., 1999), which is consistent with the observation of more
than one mRNA transcript in vivo. A (CT)28 repeat interrupted by a G, and a (CA)17
repeat interrupted by four Ts can be located between the transcription initiation site and
the ATG translation start codon in the 5'-UTR (Chau et al., 1995). The functions of these
repeat segments are not yet completely clear, but they are conserved in both the human
and mouse Hmga2 gene.
1.4.3 Transcription regulation of the Hmga2 gene
Analyzing the DNA sequence upstream of the transcription start site, neither a
TATA box nor a CAT box was found. However, a ppyr/ppur tract featuring several TCC
repeats and multiple GC boxes that potentially bind to the transcription factor Sp 1 were
present at the 5' flank region of the transcription start site (Zhou et al., 1996; Rustighi et
al., 1999). DNase I footprinting already has demonstrated that Spi binds specifically to
the ppyr/ppur tract and activates the HMGA2 promoter (Rustighi et al., 1999). Since Spl
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has been shown to recruit and stabilize the TFIID complex in vivo (Pugh & Tjian, 1991),
it can substitute TBP function in transcription from a promoter lacking a TATA box. One
feature of the TATA-less promoter is that it usually contains more than one transcription
start site. Accordingly, three Hmga2 transcripts of 4.7, 4.2 and 3.9 kb have been detected
by Northern blot analysis (Ayoubi et al., 1999). Sequence analysis has revealed that the
two longer transcripts contain longer 5'-UTR and are transcriptional products from
alternate transcription initiation sites (Chau et al., 1999). Moreover, it has been
determined that the ratio of these transcripts is altered in different cell lines. Even within
the same cells, the dominant mRNA species changes in different stages of cell growth.
The reason for the coexistence of different transcripts remains unknown. In addition to
the Spl site, some other putative transcription factor binding sites like ATF, Ets and E2F
also have been identified in the 5' region of the transcription start site; this may explain
the induction of the Hmga2 gene as a delayed early gene in G1, after serum or growth
factor stimulation (Ayoubi et al., 1999).
Another mechanism that can be used in transcription regulation involves the
posttranscriptional process of mRNA. Such a mechanism has been implicated as
potentially involved in expressing the HMGA2 gene, because it has been observed that
an active HMGA2 promoter does not express HMGA2 at a level detectable by Northern
blot, and that the level of HMGA protein does not always correlate with the amount of
mRNA (Klotzbucher et al., 1999). In investigations addressing the possible function of
3'-UTR in posttranscriptional process, three characterized regions have been defined
within the 3'-UTR of the HMGA2 transcript (Borrmann et al, 2001). The 3'-UTR
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contains 10 repeated AUUUA sequences, in addition to a 58 bp A/U rich sequence 13 bp
upstream. The role of the AUUUA motif in the destabilization and rapid degradation of
mRNA has been described. An insertion of an A/U-rich element 20-30 bp in front of the
AUUUA motif can further increase the destabilization of mRNA (Xu et al., 1997). This
is consistent with the observation that of full-length 3'-UTR leads to a 12.7-fold decrease
in HMGA2 expression, relative to a positive control. This result also can be used to
explain why transgenic mice bearing a truncated HMGA2 protein exhibit a neoplastic
phenotype (Battista et al., 1999), and why a truncated or short ectopic- sequence fused
HMGA2 protein frequently is identified in benign tumors (Hess, 1998). There is another
39 bp G/C-rich sequence conserved in both HMGA1 and HMGA2 that is found at the
beginning of the 3'-UTR, though the function of this region remains unknown.
1.5 Association of HMGA proteins with Benign and Malignant tumors
1.5.1 HMGA proteins in cell transformation
Over-expression of HMGA proteins often is associated with a malignant
phenotype. When rat thyroid epithelial cells were transfected by a Sarcoma virus or
Kirsten murine sarcoma virus that carries a retroviral transforming oncogene, v-mos or v-
ras, respectively, a significant increase was noted in the expression of HMGA proteins
(Giancotti et al., 1987, 1989). Conversely, HMGA proteins only are present at a much
lower level in untransformed cells, and are almost undetectable in differentiated cells.
The role of HMGA proteins in neoplastic transformation has been further confirmed
using an antisense HMGA construct (Berlingieri et al., 1995). Berlingieri et al. showed
that rat thyroid cells infected with oncogentic retrovirus fail to exhibit a malignant
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phenotype, if HMGA2 protein synthesis is inhibited. The cell with an antisense HMGA2
construct can neither grow in soft agar, nor induce any tumors after injection into
athymic mice. Interestingly, the expression of HMGA1 protein also was inhibited at the
mRNA level when the antisense HMGA2 construct was introduced. Since the expression
of HMGA 1 protein also correlates with the malignant phenotype of human or rat thyroid
cell neoplasms (Chiappetta et al., 1995), and because transgenic mice bearing a disrupted
HMGA2 gene develops thyroid carcinomas in the same way that wild-type mice do after
a radioactive iodine feed (Scala et al., 2001), it is possible that HMGA1, instead of
HMGA2, plays a casual role in malignant cell transformation. In order to address this
question, approximately 10 years after their antisense HMGA2 work, Berlingieri et al.
(2002) studied HMGA1 function during thyroid cell transformation, using the same
strategy. To their surprise, they discovered that transfection of a HMGA1 antiese
construct into a normal rat thyroid cell line, followed by infection with Kirsten murine
sarcoma virus, failed to result in a malignant neoplasias. Transfected cells carrying the
antisense HMGA1 construct also were unable to grow on soft agar or to stimulate
tumorgenesis in athymic mice. By RT-PCR, these investigators found that HMGA2
expression was not affected by the presence of an HMGA1 antisense construct, which is
different from the inhibition of HMGA1 in the presence of antisense HMGA2 construct
observed previously (Berlingieri et al., 1995). They explained their results by postulating
a control of HMGA2 on HMGA1 synthesis, but not vice versa. This assumption also can
be used to explain why induction of AP-1 transcriptional activity is repressed when
either an HMGA1 (Berlingieri et al, 2002) or HMGA2 (Vallone et al., 1997) antisense
construct is transfected into rat thyroid cells. Berlingieri et al. concluded that HMGA1
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plays a crucial role, and HMGA2 an accessory role in thyroid cell transformation. One
noteworthy point is that, though HMGA1 is crucial for cell transformation, over-
expression of HMGA1 in normal thyroid cells causes cell death; Cells exhibit earlier
entry into the S phase, but delays in G2M transition lead to apoptosis (Fedele et al.,
2001).
In many benign tumors, a rearrangement in chromosome 12q13-15 causes a
break within the third intron of the HMGA2 gene, which results in a C-terminal-
truncated HMGA2 or a chimeric HMGA2 containing N-terminal DNA binding domains
and ectopic sequences from other genes (Hess, 1998). To determine whether or not a
given rearranged HMGA2 gene is potentially oncogenic in vivo, Fedele et al. transfected
murine NIH3T3 embryonic fibroblasts with a construct expressing either a C-terminal-
truncated HMGA2 or a fused HMGA2 containing the three AT-hook DNA binding
domains and three LIM domains from the LPP gene (Fedele et al., 1998). They
discovered that these two arranged forms of HMGA2 are equal in their ability to
transform NIH3T3 cells, and that stable transfectants exhibit typical markers of
neoplastic transformation. They can grow on soft agar and can induce cancer when
inoculated into athymic mice. Based upon the small difference in transforming properties
they observed between the two constructs, Fedele et al. concluded that the truncated
HMGA2 containing only three DNA binding domains is sufficient to transform the
NIH3T3 cell line. The chimeric sequence obtained from other genes, at least from the
LPP gene, had no significant effect on transformation. Their data are consistent with the
fact that various fusion sequences have been characterized in different rearrangements;
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and in some cases, only a few amino acids are fused to the HMGA2 DNA-binding
domains, suggesting that truncation of the HMGA2 gene, rather than its fusion with other
genes, is responsible for cell transformation. Despite the cell transformation capacities of
these rearranged forms of HMGA2, their transformation ability is relatively weak
compared to positive controls transfected by Ret/MEN2A or the ras oncogene. The foci
number is 30-fold lower and appears roughly 1 to 2 weeks later than what is observed in
positive controls. However, it seems consistent with the observation that only benign and
non-aggressive tumors are associated with arranged forms of HMGA2.
1.5.2 HMGA proteins in the transformation of thyroid cells in vivo
As suggested by studies on the virus-induced transformation of rat thyroid cells,
the induction of both HMGA1 and HMGA2 genes is required for thyroid cell
oncogenesis (Giancotti et al., 1987, 1989). In 2001, Scala et al. studied this phenomenon
in vivo, using transgenic dwarf mice, in which the HMGA2 locus had been disrupted
(Scala et al., 2001). In their experiments, the pygmy (pg-/-) mice (Green, 1989) and wild
type mice were fed radioactive iodine. The mice were sacrificed within 40-60 weeks of
treatment, and all thyroid nodules that developed in these animals were analyzed. In
terms of carcinoma frequency and histological features, the investigators found that the
pygmy (pg-/-) mutants were the same as the wild type mice, which suggests that
HMGA2 expression is not required for radiation-induced thyroid cell transformation in
vivo. The same phenomenon was observed in another experiment in which E7 oncogene-
induced carcinomas were examined. Ledent et al. (1995) used TgE7 transgenic mice
carrying a viral oncogenetic E7 gene, under the control of a bovine thyroglobulin
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promoter. By crossing the pygmy (pg-/-) and TgE7 mice, they generated TgE7/pg-/-
offspring. Unlike their TgE7 parent, the TgE7/pg-/- mice did not develop any well-
defined thyroid cancer within 12 months. However, typical thyroid carcinoma did
develop in TgE7 mice. In conclusion, the pygmy (pg-/-) and wild type (pg+/+) mice
exhibited the same level of susceptibility to radiation or E7-mediated malignant thyroid
tumorigenesis, which indicates that HMGA2 is not necessary for in vivo thyroid cell
transformation. Moreover, over-expression of both HMGA1 and HMGA2 has been
characterized in the transformed thyroid cell lines. The expression of both HMGA
proteins in these transgenic mice has been analyzed by immunohistochemistry and RT-
PCR. Scala et al. identified no HMGA2 expression in homozygous pygmy mice, but
HMGA2 was detected in all thyroid tumors from the wild type and heterozygous mice.
As far as the expression of HMGA1 is concerned, the induction of HMGA1 gene was
observed in all samples from wild type, homozygous (pg-/-), heterozygous (pg+/-),
TgE7/pg-/- and TgE7 mice. These results, considered together, strongly argue that the
induction of the HMGA1 gene in vivo is sufficient for malignant thyroid tumor
development.
1.5.3 HMGA2 protein in human benign tumors
Chromosome rearrangement targeting 12q14-15, where the HMGA2 gene is
located, has been reported in a wide range of benign human tumors, like lipomas (Asher
et al., 1995; Petit et aL., 1996; Merscher et al., 1997; Nilsson et al, 2005), uterine
leiomyomas (Kazmierczak et al., 1995; Hennig et al., 1997; Bhugra et al., 1998),
pleomorphic adenomas (Geurts et al., 1997, 1998), aggressive angiomyxomas (Micci et
29
al, 2006), endometrial polyps (Bol et al., 1996), pulmonary chondroid hamartomas
(PCH) (Wanschura et al., 1996; Rogalla et al., 1998), and osteosarcomas (Kools & Van
de Ven, 1996). Most, but not all these tumors are of mensenchymal origin. In all these
different solid tumor types, the HMGA2 gene recombines with other chromosomal sites
through translocations, insertions, and inversions, in which either transcriptional
regulation of the HMGA2 gene has been altered, or a chimeric HMGA2 transcript has
been synthesized. Different mechanisms have been proposed for these HMGA2-
mediated tumors. However, further work is needed to definitively determine causative
mechanisms. In all these rearrangements, a breakpoint in the extremely large Intron 3 of
the HMGA2 gene appears to be the predominant target. Rearrangements within Intron 3
result in a truncated transcript lacking Exons 4 and 5, or in a fused transcript containing
Exons 1 to 3 of the HMGA2 gene linked to other sequences from other known genes or
unknown sources. In this situation, some preferred partner gene for specific
tumorigenesis has been identified. For example, the LPP (lipoma preferred partner) gene
(Petit et al., 1996) and LHFP (lipoma HMGA2 fusion partner) gene (Petit et al., 1999)
have been found in lipomas; the FHIT (fragile histidine triad) gene (Geurts et al., 1997)
and NFIB (Nuclear factor I/B) gene (Geurts et al., 1998) have been found associated with
HMGA2 in pleomorphic adenomas. Diverse collections of partner genes are from
different chromosomes and possess a variety of functions. In some cases, different
tumors share a partner gene, such as HMGA2-LPP in both lipomas and pulmonary
chondroid hamartomas (Rogalla et al., 1998). Conversely, multiple partner genes have
been described within a single tumor type, as well (Petit et al., 1999). Even though the
rearrangement details behind the phenotype may be distinct in each case, the partner
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gene seems not to be a determinant of histological type of tumor. Another interesting
point is that, in most instances, the ectopic sequence fused to the DNA binding domain
of HMGA2 only encodes a few amino acids before an in-frame stop codon (Kazmierczak
et al., 1995; Kools et al., 1996), leading to the postulation that truncation of the HMGA2
protein, rather than the fused sequence, leads to tumorigenesis. Recently, this assertion
was supported further by the results of a study on 3'-UTR of the HMGA2 gene, in which
the functions of several AUUUA destabilization elements in the regulation of mRNA
have been characterized (Borrmann et al, 2001). Borrmann et al also showed that a C-
terminal missing HMGA2 has 12-fold more transcription activity than wild type. With
this background, a breakpoint in either the third Intro or the 3'-UTR of the HMGA2 gene
can result in loss of a negative regulation element in the 3'-UTR. The posttranscriptional
process for either a truncated or fused or 3'-UTR lacking transcript will be disrupted, due
to the 12q13-15 arrangements. To date, no positive regulation of mRNA resulting from
third intron breakage has been reported. However, theoretically, this could happen, since
some RNA binding proteins may stabilize the mRNA or facilitate the translational
process. Compared to rearrangements in the third intro or the 3'-UTR, disruption of the
HMGA2 gene in the 5'-UTR has been reported infrequently. However, such a
rearrangement has been described in a few cases of PCH (pulmonary chondroid
hamartomas) (Wanschura et al., 1996). Disruption of the HMGA2 gene in this region can
alter the transcriptional regulation of HMGA2 in vivo. Placing HMGA2 under the control
of a heterogeneous promoter/enhancer may alter the transcription factors required for
transcription activation, and its response to specific stimuli.
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L 5.4 HMGA proteins in malignant tumors
Over-expression of HMGA proteins has been found to correlate with the
development of a highly malignant phenotype of rat thyroid cells transformed by viral
oncogenes (Giancotti et al., 1985, 1987). This correlation later was extended to virus-
induced thyroid carcinomas in vivo and to human thyroid cells (Giancotti et al., 1989;
Chiappetta et al., 1995). Conversely, the expression of the HMGA gene in normal,
differentiated cells was negligible. Recently, abnormal expression of HMGA proteins
has been detected in several human malignant tumors, including beast cancer (Flohr et
al., 2003), prostate cancer (Bussemakers et al., 1991) and colon cancer (Fearon &
Vogelstein, 1990). For instance, prostate cancer currently is the second most common
cancer effecting males in the United States males. In men older than 50 years, one out of
11 will be diagnosed with prostate cancer, and one-third of those affected will die from
this disease (Boring et al., 1991). A significant increase in HMGA expression
characterizes this malignant tumor. In 71 clinic samples analyzed by Tamimi et al.
(1993), HMGA1 expression was detected in metastatic prostatic tumors, but not in non-
metastatic specimens. In accordance with this, the HMGA1 mRNA level correlated with
the degree of malignancy; and was not detectable in normal tissue. A similar relationship
also exists between HMGA expression and colorectal cancer. In an analysis of samples
from human colorectal carcinomas with a malignant phenotype, the expression of
HMGA1 was detected at both the mRNA and protein levels in colorectal carcinoma
tissue, but not in normal intestinal mucosa. In addition, no HMGA1 expression was
detected in colonic polyps; whereas half of the colon adenomas expressed HMGA1.
Among the adenomas analyzed, only adenomas positive for HMGA1 exhibited evidence
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of cellular dysplasia; and they revealed considerably less intense immunohistochemical
staining, relative to malignant colonic tissue. This observation is very similar to what has
been observed in benign thyroid diseases, like goiters or adenomas, which suggests that
HMGA1 can be used as a marker, both to distinguish between benign and malignant
tumors, and to predict the existence of metastases.
The most common cancer in women is breast cancer, which has received
considerable research attention, primarily striving towards earlier diagnosis and
treatment. After analyzing 212 breast tissue specimens, Chiappetta et al. (2004),
concluded that a positive correlation exists between the level of HMGA1 expression and
the histological grade of breast carcinomas. Because of this, they suggested that HMGAI
could be used as a novel indicator, both to diagnose and predict prognosis in human
breast cancer. HMGA1 expression in breast carcinomas appears to be related to its
negative regulation of the BRCAI gene (Baldassarre et al., 2003), which has been
identified as a risk and probable causative factor for increased susceptibility to familial
breast and ovarian cancer (Miki et al., 1994). Mutation in BRCAI is associated with
approximately 50% of the cases of familial breast cancer, and reduced expression of
BRCA] is positively correlated with increased invasiveness of human breast cancer
(Thompson et al., 1995). Therefore, induction of HMGA1 expression in breast cells
might down-regulate BRCA] expression, which logically would account for the
aggressive phenotype.
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More recently, HMGA expression in lung cancer has been described by Sarhadi
et al. (2006). They analyzed the expression of both HMGA1 and HMGA2 proteins in
tissue from 152 lung carcinoma patients. Using RT-PCR and immunohistochemistry
methods, they identified a five and six-fold increase in HMGA1 and HMGA2
expression, respectively, in cancerous versus normal lung tissue; in addition, mRNA
levels correlated with the nuclear expression of the two proteins. They also assessed the
relationship between cell proliferation and apoptosis and the expression of HMGA
proteins. They found that HMGA1 expression levels do not correlate significantly with
either cell proliferation or apoptosis; on the other hand, expression of HMGA2 is
significantly positively correlated with the degree of cell proliferation. This is consistent
with the known role of HMGA2 in the transcriptional activation of the cyclin A gene
(Tessari et al, 2003), a gene which is important in cell cycle control, with the established
association between Hmga2 mutations and the mice pygmy phenotype (Zhou et al.,
1995). Because over-expression of both HMGA1 and HMGA2 protein has been detected
in up to 90% of lung carcinomas, and because increased expression levels of HMGA
proteins correlate with poor survival in lung cancer patients, these proteins may be useful
markers for use in diagnosing and predicting prognosis and course among lung cancer
patients.
Even though both HMGA1 and HMGA2 expression have been established for
several human malignant tumors, it is noteworthy that these two proteins may play
different roles in tumorigenesis. In fact, accumulating evidence suggests that HMGA1
proteins largely function in cell differentiation; meanwhile, HMGA2 has more of a role
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in cell proliferation. First of all, it has been demonstrated that HMGA 1, rather than
HMGA2, is required for malignant thyroid cell transformation in vivo. In fact, malignant
transformation is suppressed by the presence of antisense HMGA1 (Berlingieri et al.,
2002); second, in human lung cancer, HMGA2, but not HMGA1, correlates with cell
proliferation (Sarhadi et al., 2006). A similar observation has been made in the Dunning
rat prostate cancer model, in which HMGA1 levels specifically correlate with metastatic
capacity, but not with tumor-doubling time (Bussemakers et al., 1991); Third, Tamimi et
al. (1993) have noted that, in prostate cancer, HMGA1 expression is confined only to
the malignant prostatic structure, and is not detected in adjacent tissues. These results
imply distinct, but closely related, functions of the different HMGA proteins in
oncogenesis.
Transfection of the rat thyroid cell with antisense HMGA2has been shown to
suppress transformation that otherwise is inducible by the viral oncogene v-mos or v-ras
(Berlingieri et al., 1995). Later, HMGA1 antisense was shown to inhibit thyroid
transformation in vivo (Berlingieri et al., 2002). Prompted by the correlation between
HMGA1 level and the level of malignancy in all malignant tumors, Scala et al. (2000)
generated a recombinant adenovirus carrying a HMGA1 sequence in an antisense
orientation. By infecting two human thyroid anaplastic carcinoma cells (ARO and FB-1),
they demonstrated that the antisense construct inhibits the expression of HMGA1, and
leads to programmed cell death. Conversely, normal thyroid cells were unaffected. They
also demonstrated, in vivo, the suppression of xenograft tumor growth in athymic mice,
which can be transformed by anaplastic thyroid carcinoma cells in the absence of the
35
HMGA1 antisense plasmid. This interesting finding shed lights on the selective
inhibition of HMGA proteins in vivo, which suggests a novel approach to the treatment
of HMGA-related human cancers.
1.6. Transgenie Mouse model used in the study of HMGA proteins
1 6.1 Transgenic mice with a pygmy phenotype
While investigating the genomic aberrations associated with mouse spontaneous
pygmy phenotype, Zhou et al. (1995) identified a disruption of the Hmga2 gene to be the
causative factor. Two pygmy mutants, designated pgTgN40ACha and pg, were used to
localize the mutation site on the mouse genome. The mutant pgTgN4 0ACha contains a
transgenic insertion at the locus pgTgN4 0ACha; meanwhile, mutant pg is spontaneous. By
means of a bidirectional chromosomal walk along the normal mouse genome, using a
DNA sequence derived from a transgenic insertion in pgTgN4 ACha, they identified a 56 kb
common deletion in the pgTgN4 0ACha and pg mutants. The sequence of the 56 kb deletion
was compared with DNA sequence databases from GenBank and EMBL, which revealed
100% homology with the Hmga2 gene. Southern blots, using the full sequence of mouse
Hmga2 gene, further confirmed the presence of a disruption at the Hmga2 locus in both
mutants, the Hmga2 gene being completed deleted in pgTgN4 0ACha, and the 5' sequence
and Exons 1 and 2 being lost in the pg mutant. Mutation of the Hmga2 gene also was
identified in another pygmy mutant, In(10)17Rk, which was characterized by an
inversion of chromosome 10 at the third intron of Hmga2. Although distinct mutations
have been characterized in different pygmy mice strains, they share a unique growth
problem, which is HMGA2-related, rather than related to growth hormone aberration. To
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exclude the possibility that the pygmy phenotype results from other genes, they
generated a transgenic mouse, whose Exons 1 and exon 2 were replaced by a neomycin-
resistance gene. Mating this null-mutant transgenic mouse with a heterozygous mouse
carrying one mutated allele produced homozygous mutations at both Hmga2 loci. As
expected, the homozygous (Hmga2i) mice exhibited typical pygmy mice features, such
as low birth weight, much-less developed fatty tissue, and 40% the body weight of the
wild type mice. Interestingly, the heterozygous mice expressed HMGA2 at
approximately 50% the wild type level, suggesting that the wild type allele did not
increase its expression to compensate for the loss of the mutant allele. In fact, mice with
one mutated Hmga2 allele exhibited 80% the weight of the wild type mice. Because of
this, the Hmga2 mutation should be considered recessive. Meanwhile, these investigators
also found that the expression level of HMGA1 is not affected by the Hmga2 mutation,
which implicats different functions for these two related proteins during cell
development. Since it has been was observed that HMGA proteins only are expressed
during embryogenesis, and are not detectable in adult cells, their pivotal role in cell
proliferation and differentiation has been assumed.
.6.2 Transgenic mice carrying a C-terminal truncated HMGA2 gene
Rearrangement at chromosome 12q13-15, where the HMGA2 gene is located,
has been described in many benign tumors. In most of these rearrangements, a
breakpoint in the large third Intron of the HMGA2 gene results in a chimeric transcript
containing the DNA binding domain of HMGA2 and an ectopic sequence from another
gene. In many cases, the fusion sequence only contains a few amino acids without any
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obvious biological function, which indicates that truncation of the HMGA2, rather than
its fusion with other gene, is responsible for the cell transformation (Kazmierczak et al.,
1995; Hess, 1998). Furthermore, Fedele et al. (1998) have demonstrated that a C-
terminal truncated HMGA2 can transform NIH3T3 fibroblasts as well as the HMGA2-
LPP fused protein, in which the ectopic sequence does not increase or decrease the
transform ability of the truncated HMGA2. Due to its ability to malignantly transform
the NIH3T3 cell line, and because it has been observed in many benign tumors, truncated
Hmga2 could be oncogenic in vivo. To test this hypothesis, Battista et al. (1999) studied
the oncogenic potential of truncated Hmga2 using transgenic mice. Transgenic mice
bearing a C-terminal truncated Hmga2 gene were generated by means of embryonic stem
cells mediated strategy (Soriano et al., 1991; Ledermann, 2000). The cDNA of truncated
HMGA2 (HMGA2/T), deprived of the C-terminal, was linked to a cytomegalovirus
promoter (CMV) and electroporated into ES cells AB2.2. Clones with G418-resistence
were selected. Two transfected cell clones expressing the highest level of HMGA2/T
mRNA were microinjected into C57BL6/J mouse blastocysts and transferred to foster
females. Chimaeric offspring subsequently were mated with wild type C57BL6/J mice to
select HMGA2/T mutants. Battista et al. found that all of the HMGA2/T mice developed a
giant and obese phenotype, which exhibited much faster weight gain than wild type
mice. By magnetic resonance imaging (MRI) analysis of the fat deposition, the
transgenic mice were found to have extensive expansion of the retroperitoneal and
subcutaneous white adipose tissue, as well as abundant fat stores in the perirenal and
epididymal areas. In addition, other abnormalities were identified in these transgenic
mice, such as dilated bladders, mild hydronephorosis, and urinary infections. These
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results directly demonstrate the abnormal activities of adipocytes induced by HMGA2
truncation in vivo.
At almost the same time, Arlotta et al. (2000) reported their results regarding C-
terminal truncated HMGA2 in transgenic mice. Like Battista et al., Arlotta et al.
observed a giant phenotype associated with HMGA2 truncation. The transgenic mice
were an average of 15 to 28% heavier than non-transgenic mice during the early stages
of growth. Gross examination and histologic analysis revealed that the weight gain of the
transgenic mice was due to increased adipogenesis. No obvious differences were
observed between the transgenic and nontransgenic mice with respect to muscle and
skeletal development. While the majority of the obese mice exhibited normal
morphology of fat tissue, in 7 of 33, the adipose tissue was abnormal, indicating that the
transgene predisposed to lipomagenesis. Considering that lipomas seldom happen
spontaneously in mice (the authors reported no such case in 1000 wild type mice
analyzed), this result strongly supports a casual role of truncated HMGA2 in
lipomagenesis, which is consistent with the transforming ability of truncated HMGA2
that was observed in malignant transformation of NIH3T3 fibroblast cells (Fedele et al.,
1998). Even though Western blots confirmed HMGA2/T expression in all tissues except
for heart, testes and brain in the transgenic mice, only the adipose tissue was affected. No
other tissue abnormalities were observed, suggesting that the tumorigenic effects of
HMGA2/T are stringently tissue-specific. In an effort to locate candidate gene whose
transcription could be affected by disrupted HMGA2, Arlotta et al. compared the
differential expression in the adipocytes from transgenic and non-transgenic mice. They
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isolated the differentially expressed DNA and compared the DNA sequence with the
NCBI DNA database. The blast results revealed an interesting candidate that encodes the
c-Cbl associate protein, CAP (Ribon et al., 1998). CAP is expressed exclusively in
adipocytes, and has been identified as an adaptor protein between the insulin receptor
and the c-Cbl product in the insulin receptor singling pathway (Ribon et al., 1998). Since
CAP is required for the tyrosine phosphorylation of c-Cbl products by insulin receptors,
it is essential to the adipocyte response to insulin. It has been demonstrated that
transgenic mice have increased expression levels of CAP compared to wild type.mice.
Under this circumstance, abnormities that develop in HMGA2/T transgenic mice might
be associated with the enhanced CAP-mediated response of adipoctyes to insulin in the
insulin-dependent metabolic pathway.
Interestingly, HMGA1 has a negative effect on fat cell development. Melillo et
al. (2001) studied the role of HMGA1 in adipocyte growth using the 3T3-L1 cell line as
a model system. 3T3-L1 cells are pre-adipocytes, whose growth are arrested at G 1, but
which can differentiate into adipocytes upon stimulation by specific agents, like growth
hormone or fetal bovine serum (FBS) (Ayoubi et al., 1999). Differentiation of the pre-
adipocyte requires a group of transcription factors called CCAAT/e ancer-binding
proteins (C/EBPs), which are expressed at specific stages of adipogenesis (Morrison &
Farmer, 2000; Farmer, 2005). Expression of these transcription factors and their
regulation of target genes happen in a cascade fashion, which eventually promotes the
induction of several adipocyte-specific genes, including the gene for the fatty acid-
binding protein 422/aP2 and that for leptin (Christy et al., 1989, 1991). Using Northern
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and Western blots to analyze the HMA2 levels of 3T3 cells at different stages of
differentiation after FBS stimulation, Melillo et al. observed increased HMGA1 levels
relative to non-stimulated cells. HMGA1 expression reached a peak between 6 hours and
1 day, and decreased after 4 days. The correlation between Hmgal expression and
adipocyte differentiation was studied further using antisense methodology. They found
that the cell response to hormone stimulation was completely eliminated in the presence
of an antisense Hmgal construct. Moreover, the induction of two important adipocyte-
specific genes aP2 (Distel et al., 1992) and leptin (Hwang et al., 1996), was suppressed.
At the same time, they observed a much shorter doubling time in cells transfected by
antisense Hmgal, indicating an increased cell growth rate and a shorter GI arrest than
that required for the differentiation of 3T3-L1 cells. These results strongly suggest the
need for HMGA1 during adipocyte differentiation. In a study of HMGA1 effects on the
transcriptional activation of adipocyte-specific genes like the obese gene encoding for
leptin (Pelleymounter et al., 1995), they demonstrated that HMGA1 physically interacts
with C/EBP factors in vivo and in vitro. The transcriptional activity of the obese
promoter is dramatically down regulated, either because of absence of HMGAI or
mutations that impair the interaction of HMGA1 with C/EBP factors. Because transgenic
mice (Lepb/Lepob) carrying double-mutant obese alleles exhibit a giant phenotype,
HMGA1 might negatively regulate adipocyte differentiation by enhancing the
transcriptional activity of the obese gene. Combining the results described by Melillo et
al. and other related work using transgenic mice, the proliferation and differentiation of
adipocytes seems to be a balance between HMGA2 and HMGA1 activities.
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1.6.3 HMGA2 mutation reduces obesity in transgenic mice
Abnormal transcripts resulting from disruptions in the Hmga2 gene have been
observed in many benign mesenchymal tumors, including lipomas (Fedele et al., 2001).
In addition, Hmga2 mice exhibit a pygmy phenotype, as well as considerably less
developed fatty tissues. These observations have promoted interest in better
understanding HMGA2's role in adipogenesis and obesity. In the late 1990's, Anand and
Chada investigated the role of Hmga2 in obesity, using transgenic mice (Anand &
Chada, 2000). They first attempted to induce obesity by means of a high-fat diet. In this
experiment, wild type mice were fed either standard or high-fat food. RNA isolated from
individual fat depots was used to determine the expression of Hmga2. They found that
RNA isolated from the wild type mice fed standard food did not express HMGA2.
However, Hmga2 expression was detected in RNA isolated from individual fat depots
taken from wild type mice after one week on a high-fat diet. Similarly, Hmga2
expression also was observed in the individual fat depots of two genetically obese mouse
models, Lepob/Lepob and Leprdb/Lepr db (Green, 1989). As a next step, these investigators
fed the Hmga2l and Hmga2 +j mutant mice either a standard or high-fat diet. By 26
weeks, they witnessed obesity in the wild type mice, but no significant difference in the
final weights of Hmga2 or Hmga2+ mice, irrespective of diet. Besides, they found that
Hmga2 is semi-dominant, since Hmga2+1 heterozygous mutants had final weights that
were close to those of wild type mice, when a standard diet was administrated.
Interestingly, this semi-dominant property of the Hmga2 gene was not observed under
high-fat diet conditions. In fact, the Hmga2+* mice, like their homozygous sisters,
Hmga2'l, failed to develop obesity, despite a high-fat diet induction. This result
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demonstrated that mutation in one or both Hmga2 alleles can confer resistance to
obesity.
Investigators then used Lepob/Lepob transgenic mice to study obesity. Lepob/Lepob
mice are deficient in the neuroendocrine hormone leptin, so that they genetically develop
more fatty tissue than wild type (Lep*/Lep+) mice (Zhang et al., 1994). When
Lepob/Lepo was placed under the Hmga2 mutant background, they observed Hmga2+*
Lepob eob ice weighed 72% as much as wild type (Lep"b/Lepob) mice; meanwhile, the
double-homozygous mutant, Hmga2- Lepob/Lepob exhibited 27% the weight of wild type
mice. It is known that increased weight of adipose tissue in Lepblepob mice is due to
hypertrophy and hyper-proliferation of fat cells (Johnson & Hirsch, 1972). However, the
reduced weight of the Hmga2 mutant mice was not due to blocking the conversion of
pre-adipocytes to differentiated adipocytes. In fact, the adipocytes in Hmga2-
Lepoblepob mice looked similar to those in Lepblepob mice, and no difference in either
the expression or regulation of adipogenesis-related genes has been identified. Instead,
there is a decrease in the number of cells in the respective adipose depots in Hmga2'
Lepob/Lepob versus Lepob/Lepob wild type mice.
Based on these results, Anand and Chada proposed that proliferation of
undifferentiated pre-adipocytes requires HMGA2 expression. In wild type fatty tissue,
HMGA2 is not detectable, because the pre-adipocyte population is too small in the
adipose tissue. Under obesity-induction conditions, the number of adipocytes increases,
due to expansion of the pre-adipocytes population. However, in the absence of Hmga2,
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expansion of pre-adipocytes is severely inhibited, which eventually leads to retarded
growth of fatty tissue.
1.6.4 Over-expression of HMGA2 induces pituitary adenomas in vivo
In order to establish the influence of HMGA2 over-expression on tumorigenesis,
transgenic mice (HMGA2TG) bearing a Hmga2 gene under the control of a CMV
promoter were generated (Fedele et al., 2002). Abundant expression of HMGA2 was
observed in all transgenic mice tissues, but not in non-transgenic controls. At the age of
12 months, most of the transgenic mice developed a deformed skull and several
symptoms of head tilt. MRI demonstrated a large tumor at the skull base pushing the
brain upward against the cranium. Compared to male mice, female mice exhibited a
higher susceptibility to this kind of lesion. By 6 months of age, 85% of the females had
developed pituitary adenomas, while only 40% of males exhibited the same phenotype at
18 months. Fedele et al. (2006) revealed that the effect of HMGA2 in pituitary
adenomas depends upon its interaction with pRB, which thereafter affects E2F 1-
meditaed gene transcription (Fedeal et al., 2006). It has been described that HMGA2 can
transactivate the E2F-binding promoter, by releasing E2F 1 from a pRB repressor.
Meanwhile, HMGA2 displaces HDAC 1 from the pRB/E2F complex, allowing
pCAF/p300-mediate acetylation at the E2F1 binding site. This acetylation results in less
condensed chromatin at the promoter/enhancer region, which makes it available for
transcription factor binding. Fedele et al. demonstrated that the binding of HMGA2 to
pRB is required for transformation of Rat-2 cells in vivo. Rat-2 cells transfected with
HMGA2 mutant deprived of pRB binding ability did not develop any features of
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malignant transformation. Moreover, it has been reported that over-expression of
HMGA2 promots acetylation of histones and E2F 1 protein on E2F-target promoters in
vivo. These results, considered together, argue that HMGA2 might induce pituitary
adenomas by enhancing E2F1 activity. To test this, Fedele et al. generated transgenic
mice HMGA2TG E2f1 f and HMGA2TG E2f1]+ to study HMGA2 over-expression in
pituitary adenomas. By the age of 15 months, almost all (13/14) the HMGA2TG E2f1+'
mutants had developed pituitary tumors, as did the HMGA2TG E2f1++ mice. In contrast,
only 25% (4/16) of the HMGA2TG E2f1 r mice developed pituitary adenomas. This result
demonstrates how the loss of E2F1 function significantly decreases the susceptibility of
HMGA2TG mice to pituitary adenomas, which further suggests that E2F1 is required for
pituitary neoplasia in HMGA2TG mice.
1.7 Biochemical and Biophysical studies of HMGA proteins
1.7.1 CD and NMR studies
HMGA proteins initially were characterized by their low molecular weight
(around 10-12 kDa) and their solubility in 5% perchloric acid (Lund et al., 1983). All of
them contain about 100 amino acids, so they move fast during electrophoresis. In terms
of amino acid composition, HMGA proteins are enriched with both acidic and basic
polar residues and prolines, but contain only a few residues with bulky hydrophobic side
chains. This unusual amino acid component prevents the polypeptide backbone of
HMGA proteins from folding into any defined secondary structure. In fact, the circular
dichroism (CD) spectra of HMGAla in solution have revealed a "random coil"
conformation, which is characterized by a 70% unstructured polypeptide chain and only
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a 15-20% region with a secondary structural component, like an c-helix or p-sheet (Lehn
et al., 1988).
As stated earlier, in each HMGA protein, there are three highly conserved
regions, called AT-hook DNA binding domains, which are named after their predicted
structure (Reeves & Nissen, 1990). The DNA binding properties of these conserved
regions have been studied extensively by different groups (Reeves & Nissen, 1990;
Geierstanger et al., 1994; Maher et al., 1996). Among them, Reeves and Nissen
originally identified the DNA binding domain in the HMGA1 protein, and subsequently
studied the DNA binding properties of the identified region using a synthesized 11 amino
acid peptide, TPKRPRGRPKK, corresponding to one of the conserved sequences
(Reeves & Nissen, 1990). Using the Hoechst 33258 competition assay, they discovered
that this peptide specifically binds to the minor groove of AT-rich DNA, in a manner that
is indistinguishable from how the full-length HMGA1 protein binds. However, the
binding affinity was much lower than that of the intact protein. The DNA binding
specificity of the peptide was elucidated further by DNA footprinting, by which a similar
protection pattern in the AT region of the DNA was observed between the peptide and
several minor groove binding drugs, such as netropsin and Hoechst 33258.
Complementary to this earlier finding, Solomon et al. showed that the preference of
HMGA1 to bind to an A/T, instead of GIG, sequence in the minor groove was due to the
spatial hindrance caused by the 2-amino group on guanine (Solomon et al., 1986).
Replacing this 2-amino group with a hydrogen atom changed the guanine to inosine.
They found that HMGA1 can bind to poly(dI-dC)2 as well as poly(dA-dT)2, which
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confirms the 2-amino group on guanine is the major obstacle that prevents the binding of
HMGA1 to a G/C sequence.
Although, the HMGA protein exhibits a random coil conformation in solution, it
adopts a characteristic shape when it binds to DNA. Both molecular modeling and NMR
studies have revealed a planar but crescent-shaped conformation of the peptide upon
DNA binding (Geierstanger et al., 1994; Evans et al., 1995). The PRGRP core lies deep
at the bottom of the DNA minor groove, fitting snugly in the minor groove. The carboxyl
and amino groups on the peptide backbone form hydrogen bonds with adjacent AT base
pairs, while the trans-prolines on either side of the RGR core direct the flanking arginine
or lysine residues out of the minor groove. This specific conformation provides extra
contact with the DNA minor groove, in which the side chain of the residues form van der
Waals interactions with the walls of the minor groove, and the amino or guanidinium
groups form charge-charge interactions with the phosphate groups on the DNA helix.
Electrostatic interactions have been shown to be important for the binding of HMGA
proteins to DNA substrate. Ethylation of the phosphate group at an ATATTT binding
site significantly decreases its binding with HMGA1 (Solomon et al., 1986).
Consistently, in studies on HMGA2 binding to poly(dA-dT) 2 and poly(dA)poly(dT), the
polyelectrolyte effect has been determined to be the major contributor to the binding free
energy (Cui et al., 2005). Moreover, compared to certain minor groove binding drugs,
HMGA proteins bind to DNA in a more salt-dependent manner, which can be explained
if the number of charged groups is proportional to binding affinity. Since these drugs are
much less charged than HMGA proteins, their DNA binding affinities are less affected
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by salt concentration. Interestingly, if the arginine residues in the PRGRP are replaced
with lysine, the peptide completely loses its DNA-binding ability, which indicats a
crucial role of the RGR core in binding specificity (Geierstanger et al., 1994). Although
arginine and lysine both are positively charged, the remarkable difference in DNA
binding affinity between PRGRP and PKGKP underlines the significant difference
between these two residues within the context of the binding complex.
The conserved sequence KRPRGRPKK has been thought to be the dominant
DNA-binding motif; however, other regions around the DNA-binding domains also
contribute to binding (Frank et al., 1998). It has been shown that phosphorylation at
serine and threonine residues at the N- and/or C-terminal of the DNA binding domains
significantly decreased the DNA binding affinity of HMGA proteins (Piekielko et al.,
2001). Furthermore, in a recent NMR study of HMGA1 binding to the interferon p
promoter, Huth et al. attributed the significant difference in binding affinity between the
second and third DNA binding domains of HMGA1 to their different modular
components (Huth et al., 1997). According to their results, there are three modular
components that contribute to binding: (1) a central RGR core that sits deep at the
bottom of the minor groove; (2) a pair of lysine and arginine residues at either end of the
core, which mediate electrostatic and hydrophobic contacts with the DNA backbone; and
(3) in the case of the second, but not the third, DNA-binding domain, six amino acids
towards the C-terminal of the core that interact with the sugar-phosphate backbone of the
double helix. These investigators demonstrated that this last component is the
distinguishing feature between the second and third DNA binding motif, and that it
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generates additional contact with the DNA surface, which accounts for the higher
binding affinity of the second DNA-binding motif.
1.7.2 Posttranslational modification of HMGA proteins
Primarily using a short peptide, EPSEVPTPK, that represents the second DNA-
binding domain of HMGA 1, and later extending to the full-length HMGA 1 protein, Thr
53 appears to be phosphorylated by mammalian cdc2 kinase, both in vivo and in vitro, in
a cell cycle-dependent manner (Nissen et al., 1991). By 32 P labeling synchronized
NIH3T3 cells at different times during the cell cycle, Nissen et al. discovered that Thr 53
was most extensively phosphorylated in mitotic cells, whereas unphosphorylated in cells
of G0-G2 phase. Exponentially growing cells exhibited moderate phosphorylation at Thr
53, due to the random distribution of cells in different phases of the cell cycle. The cdc2
kinase recognizes substrate that contains the consensus amino acid sequence (Z)-Ser/Thr-
Pro-(X)-Z, where Z usually is lysine or arginine, X frequently is a polar residue, and the
parentheses indicates residues that appear at some, but not all sites (Holmes & Solomon,
1996). In contrast to murine HMGA1, which contains only one such consensus sequence
that can be phosphorylated by cdc2 kinase at Thr 53 (Reeves et al., 1991), human
HMGA1 has two such sites, at Thr 53 and Tbr 78 (Reeves & Nissen, 1995). Both of
these sites have been shown to be a substrate for cdc2 kinase in vitro. Phosphorylation at
Thr 53 and Thr 78 can change the DNA binding property of HMGA1 protein. It also has
been demonstrated that phosphorylation decreases the DNA binding affinity of HMGAI
(Reeves et al., 1991; Schwanbeck et al., 2000); more interestingly, DNA binding affinity
of the phosphorylated HMGA1 has been shown to be more sensitive to the ionic strength
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than that of the unphosphorylated HMGA1. At a low salt concentration (50 mM), the
difference in binding affinity between phosphorylated and unphosphorylated HMGA1 is
only 1.12 fold, but it jumps to approximately 20-fold at a physiological salt concentration
(200 mM) (Nissen et al., 1991). This significant difference suggests a possible similarity
with respect to changes in the DNA-binding affinity of HMGA1 proteins in vivo as they
are phosphorylated by cdc2 kinase in a cell cycle-dependent manner.
Assessing the effects of phosphorylation of HMGA1 protein on its binding to the
interferon p promoter, poly(dA-dT) 2 and 4 H DNA, Piekielko et al. noted decreased
DNA binding affinity of HMGA1 protein with all these DNA substrates, when they are
phosphorylated at the C-terminal by casein kinase 2 (CK2) (Piekielko et al., 2001).
Further phosphorylation by cdc2 kinase additionally attenuates the binding. Using
hydroxyl radical protein footprinting to define the changes resulting from cdc2
phosphorylation, they uncovered a general conformational change of HMGA1 protein,
both at the DNA-binding domains and within the spanning regions between ther.
Similarly, a remarkable change in the contact between HMGA2 and interferon p was
observed after phosphorylation at Ser 43 and Ser 58, two amino acids which are located
at the N- and C-terminal, respectively, of the second AT-hook binding to PRD II
(Schwanbeck et al., 2000). DNA footprinting revealed almost abolished protection of the
PRD II, after cdc2 phosphorylation, and hydroxyl-radical-based protein footprinting
demonstrated a significant change in the complex conformation in the region between
the second and third DNA binding domains. These studies demonstrate that the
properties and specific functions of HMGA proteins likely are regulated by
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phosphorylation. Whereas CK2 phosphorylation plays a constitutive role in protein
conformation (Szewczuk et al., 1999), cdc2 kinase modulates conformation in a cell
cycle-dependent manner. The DNA-binding affinity of cdc2 phosphorylated HMGA1
and HMGA2 is several times lower than that of the unphosphorylated protein; hence
conformational changes resulting from cdc2 phosphorylation may contribute to the
disassembly of promoter complexes prior to cells entering the M phase.
In addition to cdc2-mediated phosphorylation, at least two serine residues, Ser
102 and Ser 103, at the C-terminus of HMGA1 have been identified as phosphorylation
sites for CK2 (Palvimo & Linnala-Kankkunen, 1989). Even though phosphylation at the
C-terminus of HMGA1 by CK2 has been proven less influential upon DNA binding
affinity than cdc2-phosphorylation, it has been suggested that CK2-medidated
phosphorylation adds extra negative charges to the C-terminal domain, which may affect
the interactions between this domain and other basic nuclear proteins, like histones.
Additionally, reports on interleukin 4-induced phosphorylation of HMGA1 protein, both
in B lymphocytes (Wang et al., 1995) and hematopoietic cells (Wang et al., 1997)
provide further evidence for the phosphorylation-dependent regulation of HMGA
functions in the transcription of genes related to cell proliferation and differentiation,
upon extra- or intra-cellular stimulation.
Besides cdc2 and CK2 modifications, Banks et al. (2000) and Xiao et al. (2000)
have described another example of phosphorylation of HMGA 1 protein in neoplastic and
brain cells, respectively. In both cases, the tumor-promoting phorbol ester (TPA)-
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induced activation of protein kinase C (PKC) leads to the phosphorylation of HMA 1 in
vivo. Xiao et al. reported two major PKC phosphorylation sites: Ser 64, which is adjacent
to the C-terminus of the second DNA-binding domain; and Ser 44, located within the
spanning region between the first and second DNA-binding domains. They demonstrated
that the phosphorylation of HMGA1 by cdc2 and PKC together leads to more than 100-
fold decrease in the DNA binding affinity. Although Banks et al. described a similar
decrease in DNA binding affinity induced by the phosphorylation of HMGA1 by PKC;
by means of MALDI mass spectra, they identified extra target sites for PKC at amino
acids 5, 9, 21, and 75-77. They found that both HMGA1a and HMGA1b are more
extensively phosphorylated in the malignant human breast epithelial cell line MCF-
7/PKC-a than in non-transformed MCF-7 cells. In addition, HMGA b is more
extensively modified by other modifications, like methylation and acetylation, than
HMGA1a in both MCF-7/PKC-a and MCF-7 cells. However, the relationship between
phosphylation and cell malignancy is not yet clear. It is rational to relate the
phosphorylation of HMGA1 to the regulation of target genes involved in cell
development.
As for modifications other than phosphorylation, acetylation of Lys 65 at the C-
terminus of the second DNA binding domain of HMGA1 has been proven essential for
interferon P turnoff after transcription (Munshi et al., 1998). More recently, methylation
of HMGA1 a at R25 of the RGR core in the DNA binding domain has been shown to be
strictly related to the execution of programmed cell death (Sgarra et al., 2003). Among
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all the HMG proteins, HMGAla is the only species that has been found methylated in
examined human tumor or transformed cell lines. Interestingly, the methylation of
HMGAla protein remarkably increases during apoptosis (Sgarra et al., 2003). Because
chromatin condensation is required for the later stages of cell apoptosis, an increase in
HMGA I a methylation could be related to heterochromatin and chromatin remodeling in
apoptotic cells.
53
2. Research objectives
The mammalian high mobility group protein AT-hook 2 (HMGA2) is a non-
histone nuclear protein related to cell development and differentiation during
embryogenesis. Abnormal expression of this protein is associated with a variety of
benign and malignant tumors. HMGA2 contains three positively charged AT-hook
DNA-binding domains and a negatively charged C-terminus. This unique asymmetrical
charge distribution suggests that HMGA2 may be purified using a combination of cation-
and anion-exchange chromatography.
Previous studies showed that HMGA2 regulates transcription through binding to
AT-rich DNA sequences in promoter regions. Intriguingly, for different promoters, it
binds to different AT-rich DNA sequences. For example, HMGAla binds to a 27 A-
track, i.e. 5'-AAAAAAAAAAAAAAAAAAAAAAAAAAA-3' within the insulin
receptor gene promoter E3 region to modulate transcriptional activities. For other
promoter regions such as human IFN p promoter, human HIV-1 proviral promoter and
human interleukin-15 promoter region, HMGA2 binds to the alternate AT base pairs. So
far, the molecular basis of HMGA2 recognizing different AT-rich DNA sequences
remains obscure. The energetics that drives the formation of HMGA2-DNA complexes
is still unknown. A detail thermodynamic analysis should provide valuable information
regarding the mechanism by which HMGA2 recognizes different AT-rich DNA
sequences.
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Since their discovery, HMGA proteins were shown to preferentially bind to AT-
rich DNA sequences in the promoter regions. The early qualitative footprinting studies
showed that they could bind to any run of five to six AT base pairs with similar DNA
binding affinity. These studies also suggested that HMGA proteins only recognize the
minor groove configuration of AT base pairs rather than specific sequences. However,
more recent studies showed that HMGA proteins should have sequence specificity. For
example, the high affinity binding of HMGA proteins requires two to three appropriately
spaced AT-rich sequences as a single multivalent binding site. The DNA binding affinity
of this multivalent binding is much higher than that of the single valent binding. More
significantly, each HMGA protein always simultaneously binds to two to three runs of
AT base pairs in the regulatory transcription regions, such as the human interferon p
enhancer, the promoter regions of interleukin-2 gene and interleukin-2 receptor x-chain
gene. These results suggest that HMGA proteins bind to specific DNA sequences as
transcriptional factors. More evidence for sequence-specific DNA binding of HMGA
proteins comes from the NMR structural studies. The structure of an HMGA la-DNA
complex showed that the AT-hook DNA binding domain binds to the 5'-AAATT-3'
sequence in a fixed orientation with the N-terminal arginine of the core RGR sequence
located near the 3'-end of the sequence, and the C-terminal arginine located near the 5'-
end of the sequence. This binding orientation resulted from hydrophobic interactions of
the arginine side chains of the RGR core with the adenine bases of the DNA sequence,
and hydrogen bonding between the AT-hook DNA binding domains and the bases of the
binding site. These results suggest that HMGA proteins do not randomly bind to any AT-
rich DNA sequences. Until now, a systemic investigation of HMGA proteins' sequence
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selectivity has not been carried out. An in vitro selection of HMGA2's high affinity
DNA-binding sites should provide essential information towards identification of the
binding sites within genome.
In this dissertation, I have used a combination of biochemical and biophysical
experiments to explore the thermodynamics of HMGA2 binding to two AT polymers:
poly(dA-dT)2 and poly(dA)poly(dT), and its sequence selectivity. Our hypotheses are:
(1) HMGA2 should bind to cation-exchange resins, such as SP-Sepharose, and anion-
exchange resins, such as Q-Sepharose. A combination of cation- and anion-exchange
chromatography can be used to develop a rapid procedure for purifying HMGA2; (2)
HMGA2 binds to AT-rich DNA with high affinity; the binding site size of HMGA2 on
poly(dA-dT)2 and poly(dA)poly(dT) should be significantly greater than 5 base pairs; (3)
HMGA2 binds to specific AT-rich sequences.
The following are my research objectives:
Objective 1: To develop a rapid procedure for preparation of HMGA2 protein in a large
scale.
Objective 2: To characterize the interaction of HMGA2 with AT-rich DNA using a
combination of biochemical and biophysical methods.
Obiective 3: To investigate DNA sequence specificity of HMGA2 in vitro.
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3. Large Scale Preparation of the Mammalian High Mobility Group Protein A2 or
Biophysical Studies
3.1 Abstract
Due to asymmetrical charge distribution of the mammalian high mobility group
protein A2 (HMGA2), which makes HMGA2 bind to both cation- and anion-exchange
columns, we developed a rapid procedure for purifying HMGA2 in the milligram range.
This purification procedure greatly facilitated biophysical studies, which require large
amounts of the protein.
3.2 Introduction
The mammalian high mobility group protein A2 (HMGA2) is a nuclear
oncoprotein (Goodwin, 1998; Reeves, 2001). Abnormal expression of HMGA2 and its
mutants is directly linked to tumorigenesis of a variety of benign tumors of mesenchymal
origin such as lipomas, uterine leiomyomas, and fibroadenomas (Schoenmakers et al,
1995; Klotzbucher et al., 1999; Fedele et al., 2001). These solid tumors are very common
in humans. For example, approximately 39% of all hysterectomies performed in the
United States annually are uterine leiomyomas (1,361,786 cases from 1994 to 1999
(Keshavarz et al., 2002)) and up to 77% of women of reproductive age may have these
benign smooth-muscle tumors (Cramer & Patel, 1990). In many cases, rearrangements
of chromosomal bands 12ql3-15 where the HMGA2 gene is located cause disruptions of
HMGA2's normal functions (Tallini & Dal, 1999; Aman, 1999), which correlate with the
formation of the tumors. Over-expression and deregulation of HMGA proteins including
HMGA2 also causes several types of malignant tumors such as lung cancer (Sarhadi et
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al., 2006), hepatocellular carcinoma (Chang et al., 2005), prostate cancer (Tamimi et al.,
1996), oral cancer (Miyazawa et al., 2004), and leukemia (Kottickal et al., 1998). The
expression level is correlated with the degrees of malignancy and metastatic potential of
the transformed cells (Tallini et al., 1999). A recent study showed that HMGA proteins
were expressed in about 90% of lung carcinomas (152 cases), and the expression level is
inversely associated with survival rate and prognosis (Sarhadi et al., 2006). These results
suggest that HMGA proteins could be used as a biomarker for diagnosing the neoplastic
transformation and the metastatic potential of many cancers (Giancotti et al., 1991;
Rogalla et al., 1998).
HMGA2 is only expressed in proliferating, undifferentiated mesenchymal cells
and is undetectable in normal fully differentiated adult cells (Zhou et al., 1995; Gattas et
al., 1999). Disruption of its normal expression patterns causes deregulations of cell
growth and differentiation. Results from Chada's laboratory showed that Hmga2 knock-
out mice developed the pygmy phenotype (Zhou et al., 1995). These mutant mice were
severely deficient in fat cells and other mesenchymal tissues (almost 20-fold decrease).
Furthermore, it was discovered that disruption of the Hmga2 gene caused a dramatic
reduction in obesity of leptin-deficient mice (Lepob/Lepob) in a gene-dosage dependent
manner: Hmga2+f+ Lepob/Lepob mice weighed over three times more than Hmga2-
Lepob/Lepob animals, and the weight of Hmga2+f Lepblepob mice was in-between
(Anand & Chada, 2000). These results suggest that HMGA2 plays an important role in
fat cell proliferation and is a potential target for the treatment of obesity (Anand &
Chada, 2000).
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Due to its role in tumorigenesis and obesity described above, HMGA2 has been
widely studied by a variety of biochemical and biophysical methods (Solomon et al.,
1986; Huth et al., 1997; Cui et al., 2005). Unfortunately, it was difficult to purify large
quantities of recombinant HMGA2 for biophysical studies such as nuclear magnetic
resonance (NMR) and isothermal titration calorimetry (ITC) studies. One reason is that
over-expression of HMGA2 is toxic to the host cells (Reeves, 2004), which results in
low level of expression of the protein. Another reason is the lack of a rapid purification
procedure for large-scale preparation of HMGA2. As reported previously (Bustin &
Reeves, 1996), one intriguing feature of HMGA2 is the asymmetrical charge distribution
of its primary structure (Figure 3). The positive charges are concentrated in the three
"AT hook" DNA binding domains, which tightly binds to the minor groove of AT-rich
DNA sequences (Maher & Nathans, 1996; Cui et al., 2005), The negative charges are
mainly located in the C-terminus. This unique feature allowed for development of a rapid
purification procedure to prepare HMGA2 in large quantities for various biophysical
studies. Using a combination of a strong cation-exchange column, such as SP-Sepharose
FF column, and an anion-exchange column, such as Q-Sepharose FF column, we
routinely purify 50 to 100 mg of HMGA2 from 10 liters of B. coli cell culture over-
expressing recombinant HMGA2 (>98% pure).
3.3 Materials and Methods
3.3.1 Materials
Q-Sepharose FF, SP-Sepharose FF, and poly(dA-dT) 2 were purchased from
Amersham Biosciences (Piscataway, NJ). Isopropyl-beta-D-thiogalactopyranoside
59
(IPTG), DTT, lysozyme, Na2HPO 4; NaH2PO 4; NaCl; glycerol, PMSF, SDS, ethidium,
guanidine hydrochloride, urea, ampicillin, kanamycin, acrylamide, N, N'-
methylenebisacrylamide were bought from Sigma-Aldrich corporation (St. Louis, MO).
All restriction enzymes were obtained from New England Biolabs (Beverly, MA). pfu
DNA polymerase was commercially obtained from Stratagene Corporate (La Jolla, CA).
pET30a(+) was purchased from Novagen (Madison, WI). The synthetic oligonucleotides
were purchased from MWG-Biotech, Inc. (High Point, NC).
MSARGEGAGQPSTSAQGQPAAPVPQ
'KRGRGRPRKQQQEPTCEPS'PKRPRGRPK'
------- Um -W -m -
GSKNKSPSKAAQKKAETIGE'TKRPRGRPRK
WPQQVVQKKPAQIETEETSSQESAEEDI
Figure 3. The amino acid sequence of the mouse HMGA2. The
positively charged "AT hook" DNA binding domains are boxed with dot
lines and the negatively charged C-terminus are boxed with solid lines.
3.3.2 Plasmids
A plasmid, pET21c(+)-Hmga2 that contains a full length of murine Hmga2
cDNA, which directs expression of HMGA2 with a His-tag in its C-terminus, was kindly
provided by Dr. Alfredo Fusco at Universita di Catanzaro, Italy. A point mutation
(R47S), which is located in the second AT hook DNA-binding domain, was found in the
DNA sequence of Hmga2 gene in the plasmid. Since this point mutation and the His-tag
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may affect the protein's conformation and its DNA binding properties, a PCR-based site-
directed mutagenesis (Allemandou et al., 2003) was used to create a plasmid, pMGM1,
which expresses the wild type protein HMGA2 without mutation and the His-tag.
3.3.3 HMGA2 purification
E. coli strain BLR(DE3) (Novagen, Madison, WI), which contained the plasmid
pMGM1, was grown in Terrific Broth containing 50 pg/ml of the antibiotic kanamycin.
The cell growth was monitored by measuring the OD 595 every hour using an Amersham
Ultrospec 2000 UV-VIS spectrophotometer. When the 0D 595 reached 0.6-0.7, HMGA2
expression was induced by adding 1 mM of IPTG into the cell culture. After an
additional three to four hour incubation, the cells were harvested by centrifugation at
4,000 rpm for 25 minutes at 4 C. The supernatant was discarded, and the cell pellet was
re-suspended in an ice-cold lysis buffer (50 mM sodium phosphate, pH 8.0, 300 mM
NaCl, 0.5 mM PMSF, 0.1 mM DTT, 1 mg/ml lysozyme) at 3.5 ml per gram cells. The
cells in the lysis buffer were incubated on ice for one hour and then the sample was
frozen in liquid nitrogen and stored in a -80 0C freezer. In the following day, the frozen
cells were thawed and the salt concentration was adjusted to 1M by adding solid NaCl.
The solution was sonicated on ice 8 times at 300W each time with a 10 second interval
between each sonication. This was followed by centrifugation of the solution at 16,000
rpm for 20 minutes at 4 *C. After centrifugation, the supernatant was dialyzed against
buffer A (50 mM sodium phosphate, pH 8.0, 0.5 mM PMSF, 0.1 mM DTT, 10%
glycerol) plus 200 mM NaCl at 4 C overnight. After dialysis, the solution was loaded
onto a 40 ml SP-Sepharose cation-exchange column pre-equilibrated with buffer A plus
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200 mM NaCl. The loaded column was washed with 120 ml of buffer A plus 300 mM
NaCl. Then the protein was eluted with a 300 ml NaCl gradient of 0.3 to 0.8 M NaCl in
buffer A. HMGA2 was eluted at approximately 0.55 M NaCl. Peak fractions containing
electrophoretically identified HMGA2 were pooled and dialyzed against buffer A plus 20
mM NaCl. The dialyzed protein was loaded onto a 40 ml Q-Sepharose anion-exchange
column pre-equilibrated with buffer A plus 20 mM NaCl. Then the protein was eluted
with a 300 ml NaCl gradient 20 to 300 mM NaCl in buffer A. The HMGA2 protein was
eluted at approximately 190 mM NaCl.
3.3.4 Measurement of UV absorption and fluorescence emission spectra
Ultraviolet absorption spectrum of HMGA2 proteins in BPE buffer (6 mM
Na2HPO4 , 2 mM NaH2PO 4, and 1 mM Na2EDTA, pH 7.0) plus 4 mM NaCl was
recorded in an Amersham Ultrospec 2000 UV-VIS spectrophotometer at 24 'C.
Fluorescence measurements were made using a Jobin Yvon's FluoroMax-3
spectrofluorometer with Xex at 280 nm and both slits of 5 nm.
3.3.5 Differential scanning calorimetry (DSC)
DSC experiments were carried out using a VP-DSC calorimeter (Microcal Inc.).
Samples were extensively dialyzed against BPE buffer containing 50 mM NaCl. DSC
scans were conducted between 0 and 110 0C at a rate of 60 degrees per hour. Baselines,
obtained by filling both calorimeter cells with the corresponding buffer, were subtracted
from the sample experimental thermograms.
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3.3.6 Isothermal titration calorimetry (ITC)
ITC experiments were carried out using a VP-ITC titration calorimeter (Microcal
Inc.). Samples were extensively dialyzed against BPE buffer containing 100 mM NaCl.
Typically, the titration was set up so that 15 pd of a 50 pM HMGA2 sample was injected
every 200 seconds, up to a total of 18 injections, into a DNA sample (1.7 ml of 100 piM
(bp)) in the sample cell. The heat liberated or absorbed with each injection of ligand is
observed as a peak that corresponds to the power required to keep the sample and
reference cells at identical temperatures. The peaks produced over the course of a
titration are converted to heat output per injection by integration and corrected for cell
volume and sample concentration. Control experiments were carried out to determine the
contribution to the measurement by the heats of dilution arising from (1) protein into
buffer and (2) buffer into DNA. The net enthalpy for each protein-DNA interaction was
determined by subtraction of the component heats of dilution.
3.3.7 Nuclear magnetic resonance (NMR) spectroscopy
Proton NMR spectra of HMGA2 were recorded at 25 0C on a Bruker Avance 600
FT NMR spectrometer operating at a proton frequency of 600.13 MHz. The residual
solvent signal was suppressed with presaturation during relaxation delay. Chemical shift
values were referenced to the residual HDO signal at 4.81 ppm.
Phase-sensitive NOESY spectra of HMGA2 were acquired at 25 C with mixing
times ranging from 100 ms to 800 is. Typical NOESY spectra were collected with 256
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experiments in F1 dimension using the hypercomplex method of States et al. In general,
80 scans were accumulated for each F1 experiment, which was acquired with 4096
complex points in F2 dimension over a spectral width of 9 to 12 klz. The residual
solvent signal in all NOESY experiments was suppressed using a 2s presaturation with a
weak decoupler power. All 2D data were processed on a Dell Dimension 8400 PC with
Pentium 4 processor using Felix 2004 (Accelrys, Inc.).
3.4 Results and Discussion
3.4.1 Purification of HMGA2
The mammalian HMGA2 is a small nuclear protein with several unique
biochemical and biophysical properties: it has unusual high contents of basic, acidic,
glycine, and proline residues; the charge distribution is asymmetrical with the positive
charges mainly concentrated in the "AT hook" DNA binding domains and the negative
charges located in the C-terminus (Figure 3); and the protein does not have a defined
secondary structure (Huth et al., 1997). Therefore, we reasoned that HMGA2 should
bind to both cation- and anion-exchange columns, such as SP-Sepharose FF and Q-
Sepharose FF columns. Indeed, our results showed that HMGA2 binds to both types of
ion-exchange columns. The basic purification steps include cell lysis, sonication, SP-
Sepharose and Q-Sepharose ion-exchange chromatography. The purification can be
completed in less than four days, which usually produces 50 to 100 milligrams of pure
HMGA2 (the purity > 98% as judged by SDS-PAGE gels) from ten liters of cell culture.
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(i) Cell growth and lysis. In this study, we used B coli strain BLR(DE3) and a
pET vector (pET30a(+)) for expression of HMGA2 in which the mouse Hmga2 gene was
subcloned into Ndel and XhoI sites to yield pMGM1. Over-expression of HMGA2 can
be induced by IPTG. After addition of IPTG, the cell growth was significantly slowed
down, which may result from over-expression of HMGA protein that is toxic to the host
cells (Reeves, 2004). After additional three to four hour incubation, we harvested the
cells by centrifugation at 4 ®C. We also adopted a mild lysis procedure for cell lysis.
Lysozyme (1 mg/mI) was used to digest the cell wall. After freezing and thawing, the
cell's membrane was broken, resulting in a cell lysate with very high viscosity. The
viscosity can be greatly reduced by sonication or incubation at 4 'C in the presence of
DNase I. Cell debris was removed by centrifugation at 11,000 rpm at 4 C. This cell lysis
procedure is different from the previous one in which 5% perchloric acid or
trichloroacetic acid and triton X-100 were used (Reeves, 2004). Although HMGA
proteins do not have a defined structure (Huth et al., 1997), this harsh condition may
cause the hydrolysis of certain groups of HMGA proteins, especially those isolated from
mammalian cells and tissues.
(ii). SP-Sepharose FF column. After dialysis, the cell extract was loaded onto a
SP-Sepharose FF column, a strong cation-exchange column equilibrated with the dialysis
buffer. We usually washed the loaded column using 2 to 3 column volumes of buffer A
plus 300 mM NaCl. No detectable HMGA2 was eluted at this stage. HMGA2 was eluted
from the SP-Sepharose FF column using buffer A with a 0.3-0.8 M NaCl gradient.
Figure 4a shows the elution profile in which HMGA2 was eluted in buffer A from 400 to
65
600 mM NaCl (the fractions before 400 mM NaCl are other proteins plus nucleic acid
contaminants). There is an additional peak in this graph, which also contained HMGA2.
(iii). Q-Sepharose FF column. The pooled fractions from the SP-Sepharose FF
column was dialyzed against buffer A plus 20 mM NaCl and loaded onto a Q-Sepharose
FE column equilibrated with buffer A plus 20 mM NaCl. HMGA2 was eluted using
buffer A with a 20 to 300 mM NaCl gradient. Figure 4b shows the elution profile in
which HMGA2 was eluted in buffer A with approximately 200 mM NaCl. The
negatively charged C-terminus is required for HMGA2 binding to the Q-Sepharose
column. Therefore, this step is extremely efficient to remove the C-terminal truncated
form of HMGA2, which may result from proteolytic degradation of HMGA2 inside the
bacterial cells (Reeves, 2004). At this stage, HMGA2 is essentially pure as judged from
SDS-PAGE gels (lane 6 of Figure 5). Figure 5 is a 15% SDS-PAGE gel of protein
samples at various stages of HMGA2 purification.
3.4.2 Physical properties of HMGA2
Since HMGA2 contains a tryptophan residue, it has a maximum absorbance at
280 nm and also a maximum fluorescence around 360 nm when excited at 280 nm. The
extinction coefficients of HMGA2 were determined to be 5,810 cm'M- at 280 nm by
Von Hippel's method (Gill & von Hippel, 1989). Ionic strength has no apparent effect on
the extinction coefficients.
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Figure 4. Ion-exchange chromatography of HMGA2. (a) Cation-
exchange chromatography of HMGA2 on SP-Sepharose FF
column. (b) Anion-exchange chromatography of HMGA2 on -
Sepharose FF column.
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Figure 5. SDS-PAGE (15%) of the fractions from different purification
stages. Lane 1 LMW-SDS Marker (Amersham Biosciences). Lane 2
Cell extracts prepared from BLR(DE3)/pMGM1 in the absence of
IPTG.. Lane 3. Cell extracts prepared from BLR(DE3)/pMGMI after 3
hour induction with 1 mM IPTG.. Lane 4. Cell lysates prior to loading
onto SP-Sepharose FF column. Lane 5. HMGA2 prior to loading onto
Q-Sepharose FF column (pooled peak fractions). Lane 6. Pure HMGA2
after eluted from Q-Sepharose FF column.
As demonstrated previously (Huth et al, 1997), HMGA2 is an intrinsically
unstructured protein. Here, we used differential scanning calorimetry (Figure 6a) and 2-
D NMR measurement (Figure 6b) to further confirm that HMGA2 is unstructured. No
obvious transition in the thermogram and lack of spectral dispersion in NMR spectrum
indicate an "unstructured" nature for the protein.
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The purification of HMGA2 in large quantities allows us to investigate its DNA-
binding properties using isothermal titration calorimetry. Figure 7 shows a typical ITC
experiment in which HMGA2 was titrated into a poly(dA-dT)2 solution containing 100
mM Na+. Binding HMGA2 to poly(dA-dT) 2 is an exothermic reaction yielding a large
negative enthalpy of -22.4 ( 0.5) kcal mol'. The binding stoichiometry was determined
to be 15 base pairs per HMGA2 molecule, in agreement with our previous published
results (Cui et al., 2005).
3.5 Conclusion
Based on a unique property of HMGA2, the asymmetrical charge distribution
along the primary structure, we have developed a rapid purification procedure to prepare
HMGA2 on a large scale for biophysical studies. Using a combination of cation- and
anion-exchange chromatography, we can purify 50 to 100 mg of HMGA2 in four days
from 10 liters of cell culture, which is free of nucleases and nucleic acids. The purity of
the protein was more than 98% as judged by SDS-PAGE gels. HMGA2 purified from
this rapid procedure was successfully used in various biophysical studies such as NMR
measurements, DSC studies, and ITC analyses.
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Figure 6. (a) Results of differential scanning calorimetry studies of HMGA2
in BPE plus 50 mM NaCl. Increasing concentrations of HMGA2 (37, 53, and
98 M from top to bottom) are used and the buffer-buffer baseline was
substracted from the thermograms. (b) NMR measurement: 600-MHz phase
sensitive H NOESY spectra of -2 mM HMGA2 in D20 were taken with a
mixing time of 350 ms. The spectrum was collected at 293 K in 0.1 M
phosphate buffer containing 5 mM mercaptoethanol at pH 7.0.
70
Time (min)
10 0 1Q20 30 40 5060 700 90100
0.00
0.05
-5i
-~0,1s
10
-1 3S
~i
Kf
-20
0.00 0.01 0.02 0.03 0.04 0.0 0.O6
Molar Ratio
Figure 7. Sample raw data for the titration of HMGA2 into poly(dA-
dT)2 at 25 *C in BPE buffer containing 100 mM Nat. Top, each peak
shows the heat produced by injection of an aliquot of 15 ptl of
HMGA2 (50 pM) into DNA solution (I .7 ml of 100 ptM (bp)).
Bottom, binding isotherm resulting from integration with respect to
time with appropriate dilution correction.
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4. Energetics of Binding the Mammalian High Mobility Group Protein HMGA2 to
poly(dA-dT) 2 and poly(dA)poly(dT)
4.1 Abstract
The mammalian high mobility group protein HMGA2 is a chromosomal
architectural transcription factor involved in oncogenesis and cell transformation. It has
three "AT-hook" DNA binding domains, which specifically bind to the minor groove of
AT DNAs. The interaction of HMGA2 with poly(dA-dT)2 and poly(dA)poly(dT) has
been investigated using the ethidium displacement assay, the isothermal titration
calorimetry, and UV melting studies. Each "AT hook" DNA binding domain was found
to bind to 5 bp and each HMGA2 molecule binds to 15 bp. Although an individual "AT
hook" DNA binding domain binds to AT DNAs with moderate affinity, HMGA2 binds
with very high affinity to both DNAs in solutions containing 20 mM Na+ at 250C. The Ka
and binding enthalpy for poly(dA-dT) 2 were determined to be, respectively, 1.9 x 101
M- and -29.1 ( 0.5) kcal/mol. The binding reaction is enthalpy-driven with a favorable
free energy of -19.5 kcal/mol and unfavorable entropy of -32.5 cal/mol/K (-TAS = +9.7
kcal/mol) at a 1 M reference state. Interestingly, although HMGA2 binds to
poly(dA)poly(dT) with a binding constant of 9.6 x 1012 M-, the binding reaction is
entropy-driven with an unfavorable enthalpy of +0.6 kcal/mol, a free energy of -17.7
kcal/mol and an entropy of +61.4 cal mol/K (-TAS = -18.3 kcal/mol) at the 1 M state.
The enthalpy-entropy compensation is similar to that of several minor groove-binding
drugs such as netropesin, distamycin A and hoechst33258 and may be a reflection of
dehydration difference of different ligand-DNA complexes. The salt-dependence of the
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binding constant of HMGA2 with both DNAs showed that electrostatic interaction is a
dominant force for the binding reactions. The temperature dependence of binding
enthalpy for poly(dA-dT)2 indicates a large heat capacity of binding of --705 ( 113)
cal/mol/K, consistent with an important role of solvent displacement in the linked
folding/binding processes in this system.
4.2 Introduction
The mammalian high mobility group protein HMGA2 (old name: HMGI-C) is a
non-histone chromosomal protein that is involved in oncogenesis and cell transformation
(Goodwin, 1998; Bustin, 1999; Reeves, 2001, 2003; Sgarra et al., 2004). It was first
identified as a nuclear protein in proliferating fibroblasts and embryos, and also in
transformed thyroid cells infected by oncogenic viruses (Goodwin et al., 1985; Giancotti
et al., 1985). Aberrant expression of HMGA2 gene and its mutants is directly linked to
tumorigenesis of different benign tumors of mesenchymal origin such as lipomas, uterine
leiomyomas, and fibroadenomas (Schoenmakers et al., 1995; Klotzbucher et al., 1999;
Ligon & Morton, 2000; Fedele et al., 2001). In many cases, rearrangements of
chromosomal bands 12q13-15 where HMGA2 gene is located cause disruptions of
HMGA2's normal functions (Tallini & Dal, 1999; Aman, 1999). Several types of
malignant tumors such as lung cancer, breast cancer, and leukemia were also found to be
related to the expression of HMGA proteins including HMGA2 (Kazmierczak et al.,
1996; Rogalla et al., 1998; Reeves & Beckerbauer, 2001; Kayser et al., 2003; Evans et
al., 2004). The expression level is correlated with the degrees of malignancy and
metastasis potential of the transformed cells (Abe et al., 1999; Tallini & Dal, 1999;
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Evans et al., 2004). Therefore, HMGA proteins may serve as a biomarker for diagnosing
the neoplastic transformation and the metastasis potential of many cancers (Giancotti et
al., 1991; Rogalla et al., 1998; Reeves & Beckerbauer, 2003; Sgarra et al., 2004).
HMGA2 is only expressed in proliferating, undifferentiated mesenchymal cells and is
undetectable in normal fully differentiated adult cells (Zhou et al., 1995; Gattas et al.,
1999). Disruption of its normal expression patterns causes deregulations of cell growth
and differentiation. Zhou et al. showed that inactivation of Hmga2 gene results in the
pygmy phenotype in transgenic Hmga2 (-/-) mice (Zhou et al., 1995). These mutant mice
showed a severe deficiency of fat cells (almost 20-fold decrease) and a reduction of
mesenchymal tissues. Microinjection of HMGAla, another member of the HMGA
family, into mouse embryos induces early activation of gene transcription (Beaujean et
al., 2000) and causes gigantism and tumor formation (Battista et al., 1999; Baldassarre et
al., 2001). It has been demonstrated that these in vivo effects are mediated by the binding
of HMGA proteins to their target DNA sequences (Beaujean et al., 2000).
HMGA2 is a member of the HMGA family, which consists of three proteins,
HMGAla (old name: HMGI), HMGA1b (old name: HMGY), and HMGA2. HMGAla
and HMGA1b are splice variants of the same gene, HMGA1 gene (Friedmann et al.
1993). HMGA2 is the product of a separate gene, HMGA2 gene (Chau et al., 1995). The
unique feature of HMGA proteins is that all have three "AT-hook" DNA binding
domains, which contains a consensus palindromic sequence, PRGRP, flanked on each
side by one or two positively charged amino acid residues (arginine or lysine). Circular
dichroism (CD) and nuclear magnetic resonance (NMR) studies have shown that the
74
"AT-hook" DNA binding domain, in the absence of DNA, has no defined structure
(Lehn et al., 1988; Huth et al., 1997). However, when it binds to the minor groove of AT
base pairs, this domain adopts a defined conformation (Huth et al., 1997). The central
core, RGR, deeply penetrates into the minor groove of AT base pairs with two arginine
residues forming extensive electrostatic and hydrophobic contacts with the floor of the
minor groove (Huth et al., 1997). This property is a signature of several small minor-
groove binders, such as netropsin and Hoechst33258 (Zimmer & Wahnert, 1986; Neidle,
2001). All prefer binding to the minor groove of AT base pairs without causing a large
disruption of the DNA conformation (Kopka et al., 1985; Pjura et al., 1987). In the NMR
structure of the "AT-hook" peptide-DNA complex (Huth et al., 1997), two prolines on
each side of the RGR core direct the protein away from the floor of the minor groove and
position the positively charged arginine or lysine near the negatively charged phosphate
backbone, thereby making further contacts (Figure 8(a)). This disordered to ordered
conformational change significantly increases HMGA proteins' adaptability and allows
them to participate in a variety of nuclear activities such as gene transcription, DNA
replication, and chromatin remodeling (Goodwin, 1998; Reeves, 2003).
HMGA proteins are general transcriptional factors, proteins that regulate
transcriptional activities by modulating DNA conformation and providing a framework
for organizing functional transcriptional machinery (Wolffe, 1994). They prefer binding
to appropriately spaced two to three runs of 5 AT base pairs (Maher & Nathans, 1996).
However, for different promoter regions, they bind to different AT rich DNA sequences.
For example, HMGAla binds to a 27 A-track, i.e. 5'-
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AAAAAAAAAAAAAAAAAAAAAAAAAA-3' within the insulin receptor gene
promoter E3 region to modulate transcriptional activities (Foti et al., 2003). For other
promoter regions such as human IFN p promoter (Whitley et al., 1994), human HIV-1
proviral promoter (Henderson et al., 2000) and human interleukin-15 promoter region
(Baldassarre et al., 2001), HMGA proteins bind to the alternate AT base pairs. These AT
rich sequences do not share a consensus sequence. Clearly, HMGA proteins recognize
the minor groove of different AT base pairs. An understanding of the thermodynamics of
the interactions between HMGA proteins and AT DNAs can provide insight into the
physical basis of HMGA specificity. In this study, we have used a combination of
isothermal titration calorimetry (ITC) and DNA UV melting experiments to characterize
the interactions of HMGA2 with poly(dA-dT)2 and poly(dA)poly(dT). Poly(dA-dT) 2 has
alternate AT base pairs and poly(dA)poly(dT) contains A tracks only. ITC directly
measures the size of the DNA binding site, the enthalpy, and the heat capacity change for
binding. The UV melting curves obtained as a function of increasing ligand
concentration can be analyzed by the rigorous statistical mechanical models of Crothers
(Crothers, 1971) and McGhee (McGhee, 1976) to obtain the protein- DNA binding
constant. Our results showed that HMGA2 binds very strongly to both poly(dA-dT) 2 and
poly(dA)poly(dT). Interestingly, the binding reaction of HMGA2 to poly(dA-dT) 2 was
enthalpy driven and the binding reaction of HMGA2 with poly(dA)poly(dT) was
entropy-driven.
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Figure 8. (a) The NMR structure of the complex of a "AT hook" DNA binding
domain with DNA determined by Huth et al. (b) The amino acid sequence of
the mouse high mobility group protein HMGA2. (c) The amino acid sequence
of a synthetic peptide containing the third "AT hook" DNA binding domain of
HMGA2 (the ATHP).
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4.3 Materials and Methods
4.3.1 Materials
Ion exchange resins Q-Sepharose Fast Flow and SP-Sepharose Fast Flow were
purchased from Amersham Biosciences (Piscataway, NJ). DNA poly(dA-dT) 2 (molar
extinction coefficient, 13,200 cm' M-) and poly(dA)poly(dT) (molar extinction
coefficient, 12,000 cm' M-) were also purchased from Amersham Biosciences and used
without further purification. Isopropyl-beta-D-thiogalactopyranoside (IPTG), DL-
dithiothreitol (DTT), lysozyme, Na 2HPO 4, NaH 2PO4, NaCl, glycerol,
phenylmethanesulfonyl fluoride (PMSF), SDS, ethidium, netropsin, distamycin A,
ampicillin, kanamycin, acrylamide, and N,N'-methylenebisacrylamide were from Sigma-
Aldrich corporation (St. Louis, MO). All restriction enzymes were obtained from New
England Biolabs (Beverly, MA). pfu Turbo DNA polymerase was purchased from
Stratagene Corporation (La Jolla, CA). Plasmid pET30a was purchased from Novagen
(Madison, WI). Synthetic deoxyoligonucleotides were purchased from MWG-Biotech,
Inc. (High Point, NC). A peptide containing the third "AT hook" DNA-binding domain
(KRPRGRPRKW), therefore designated the "AT hook" peptide (ATHP), was custom
synthesized by advanced ChemTech, Inc. (Louisville, KY) with 95% purity and used
without further purification.
4.3.2 Plasmid construction and protein purification
A plasmid, pET21 c(+)-Hmga2 that contains a full length of murine Hmga2
cDNA and expresses a his-tag HMGA2, was kindly provided by Dr. Alfredo Fusco at
Universita di Catanzaro, Italy. In this study, we used a PCR-based method to create a
78
plasmid pMGM1 to express wild type HMGA2 (without the C-terminal his-tag). The
sequence of Hmga2 gene was confirmed by DNA sequencing. Since HMGA2 has a basic
N-terminus and an acidic C-terminus, it should bind to both anion exchange column,
such as Q-Sepharose Fast Flow column, and cation exchange column, such as SP-
Sepharose Fast Flow column. Indeed, this unique property allowed us to adopt a simple
procedure to purify large quantities of pure wtHMGA2. E coli strain BLR
(DE3)/pMGM1 was grown in Terrific Broth containing 50 [g/mnl of the antibiotic
kanamycin. The cell growth was monitored by measuring 0D5 95 every hour using an
Amersham Ultrospec 2000 UV-VIS spectrophotometer. When 0D5 95 reached 0.6-0.7,
HMGA2 expression was induced by the addition of 1 mM of IPTG to the cell culture.
After a three-hour incubation or when the 0D5 95 reached approximately 1.5, the cells
were harvested by centrifugation at 4,000 rpm for 25 minutes at 4 C. The supernatant
was discarded and the cell pellet was re-suspended in an ice-cold lysis buffer (50 mM
sodium phosphate, pH 8.0, 300 mM NaCl, 0.5 mM PMSF, 0.1 mM DTT, 1 mg/ml
lysozyme) at 3.5 ml per gram of cells. The cells in the lysis buffer were incubated on ice
for one hour and then the sample was frozen in liquid nitrogen and stored in a -80C
freezer. In the following day, the frozen cells were thawed and the salt concentration
was adjusted to 1 M by adding solid NaCl. The solution was sonicated on ice for a total
of 8 times at 300 W each time with a 10 second interval between each sonication. This
was followed by centrifugation of the solution at 18,000 rpm for 20 minutes at 4'C.
After centrifugation, the supernatant was dialyzed against buffer A (50 mM sodium
phosphate, pH 8.0, 0.5 mM PMSF, 0.1 mM DTT, 10% glycerol) plus 200 mM NaCl at
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4 C overnight. After dialysis, the solution was loaded onto a 40 ml SP-Sepharose Fast
Flow cation exchange column pre-equilibrated with buffer A plus 200 mM NaCl. The
loaded colum was washed with 120 ml of buffer A plus 300 mM NaCl. Then the
protein was eluted with a 300 ml NaCl gradient of 0.3 to 0.8 M NaCl in buffer A.
HMGA2 was eluted at approximately 0.5 M NaCl. Peak fractions containing
electrophoretically identified HMGA2 were pooled and dialyzed against buffer B (50
mM sodium phosphate pH 8.0, 10% glycerol, 0.1 mM DTT) plus 20 mM NaCl. The
dialyzed protein was loaded onto a 40 ml Q-Sepharose Fast Flow anion exchange
column pre-equilibrated with buffer B plus 20 mM NaCl. Then the protein was eluted
with a 300 ml NaCl gradient 20 to 300 mM NaCl in buffer B. HMGA2 eluted at
approximately 190 mM NaCl. The pooled Q-Sepharose fractions contained HMGA2
with purity greater than 98% judged from SDS-PAGE gels, and are free of nucleases and
nucleic acids.
4.3.3 Ethidium displacement assay
Binding stoichiometries of HMGA2 or ATHP to DNA (bp) were determined by
ethidium displacement assays. An aqueous solution containing 10 pM (bp) either
poly(dA-dT) 2 or poly(dA)poly(dT) and 5 gM ethidium was prepared in BPE buffer (6
mM Na2HPO 4, 2 mM NaH2PO4, 1 mM Na2EDTA, pH 7.0) containing 4 mM NaCl. A
sample (3 ml) of this solution in a fluorescence quartz cuvette, was titrated by adding 10
pl aliquots of 25 pM HMGA2 or the ATHP stock solution until the fluorescence
intensity no longer changed. The fluorescence intensity was measured on a Jobin Yvon
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FluoroMax-3 spectrofluorometer with Xex = 520 nm and Xem = 600 nm. The percentage
of the fluorescence quenched was plotted against the binding ratio of protein to DNA,
which was used to determine the apparent DNA binding site size.
4.3.4 Isothermal titration calorimetry
Calorimetric experiments were carried out using a VP-ITC titration calorimeter
(Microcal Inc., Northampton, MA, USA) interfaced to a PC. Origin 5.0 software,
supplied by the manufacturer was used for data acquisition and analysis. Samples were
extensively dialyzed against BPE buffer containing 4 mM NaCl. Typically, the titration
was set up so that 15 pl of a 50 pM HMGA2 sample was injected every 200 seconds, up
to a total of 18 injections, into a DNA sample (1.7 ml of 100 pM (bp)) in the sample cell.
The heat liberated or absorbed with each injection of ligand is observed as a peak that
corresponds to the power required to keep the sample and reference cells at identical
temperatures. The peaks produced over the course of a titration are converted to heat
output per injection by integration and corrected for cell volume and sample
concentration. Control experiments were carried out to determine the contribution to the
measurement by the heats of dilution arising from (1) protein into buffer, and (2) buffer
into DNA (usually the heat from the addition of buffer into DNA is very small and was
ignored). The net enthalpy for each protein-DNA interaction was determined by
subtraction of the component heats of dilution.
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4.3.5 DNA UV melting studies
Ultraviolet DNA melting curves were determined using a Beckman DU-600
UV/VIS spectrophotometer equipped with a thermoelectric temperature controller.
Poly(dA-dT) 2 and poly(dA)poly(dT) in BPE buffer plus 4 mM NaCl were used for
melting studies. DNA samples (final concentration of 2.0 x 105 M bp) were prepared by
direct mixing with aliquots from a HMGA2 stock solution, followed by incubation for
several hours at 24'C to ensure equilibration. Samples were heated at a rate of 1 C min,
while continuously monitoring the absorbance at 260 nm. Primary data were transferred
to the graphics program Origin (MicroCal, Inc., Northampton, MA) for plotting and
analysis.
4.3.6 Determination of DNA binding constants
The DNA binding constant was determined with DNA UV melting studies.
According to Crothers' (Crothers, 1971) and McGhee's theories (McGhee, 1976), in the
presence of saturated binding ligands, DNA melting temperature is a function of the
DNA binding constant, the binding site size, and the ligand concentration described by
the following equation with an assumption of no interaction of the ligand with single-
stranded DNA:
1 1 R
(Q 77 ) ln(1+ K L) (1)
T, T. m H,
where Tm0 is the melting temperature of the DNA alone, Tm is the melting temperature in
the presence of saturating amounts of ligand, AHm is the enthalpy of DNA melting (per
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mol bp), R is the gas constant, KTm is the ligand binding constant with double stranded
DNA at Tm, L is the free ligand concentration (approximated at Tm by the total ligand
concentration), and n is the ligand site size for double stranded DNA.
The DNA binding constants at lower temperatures was determined by the van't
Hoff equation:
K __ 1 1
ln( )=- AIb( )(2
KT, R T T,,,
where K is the DNA binding constant at temperature T (Kelvin) and AHb is the ligand's
DNA binding enthalpy.
The DNA binding constant of HMGA2 and the ATHP was also determined by
analysis of complete UV melting curves at less than saturating ligand concentrations,
using McGhee's theory of DNA melting in the presence of ligands. A detailed
description of the theory is given in the original paper (McGhee, 1976). Briefly, if
HMGA2 and the ATHP are assumed not to bind to single-stranded DNA, complete
melting curves at a given ligand concentration may be calculated by McGhee's algorithm
from the parameters Tm0 , AHm, s, 9, Oh, AHb, K, and n. The parameters are defined as
follows: Tm0 is the melting temperature of the DNA in the absence of ligand; AHm is the
enthalpy for DNA melting in the absence of ligand; s is the equilibrium constant for
forming a helix base pair from two coil nucleotides; a is the nucleation parameter for
forming a single stranded base pair within a stretch of helix; Coh is the cooperative
parameter for the ligand binding to helical base pairs; AHb is the enthalpy for the ligand
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binding to helical base pairs; K is the DNA binding constant; and n is the neighbor
exclusion parameter, the number of DNA base pairs in the binding site. In order to
generate melting curves, Tm, AHm, s, (Oh, and AHb were independently determined and
constrained. The parameters K, a, and n were estimated by successive approximation.
Each parameter was systematically adjusted to produce "best fit" curves that gave a
minimum value of the sum-of-squares of residuals (SSR), the differences between
observed and calculated values of melting curves, i.e., SSR =(yobs. - yaic)2 (Len et al,
1998). In this fitting process, one parameter (K, n, a) was varied to construct different
melting curves while all other parameters were constrained to a given value. The data
derived from these calculated melting curves were used to generate SSR profiles. A
FORTRAN program for calculating the DNA melting curves according to McGhee's
theory was kindly provided by Dr. James McGhee and was edited and recompiled by Dr.
Susan Wellman.
The DNA binding constants of HMGA2 and the ATHP at different salt
concentrations were determined by DNA UV melting studies and were corrected to 20 C
by the method described above. The data were plotted as logK against log[Na+]. The
slope of this graph gives an estimate of SK of dlogK/dlog[Na+]. This parameter can then
be used to dissect the binding free energy into its polyelectrolyte and nonpolyelectrolyte
components using polyelectrolyte theory (Leng et al., 1998).
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4.4 Results
4.4.1 Determining the apparent DNA binding site size for the ATHP and HMGA2
by the ethidium displacement assay
Mouse HMGA2 is a 108 amino acid residue protein with a single tryptophan
residue located at position 84 in the C-terminal side of the third "AT hook" DNA binding
domain (Figure 8(b)). Therefore, it has a near UV absorption spectrum with maximum
absorbance at 280 nm, which can be used to precisely determine the protein
concentration (an extinction coefficient of 5,810 M-1 cm-1 at 280 nm was determined by
Gill and von Hippel's method (Gill & von Hippel, 1989)). It also has a fluorescence
emission spectrum with maximum near 360 nm, indicating that the tryptophan residue
has a substantial contact with aqueous phase. The tryptophan fluorescence may be
quenched upon forming HMGA2-DNA complex, which could be used to determine the
apparent DNA binding site size and other thermodynamic parameters (Lohman &
Overman, 1985). However, the fluorescence change is too complicated to derive useful
data (unpublished results). Therefore, an ethidium displacement assay (Boger et al.,
2001) was used to derive the apparent DNA binding site size for the ATHP and HMGA2
. As an initial step, the apparent DNA binding site size for several well-characterized
DNA minor groove binders, such as distamycin A, netropsin and hoechst33258, binding
to both poly(dA-dT) 2 and poly(dA)poly(dT) were examined. It was found that these
minor groove binders bind to 4 to 5 AT base pairs. These results are consistent with the
previously published observations (Boger et al., 2001).
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Figure 9(a) shows the results of the ATI HP titrating into a solution containing
poly(dA)poly(dT)-ethidium complex. The inflection point between the pre- and post-
saturation corresponds to a peptide to DNA mole ratio of 0.2. This is equivalent to a
stoichiometry of 5 mol of bp per mole of the ATHP, the stoichiometry expected for
binding of one "AT hook" DNA-binding domain to the minor groove of the AT base
pairs (Huth et al, 1997). Similar results were also obtained for the ATHP binding to
poly(dA-dT)2; however, the titration curve is rather gradual and the inflection point is
less obvious for the pre- and post-saturation (data not shown). This may result from the
properties of poly(dA-dT)2 or the experimental conditions used here. Nevertheless, the
stoichiometry of 5 bp per peptide molecule was confirmed in our ITC experiments
(Figure 10) and our UV melting studies (Table 1) for both poly(dA)poly(dT) and
poly(dA-dT) 2.
Figure 9(b) and 9(c) show the results of HMGA2 titrating into solutions
containing poly(dA-dT) 2-ethidium complex and poly(dA)poly(dT)-ethidium complex
respectively. Both plots show an inflection point between the pre- and post-saturation
corresponding to HMGA2 to DNA mole ratio of 0.067. These results suggest that
HMGA2 binds to 15 base pairs of the AT DNAs. These binding stoichiometris are
consistent with our results obtained from ITC and the UV melting studies (Table 1; see
below for details).
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Figure 9. Ethidium displacement assays were performed according to conditions
as described under "Materials and Methods". (a) The ATHP was titrated into a
solution containing poly(dA)poly(dT)-EB complex. (b) HMGA2 was titrated into
a solution containing poly(dA-dT)2-EB complex. (c) HMGA2 was titrated into a
solution containing poly(dA)poly(dT)-EB complex.
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4.4.2 Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was used to investigate the DNA binding
characteristics of the ATHP and HMGA2. With ITC, we directly measure the DNA
binding enthalpy and the DNA binding stoichiometry. Figure 10(a) shows results from a
typical ITC experiment in which the ATHP was titrated into the poly(dA-dT) 2 solution.
There were two distinct binding processes in this titration experiment. The first results in
a binding enthalpy of -6.8 ( 0.3) kcal molE and an apparent binding site size of 5 bp per
ligand molecule; the second has a binding enthalpy of -3.0 ( 0.1) kcal molE and a
binding stoichiometry of 2.5 bp per peptide. We observed precipitation during the second
binding process, suggesting that high concentrations of the ATHP may cause DNA
condensation. Figure 10(b) shows results from the titration experiment in which the
ATHP was titrated into the poly(dA)poly(dT) solution. Interestingly, a positive DNA
binding enthalpy (+3.1 ( 0.1) kcal molE) was obtained with an apparent DNA binding
size of 5 bp per peptide molecule. These differences in binding enthalpy for the two
DNA molecules are discussed below. Nevertheless, the binding stoichiometry obtained
from the ITC experiments is the same as that determined from the ethidium displacement
assays, i.e. 5 bp per the ATHP. Since we used high concentrations of the ATHP (2.0 x
10 - M) in the titration experiments, the binding is nearly stoichiometric and it is
inappropriate to derive the DNA binding constant from such experiments. All other
thermodynamic parameters will be obtained from UV melting studies.
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molecule, in agreement with the binding stoichiometry measured by the ethidium
displacement assay (Figure 9). Since HMGA2 binds avidly to poly(dA-dT) 2 (see below
for details) and the binding is nearly stoichiometric, we could not determine the DNA
binding constant by ITC. HMGA2 was also used to titrate into a solution containing
poly(dA)poly(dT), which produced a small positive enthalpy of +0.6 ( 0.1) kcal moP-.
Because of the small magnitude of heat, we could not obtain a reliable titration curve and
measure the binding stoichiometry.
4.4.3 Determination of the DNA binding constant of the ATHP and HMGA2 by UV
melting studies
Since the DNA binding enthalpy and the DNA binding stoichiometry of the
ATHP and HMGA2 have been determined, DNA UV melting studies were used to
derive the Ka values for the interactions of the ATHP and HMGA2 with poly(dA-dT)2
and poly(dA)poly(dT) in BPE buffer plus 4 mM NaCl (20 mM total Na+). The Tm of
poly(dA-dT)2 and poly(dA)poly(dT) alone were 45.9"C and 52.9 C respectively. In the
presence of 5 pM of the ATHP, a concentration sufficient to saturate the DNA lattice, the
Tm values of poly(dA-dT) 2 and poly(dA)poly(dT) were elevated to 63.90C and 76.9 C
respectively. In the presence of 2 pM HMGA2, a concentration also sufficient to saturate
the DNA lattice, the Tm of poly(dA-dT)2 and poly(dA)poly(dT) were increased to 68.9"C
and 81.90C respectively. The DNA melting enthalpy of poly(dA-dT) 2 and
poly(dA)poly(dT) have been previously determined by differential scanning calorimetry
to be 8.4 and 8.9 kcal/mol respectively (Haq et al., 1997). Equation 1 can be used to
90
calculate the DNA binding constants at the melting temperature. For the ATHP, the
DNA binding constant of poly(dA-dT)2 and poly(dA)poly(dT) were 6.7 x 106 M- (at
63.90C) and 2.2 x 107 M- (at 76.9"C) respectively, while for HMGA2, the DNA binding
constant for poly(dA-dT) 2 and poly(dA)poly(dT) were 3.5 x 1011 M (at 68.90C) and 1.1
x 1013 M (at 81.90C) respectively. By application of the standard van't Hoff equation
(equation 2), the binding constants for the ATHP & poly(dA-dT) 2, the ATHP &
poly(dA)poly(dT), HMGA2 & poly(dA-dT) 2, and HMGA2 & poly(dA)poly(dT) were
calculated to be 2.5 x 107, 1.0 x 107, 1.9 x 1014, and 9.6 x 1012 M respectively.
Knowledge of the binding constant and binding enthalpy allowed us to construct the
complete thermodynamic profiles for binding both the ATHP and HMGA2 to poly(dA-
dT)2 and poly(dA)poly(dT). The free energy is obtained from the standard relation AG
-RTlnK and the entropy is computed with the equation -TAS = AG - AH. The values of
these parameters are summarized in Table 1.
The DNA binding constant for the ATHP binding to poly(dA-dT) 2 and
poly(dA)poly(dT) were also determined by fitting experimental UV melting curves to
McGhee's model of the helix-coil transition of DNA in the presence of ligands
(McGhee, 1976).It was assumed that the ATHP does not bind to single-stranded DNA.
For the ATHP binding to poly(dA-dT)2, the following parameters were used and
constrained in the fitting procedure: AH, = 8.4 kcal mor- of bp, AHb = -6.8 kcal mol',
[DNA] = 2.0 x 04 M bp, and (0h - 1.0. The other four parameters (n, K, Co, and the
effective [ATHP]) were adjusted to produce best-fit curves using methods described in
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Figure 11. Sample raw data for the titration of HMGA2 into poly(dA-dT) 2 at
250 C in BPE buffer plus 4 mM NaCl (total 20 mM Na+). Top, each peak shows
the heat produced by injection of an aliquot of 15 pl of HMGA2 (50 pM) into
DNA solution (1.7 ml of 100 pM (bp)). Bottom, binding isotherm resulting
from integration with respect to time with appropriate dilution correction.
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Materials and Methods and also in our previous publications (Leng et al., 1998). The
experimental and the best fit melting curves are compared in Figure 12(a), and the
resulting optimized parameters are summarized in Table 2. The analysis of five melting
curves at varying the ATHP concentrations yielded an estimate for Ka = 1.7 ( 0.2) x 107
M- and n = 5.0 ( 0.1) bp at 25"C. The DNA binding constant is in excellent agreement
with that based on Tm measurements at saturating concentrations of the ATHP described
above; the DNA binding site size equals the values determined by ethidium displacement
assays and ITC experiments. Melting curves of poly(dA)poly(dT) in the presence of the
ATHP were also fitted to McGhee's Model by constraining the following parameters in
the fitting process: AHm = 8.9 kcal mo-' (bp), AHb =+3.1 kcal mol-, [DNA] = 2.0 x 10-
M bp, and 0h = 1.0 (Figure 12(b) and Table 3). The resulting DNA binding constant (9.6
( 0.4) x 106 M') and binding site size (5.1 ( 0.2) bp per ligand) are also in excellent
agreement with the values determined as described above.
We also attempted to fit the melting curves of poly(dA-dT) 2 and
poly(dA)poly(dT) in the presence of HMGA2 to McGhee's model. The experimental and
the best fitting melting curves are compared in Figures Si and S2 (Appendix 1), and the
resulting optimized parameters are summarized in Tables S1 and S2 (Appendix 1). The
melting curves in the presence of unsaturating HMGA2 concentrations did not fit well to
the experimental curves. Nevertheless, the DNA binding constants and the binding site
size are in good agreement with the values determined as described above.
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Figure 12. Fits of (a) poly(dA-dT)2 and (b) poly(dA)poly(dT) DNA melting
curves in the presence of various amounts of the ATHP to McGhee's theory.
The dotted lines are experimental data, and the solid lines are theoretical
curves with the parameters listed in Tables 2 and 3.
4.4.4 Salt dependence of the binding constants
The salt dependence of the ATHP and HMGA2 binding to poly(dA-dT) 2 and
poly(dA)poly(dT) was investigated by UV melting experiments. Differences between the
DNA melting temperatures of DNA alone and in the presence of saturating amounts of
the ATHP or HMGA2 at different NaCl concentrations were used to calculate DNA
binding constants of the ATHP and HMGA2 at the melting temperature. The DNA
binding enthalpy of the ATHP and HMGA2 binding to poly(dA-dT)2 was independently
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determined by ITC. Both binding reactions are exothermic over a wide range of NaCI
concentrations (Figure 13) and the DNA binding enthalpy decreases greatly with
increasing NaCI concentration. Since the magnitude of the heat produced by the binding
of the ATHP and HMGA2 to poly(dA)poly(dT) is so small, the DNA binding enthalpy at
different NaCI concentrations could not be determined. It was assumed that the binding
enthalpy of the ATHP and HMGA2 binding to poly(dA)poly(dT) is independent of salt
concentration.
With the knowledge of the DNA binding enthalpy, the Ka values for DNA
binding by the ATHP and HMGA2 to both poly(dA-dT)2 and poly(dA)poly(dT) were
corrected to 250C by applying the standard van't Hoff equation (equation 2). Figure 14
shows the dependence of Ka at 25 C on the concentration of Na+ as determined by UV
melting studies. The Ka for both the ATHP and HMGA2 decrease with increasing salt
concentrations, due to counterion release that accompanies the binding of the charged
ligands to DNA. Based on the polyelectrolyte theory of Record et al. (Record et al.
1978), the slopes of the lines in Figure 14 are equal to
8 log K 
_
SK Dog[Na*]
where Z is the charge on the ligands and y is the fraction of counterions associated with
each DNA phosphate (y= 0.88 for the double-stranded B-form of DNA). The quantity
SK is equivalent to the number of the counterions released upon binding of a ligand with
net charge Z. For the ATHP binding to poly(dA-dT)2 and poly(dA)poly(dT), it was
found that 2.66 and 2.54 counterions, respectively, are liberated from the DNA. For
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HMGA2 binding to poly(dA-dT)2 and poly(dA)poly(dT), 5.91 and 5.61 counterions,
respectively, are released from the DNA. From these values of Zy, the charges on each
ligand are as follows: +3.01 for the ATHP binding to poly(dA-dT) 2, +2.89 for the ATHP
binding to poly(dA)poly(dT), +6.72 for HMGA2 binding to poly(dA-dT) 2 , and +6.38 for
HMGA2 binding to poly(dA)poly(dT).
4.4.5 Determination of the heat capacity change (ACp) for HMGA2 binding to
poly(dA-dT) 2
ACP for the interaction is 6AH/8T, the temperature dependence of the enthalpy of
binding. AH values for the interaction between HMGA2 and poly(dA-dT)2 were
determined at different temperature (from 200C to 30"C) by ITC. Figure 15 shows that
the slope of a linear least-squares fit gives a value for ACp of -705 (+131) cal mo-' K-1.
The free energy of DNA binding (AG = -RTlnK) was calculated from UV melting
studies. It should be noted that the AG of binding is concentration dependent. By
convention it is normally calculated at a standard 1 M reference state. However, as
discussed previously, AG values under the conditions used in our experiments are less
negative than at the 1 M state. For example, ITC studies were conducted at
concentrations in the 10 pM range where AG of binding will be 6.82 kcal mol' less
negative than the values given in Table 1. For the ATHP binding to poly(dA-dT) 2, under
these conditions, AG1,1o M is -3.3 kcal mol and TAS, -3.5 kcal mol. Interestingly, the
free energy change is less sensitive to temperature than AH. The values for the binding
enthalpy and entropy seem to be linearly correlated; the large heat capacity change is
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compensated by changes in the entropy to produce relatively small changes in the free
energy.
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Figure 13. Ionic strength dependence of the Gibbs free energy (AG), enthalpy (AH), and
entropy (TAS) for the binding reactions between (a) the ATHP and poly(dA-dT)2 or (b)
HMGA2 and poly(dA-dT) 2. The Gibbs free energy (AG) was calculated according to
equation AG = -RTInK where K is the DNA binding constant determined by UM
melting studies. AH was measured directly by ITC experiments. AS was computed by
equation -TAS = AG - AH. The standard deviation of AH for the ATHP binding to
poly(dA-dT) 2 was estimated to be 0.2 (20 mM Nat), 0.1 (50 mM Na+), 0.1 (75 mM
Na+), and 0.1 (100 mM Nat) kcal mol' respectively; the standard deviation of AH for
HMGA2 binding to poly(dA-dT) 2 was estimated to be 0.2 (20 mM Na+), 0.2 (50 mM
Na+), 0.1 (100 mM Na+), 0.1 (200 mM Na+), and 0.1 (500 mM Nat) kcal mol'
respectively.
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Figure 14. Dependence of DNA binding constants at 250C on the salt
concentration. (a) HMGA2 binding to poly(dA-dT) 2 (solid circles) and
poly(dA)poly(dT) (open circles) in the presence of various NaCl
concentrations. (b) The ATHP binding to poly(dA-dT)2 (solid circles) and
poly(dA)poly(dT) (open circles) in the presence of various NaCl
concentrations. The linear least-squares fits to the data are shown.
4.5 Discussion
The results presented in this article provide a detailed thermodynamic profile
(AG, AH, AS, n, and ACp) for the interactions of two minor groove binding ligands, the
ATHP and the mammalian high mobility group protein HMGA2, with DNA. The ATHP
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Figure 15. Heat capacity change (ACp) for binding HMGA2 to poly(dA-
dT)2 . Linear least-squares fitting of the enthalpy data (squares) determined
by ITC gives a ACp value of -705 cal mol1 K1. The dependence of AG
(circles) and TAS (triangles) on temperature are shown. The standard
deviation of AH at different temperature was estimated to be 0.1 (20 C), 0.1
(22.5'C), 0.2 (25-C), 0.1 (27.5 C), and 0.1 (304C) kcal mol-1 respectively.
is a synthetic peptide containing one "AT hook" DNA binding domain whereas HMGA2
has three "AT hook" DNA binding domains. These results provide an opportunity to
compare the energetics of multidentate binding by HMGA2 and its single domain
counterpart, the ATHP, to two different AT DNAs: poly(dA-dT)2 and poly(dA)poly(dT).
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4.5.1 Binding stoichiometry
Binding stoichiometry is a key parameter for describing and understanding a
ligand-DNA interaction. The NMR structure (Huth et al., 1997) indicates that one "AT
hook" DNA binding domain occupies 5 AT base pairs. This is clearly confirmed by our
ethidium displacement assays (Figure 9(a)) and ITC experiments (Figure 10) with the
ATHP (Figure 16(a)). Also, our results showed that HMGA2 binds to 15 AT base pairs.
Since HMGA2 contains three "AT hook" DNA binding domains, it is possible that all
three "AT hook" domains simultaneously bind to the minor groove of the AT DNAs
(Figure 16(c)) so that the whole protein will wrap around 1.5 turns of the DNA double
helix. Alternatively, two of the three "AT hook" DNA binding domains could bind to the
minor groove of the AT base pairs with each DNA binding domain binding to 5 base
pairs with a 5 base pair space in the middle position (Figure 16(b)). In such a situation,
HMGA2 binds to DNA only on one side. This binding mode is consistent with previous
studies by Schwanbeck et al (Schwanbeck et al., 2000) who demonstrated that only the
first and second DNA binding domains bind to the minor groove of a fragment of the
beta-interferon promoter. However, all three AT hooks are involved in binding to long
AT stretches of DNA and this is likely to be the situation in our experiments because the
ATHP corresponds to the third DNA binding domain of HMGA2. Therefore, our results
show that a stretch of five AT base pairs is the basic binding unit for the "AT hook"
DNA binding domain and HMGA2 uses multiple "AT hook" DNA binding domains
(probably three) to bind to the target DNA sequences, which is consistent with previous
results (Solomon et al., 1986; Maher & Nathans, 1996).
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Figure 16. Possible binding modes for the interaction of HMGA2 with DNA.
Symbols: red oval, one "AT hook" DNA binding domain; blue rectangle, the negative
charged C-terminal motif. (a) One "AT hook" DNA binding domain binds to 5 AT
base pairs. (b) HMGA2 binds to 15 AT base pairs using only two "AT hook" DNA
binding domains. (c) HMGA2 binds to 15 AT base pairs using all three "AT hook"
DNA binding domains.
4.5.2 Binding affinity
Since the ATHP does not have a defined structure when free in aqueous solution
(Huth et al., 1997), it is reasonable to assume that increasing temperature would not
significantly affect its conformation. The far and near UV CD spectrum of HMGA2
suggests that it has very little secondary structure (data not shown; a temperature
dependent CD study showed little change of HMGA2's CD spectrum upon heating) and
we assume in our analysis that it is also unfolded in the absence of DNA in the
temperature range of our experiments. Therefore, DNA UV melting studies should be an
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appropriate approach to study the DNA binding characteristics of both the ATHP and
HMGA2. Here we used ITC and UV melting studies to determine the DNA binding
constants; these studies indicate that in a solution containing 20 mM Na, at 250C, the
ATHP binds to poly(dA-dT) 2 and to poly(dA)poly(dT) with binding constants of 2.5 x
10 7 M and 1.0 x 107 M, respectively. Under the same ionic conditions, our results
showed that HMGA2 binds extremely tightly to AT DNAs with Ka values for poly(dA-
dT)2 and poly(dA)poly(dT) of 1.9 x 101 M- and 9.6 x 101 M-, respectively. Since
poly(dA-dT) 2 has two different sites, i.e. 5'-AT-3' and 5'-TA-3', the binding constant
determined by this approach represents an average value for these two different sites.
Melting curves of poly(dA-dT) 2 and poly(dA)poly(dT) in the presence of
increasing concentrations of the ATHP were fitted to McGhee's model of the helix to
coil transition in the presence of ligands (McGhee, 1976). This method provides an
independent verification of the binding site size and binding constant, along with a more
reliable estimate of the uncertainty in the parameters. Figure 12 shows that the agreement
between the calculated curves and the experimental results are excellent. In particular,
the shapes and biphasic of the experimental melting curves are matched very well by the
calculated curves. Our best fit produces the DNA binding site size of 5 base pairs and
binding constants of 1.7 x 107 M- for poly(dA-dT)2 and 9.6 x 106 M 4 for
poly(dA)poly(dT). The DNA binding site size is exactly the same one determined
independently by ITC experiments (Figure 10) and also by ethidium displacement assays
(Figure 9(a)); it also matches the value determined by NMR studies in which an "AT
hook" DNA binding domain occupies 5 AT base pairs (Huth et al., 1997). The DNA
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binding constant is in good agreement with the one calculated according to equations 1
and 2 at saturating concentrations of the ATHP.
The same method was also used to fit DNA melting curves in the presence of
HMGA2 to McGhee's model of the helix to coil transition in the presence of ligands.
The best fits are shown in Figures S 1 and S2 (Appendix 1). The melting curves in the
presence of sub-saturating concentrations of HMGA2 do not match exactly with the
computed curves. This deviation may partially reflect the conformational transition of
HMGA2 upon DNA denaturation. Alternatively, since HMGA2 uses multiple "AT
hook" DNA binding domains to interact with a total of 15 AT base pairs, individual "AT
hook" DNA binding domains may bind to sections of 5 AT base pairs with different
binding affinities. On heating, the different DNA segments that associate with the
different "AT hook" DNA binding domains, may not melt in a single cooperative
transition but at different temperatures, thus causing the deviation (McGhee's model
neglects such a situation). Despite this uncertainty in interpretation, this analysis yields a
DNA binding site size of 15 base pairs for HMGA2 binding to AT DNAs, in agreement
with those determined independently by ITC (Figure 11) and ethidium displacement
(Figures 9(b) and 9(c)).
The DNA binding constants determined in this study are in excellent agreement
with previously published results. Using electrophoretic mobility shift assay (EMSA)
Maher and Nathans showed that HMGA proteins bind tightly to a DNA binding site
containing two to three 5 bp AT tracks with appropriate spacing (Maher & Nathans,
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1996). Their data indicate that the DNA binding constant for HMGA2 binding to a high
affinity binding site is 2 x 1010 M- in a solution containing 50 mM K+ at 22®C, a value
comparable to that determined in the present study. Furthermore, Piekielko et al
demonstrated that HMGA2 binds tightly to a 34 bp fragment of the promoter of the IFNs
gene with a DNA binding constant of 1.7 x 107 M- in a solution containing 180 mM K+
and 1 mM Mg2+ at 200C (Piekielko et al., 2001). This value is also in the same order of
magnitude as our DNA binding constant under similar ionic conditions (Figure 14(a)).
Reeves and Nissen reported that two other members of the HMGA family, HMGA 1 a and
lb bind to an AT rich 3'-UTR of the bovine interleukin-2 cDNA with a binding constant
of 9.7 x 108 M 1 and 7.2 x 108 M- respectively in a solution containing 52 mM Na+ at
25 C (Reeves & Nissen, 1990). They used a 300 bp DNA fragment containing multiple
binding sites for HMGA proteins. It is not surprising that their values are slightly lower
than those determined in this paper and they may represent an average value for different
binding sites. Recently, Dragan et al (Dragan et al., 2003) showed that in a solution
containing about 120 mM K+ at 200C, one "AT hook" DNA binding domain binds to AT
base pairs with a binding constant of 1.4 x 104 M-. This value is about 5 times lower than
the value we obtained here (Figure 14(b)), possibly reflecting the fact that these authors
used a short, 12 bp, oligomer for their studies. Short oligomers usually have different
thermodynamic properties from their polymeric counterparts, especially with respect to
end effects which may significantly weaken the ligand-oligomer interactions (Ballin et
al., 2004).
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4.5.3 Salt dependence of binding
The ATHP and HMGA2 are both cations, so their binding to DNA is
thermodynamically linked to Na+ binding to DNA, and their DNA binding constants (Ka
values) depend on the total Na+ concentration. Polyelectrolyte theories based on
Manning's counterion condensation model provide a basis for interpreting our data
(Record et al., 1978; Manning et al., 1978). Our calculations indicate that the interaction
of the ATHP (one DNA binding domain) uses only three out of six positive charges at
neutral pH binding to AT DNAs. The NMR structure (Huth et al., 1997) (Figure 8),
suggests that two positive charges from the central RGR motif, which deeply penetrates
into minor groove, may fully participate the binding process while the other four positive
charges partially contribute to the DNA binding. With HMGA2, which has 25 positive
charges at neutral pH, our results (Figure 14) indicate that only 6 to 7 charges contribute
to the DNA binding process. It is likely that all these charges are from the "AT hook"
DNA binding domains. Our results are in excellent agreement with previous published
studies of the ATHP binding to synthetic oligonucleotides (Dragan et al., 2003).
From the dependence of the binding constant on salt concentration, the observed
binding free energy (AGobs) can be partitioned into two contributions:
AG'b, =-R T In K = AG, + AG,
where AGt is the nonpolyelectrolyte contribution to the binding free energy and AG, is
the polyelectrolyte contribution. The latter term may be calculated from experimentally
a ln K_
determined quantity ( - SK). Ballin et al (Ballin et al., 2004) have shown
ln[Na+
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that AGP, = (SK)RT ln[X], where MX is the monovalent salt concentration. Values for
parameters calculated using these equations are give in Table 1. The magnitude of AGt
provides a measure of the nonpolyelectrolyte forces that stabilize the DNA-protein
complexes (nonelectrolyte forces include all other type of molecular interactions and
transfer processes other than polyelectrolyte effects). AGp, is the free energy contribution
arising from coupled polyelectrolyte effects, especially the release of the condensed
counter-ions from the DNA helix upon binding the charged ligands. Although non-
polyelectrolyte forces contribute substantially to the stability of ligand-DNA complexes,
the polyelectrolyte interactions provide most of the free energy of association.
4.5.4 Comparison of the ligands binding to poly(dA-dT) 2 and poly(dA)poly(dT):
enthalpy and entropy compensation
The ATHP binds to poly(dA-dT) 2, at 250C, with a AH of -6.8 kcal mor-, a AG of
-10.1 kcal mol 1 , and a small AS of +11.1 cal moP- K- (-TAS, -3.3 kcal mol'). This
binding reaction is therefore overwhelmingly enthalpy-driven. Surprisingly, the binding
of the ATHP to poly(dA)poly(dT), at 25"C, is entropy-driven with a small unfavorable
AH of +3.1 kcal mol-, a favorable AG of -9.6 kcal moP', and a large favorable TAS of
+42.6 cal moP- K (-TAS = -12.7 kcal mol-). Similar results were obtained for HMGA2
binding to AT DNAs. HMGA2 binds to poly(dA-dT)2, at 25*C, through an enthalpically-
driven interaction with a large favorable AU of -29.1 kcal moP', a AG of -19.5 kcal mol
1, and an unfavorable -TAS = +9.7 kcal moP-. In contrast, the interaction 
of HMGA2
with poly(dA)poly(dT), at 25C is entropically-drive with a small unfavorable AU of
109
+0.6 kcal mo-1, a favorable AG of -17.7 kcal mol, and a large favorable -TAS of -18.3
kcal moE-. This is a typical example of enthalpy/entropy compensation for the two
ligands binding to different DNA substrates with similar binding free energies (Breslauer
et al., 1987; Jen-Jacobson et al., 2000). This DNA binding property is a hallmark for
several minor groove binding drugs, such as netropsin, binding to different DNA
substrates (Breslauer et al., 1987). As demonstrated by Breslauer and his co-workers
(Marky et al., 1987), the binding of netropsin to polyd(dA-dT)2 is overwhelmingly
driven by enthalpy but the binding to poly(dA)poly(dT) is driven by entropy. They
attributed this difference (enthalpy/entropy compensation) to the formation of a more
dehydrated poly(dA)poly(dT)-netropsin complex than the corresponding poly(dA-dT)2 -
drug complex (Chalikian et al., 1994). Specifically, netropsin binding to
poly(dA)poly(dT) releases 18 more water molecules than when it binds to poly(dA-dT) 2
(Chalikian et al., 1994). The ATHP and HMGA2 may have analogous binding properties
to these small minor groove binding antibiotics; their binding to poly(dA)poly(dT) may
release more water molecules than their binding to poly(dA-dT) 2. Another possibility of
the unusual thermodynamic profile of HMGA2 binding to poly(dA)poly(dT) may result
from the conformational transition in poly(dA)poly(dT) coupled to the binding reaction.
As demonstrated previously (Herrera & Chaires, 1989), certain small DNA binding
ligands binding to poly(dA)poly(dT) is coupled to the DNA conformational transition.
The positive binding enthalpy may come from a helix to helix transition of
poly(dA)poly(dT). Nevertheless, the coupled conformational transition is directly linked
to the disruption of hydration in poly(dA)poly(dT) (Herrera & Chaires, 1989).
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The binding of both the ATHP and HMGA2 to poly(dA-dT) 2 is associated with
large favorable enthalpy contributions. This favorable enthalpy probably arises from the
formation of different non-covalent bonds such as hydrogen bond, electrostatic
interactions and nonpolar contacts between proteins and DNA. Interestingly, the DNA
binding enthalpy for both ligands is strongly dependent on the ionic strength (Figure 13),
suggesting that ionic dependent enthalpy significantly contributes to ligand-DNA
interaction. These results contradict with Manning's counterion condensation theory
where ligand-DNA interactions, including specific and nonspecific interactions, are
driven by the entropic release of counterions associated with the DNA backbone (Record
et al., 1978; Manning, 1978). More recently, Honig and his co-workers used the
nonlinear Poisson-Boltzmann (PB) equation to evaluate the salt dependent contribution
to the electrostatic binding free energy of several small minor groove binders (Misra et
al., 1994). They found that the electrostatic free energy of ligand-DNA interactions has
significant enthalpic and entropic contributions. In their theory, the counterion
atmosphere around a polyion (such as DNA) is modeled as a single population described
by a continuously distributed salt dependent ion atmosphere. In such a case, the
electrostatic enthalpy is strongly dependent on the bulk salt concentration. For the ATHP
and HMGA2 binding to poly(dA)poly(dT), the favorable enthalpy gained from
electrostatic ion-macromolecule or ion-ion interactions may be used up to release more
water molecules from ligand-DNA complexes, which results in an increase in entropy
(enthalpy-entropy compensation). Figure 17 summarizes the enthalpic and entropic
contributions to the binding free energy for the ATHP and HMGA2 binding to poly(dA-
dT)2 and poly(dA)poly(dT).
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Figure 17. Comparison of the thermodynamic profiles for the ATH and
GA2 binding to oly(A-dT)2 and oly(A)poly(dT).
4.5.5 Temperature dependence of binding enthalpy
As demonstrated by Dragan et al (Dragan et ae, 2003), the binding of AT hook
peptides, which contain one "AT hook" DNA binding domain, to a DNA duplex 5'%
GGGAAATTCCGC-3' (top strand) is accompanied by a negative heat capacity change
(ACp). In their case, the AT hook peptides bind to DA with an unfavorable positive
enthalpy and a favorable entropy contribution. The binding reaction is entropy-driven,
which is similar to the binding process between our ATHP or H-MGA2 and
poly(d.A)poly(dT). Furthermore, they suggested that the heat capacity change is a result
of dehydration of the groups forming the interface in the complexes (As shown
previously (Spolar & Record, 1994), a large heat capacity change is associated with the
formation of a highly complementary interface between protein and DNA; ACp can be
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calculated from changes in water-accessible nonpolar and polar surface area (Spolar &
Record, 1994)). However, the experimental value is twice as large as the ACp calculated
from their water-accessible surface areas (Dragan et al., 2003). We also found that
HMGA2 binding to poly(dA-dT)2 is accompanied with a large negative heat capacity
change (-705 ( 113) cal mol' K- or -2.9 ( 0.5) kJ mo- K-1). This value is
significantly larger than the ACp determined by Dragan et al (-0.30 to -0.6 kJ mol- K-).
These results suggest that dehydration upon forming the HMGA2-DNA complex alone
cannot explain the large heat capacity change. One possible mechanism for the ACp
discrepancy is protein folding induced by DNA binding (Spolar & Record, 1994). Our
CD studies suggest that, in the absence of DNA, HMGA2 has little secondary structure
and may be unfolded. NMR studies show that on binding to DNA, AT hook domains
adopt a crescent-shaped conformation (Huth et al., 1997). This induced disorder to order
conformational transition may significantly contribute to ACp.
Another explanation for ACp discrepancy stems from the charge-charge
interactions between highly positively charged HMGA2 and highly negatively charged
DNA. As described by Sturtevant (Breslauer & Sturtevant, 1977), creation of a positive
and negative pair of charges in aqueous solution leads to ACp = -20 to -50 cal mol K-.
Inspection of the NMR structure of a truncated form of HMGA1 and DNA showed
several well defined electrostatic contacts between the side chains of Arg and Lys and
the DNA phosphates (Huth et al., 1997). Particularly, two Arg residues in the RGR core
of the "AT hook" DNA binding domain deeply penetrate into the narrow minor groove.
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Since the minor groove has a high negative potential (Lavery & Pullman, 1981) and a
low dielectric constant (Jin & Breslauer, 1988), the contribution of the electrostatic
interaction (Columbic forces) in the minor groove to the AG, AH and ACP of binding
should be substantial. Recently, Holbrook et al demonstrated that binding of integration
host factor (IHF) of E. coli (another minor groove binding protein) to its cognate
sequence from X phage DNA produces a large negative binding enthalpy and a negative
heat capacity change; the magnitudes of enthalpy and heat capacity changes decrease
strongly with increasing [K+] (Holbrook et al., 2001). They interpreted these data by
hypothesizing that 22 of the 23 IHF cationic side chains contacting with DNA phosphate
oxygen atoms in the IHF-DNA complex are masked in the absence of DNA by pairing
with negatively charged carboxylate groups, i.e. forming dehydrated ion-pairs. IHF
binding to DNA results in disruption of multiple salt bridges on the protein surface
followed by hydration of the unmasked charged groups and formation of interactions
between positively charged groups and DNA. Interestingly, the charge distribution of
HMGA2 is asymmetrical with the positively charged residues mainly concentrated in the
center of the sequence and the negatively charged residues at the C-terminus. We found
that the negatively charged C-terminus interacts with the positively charged "AT hook"
DNA binding domains in the absence of DNA by forming multiple salt bridges
(unpublished results). Potentially, these salt bridges could be disrupted when HMGA2
binds to DNA. Further studies are required to fully understand the high ACp.
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4.5.6 Binding selectivity
It has been suggested that the "AT hook" proteins, HMGA 1 a, HMGA I b, and
HMGA2, only recognize the minor groove of AT DNAs and do not recognize specific
DNA sequences (Solomon et al., 1986). However, the solution structure of an ATHP-
DNA complex showed that the "AT hook" DNA binding domain binds to the DNA
sequence 5'-A4 AATT8-3' (numbers 4 and 8 represent the positions of the bases in the
DNA dodecamer used for the structure determination) in a specific orientation with the
N-terminal Arg of the core RGR located near base pair 8 and C-terminal Arg located
near base pair 4 (Figure 8(a)) (Huth et al., 1997). There are extensive hydrophobic and
polar contacts between the "AT hook" DNA binding domain and DNA. We showed here
that both the ATHP and HMGA2, at 250C, bind to poly(dA-dT) 2 with a higher affinity
than for poly(dA)poly(dT) (Table 1). These studies suggest that the "AT hook" DNA
binding domain does have sequence selectivity. Similar to other small minor groove
binders, the "AT hook" DNA binding domain rmay recognize all 5 bp AT sequences but
with different binding affinities. The sequence selectivity of the ATHP is currently under
investigation in our laboratory.
4.6 Conclusions
The following are major conclusions drawn from this study: (1) One "AT hook"
DNA binding domain binds to 5 AT base pairs and one HMGA2 molecule binds to 15
AT base pairs. (2) HMGA2 binds with very high affinity to both poly(dA-dT) 2 and
poly(dA)poly(dT) and electrostatic interactions are a dominant force in their interactions
with DNA. (3) The interaction of HMGA2 and poly(dA-dT)2 is enthalpy driven. In
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contrast, the interaction between HMGA2 and poly(dA)poly(dT) is entropy driven. This
enthalpy-entropy compensation property is a signature for DNA minor groove binders,
and may be a reflection of dehydration difference of different ligand-DNA complexes.
(4) The binding reaction between HMGA2 and poly(dA-dT) 2 was temperature-dependent
with a ACP of -705 ( 113) cal mo-'K-.
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5. Specific Recognition of AT-Rich DNA Sequences by the Mammalian High
Mobility Group Protein AT-hook 2: A SELEX study
5.1 Abstract
The Mammalian high mobility group AT-hook 2 (HMGA2) is a transcriptional
factor involved in cell differentiation and transformation. Disruption of its normal
expression pattern is directly linked to oncogenesis and obesity. HMGA2 contains three
"AT-hook" DNA binding domains, which specifically bind to the minor groove of AT-
rich sequences. Using a PCR-based systematic evolution of ligands by exponential
enrichment (SELEX) procedure, we have identified two consensus sequences for
HMGA2: 5'ATATTCGCGAWWATT3' and 5'-ATATTGCGCAWWATT-3' where W
represents A or T. These two consensus sequences have a unique and interesting feature:
the first five base pairs are AT-rich, the middle four base pairs are GC-rich, and the last
six base pairs are AT-rich. Our results showed that all three of these segments are critical
for high affinity binding of HMGA2 to DNA. For example, if one of the AT-rich
sequences is mutated to a non-AT-rich sequence, the DNA binding affinity of HMGA2
is reduced at least 100-fold. Intriguingly, if the GC-segment is replaced by an AT-rich
segment, the binding affinity of HMGA2 is reduced approximately 5-fold. Identification
of the consensus sequences for HMGA2 represents an important step towards finding its
binding sites within the genome.
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5.2 Introduction
The mammalian high mobility group protein AT-hook 2 (HMGA2) is a
transcriptional factor regulating mesenchymal cell development and differentiation
(Wolffe et al., 1994; Zhou et al., 1995; Anand et al., 2000; Reeves, 2003). It was first
discovered as a nuclear protein in proliferating fibroblasts and embryos, and also in
transformed thyroid cells infected by oncogenic viruses (Goodwin et al., 1985; Giancotti
et al., 1985). The aberrant expression of HMGA2 has been attributed to the formation of
a variety of tumors, including benign tumors, such as lipomas (Ashar et al., 1995;
Schoenmakers et al., 1995) and uterine leiomyomas (Kools et al., 1995; Schoenmakers et
al., 1999; Klotzbucher et al., 1999), and malignant tumors, such as breast cancer
(Rommel et al., 1997), lung cancer (Rogalla et al., 1998; Sarhadi et al., 2006; Meyer et
al., 2007), and leukemia (Rommel et al., 1997; Kottickal et al., 1998). The expression
level is correlated with the degrees of malignancy and metastatic potential of the
transformed cells (Tallini et al., 1999), suggesting that HMGA2 can be used as a
biomarker for diagnosing the neoplastic transformation and the metastatic potential of
many cancers (Giancotti et al., 1991; Rogalla et al., 1998). HMGA2 is only expressed in
proliferating, undifferentiated mesenchymal cells and is undetectable in normal fully
differentiated adult cells (Zhou et al., 1995; Gattas et al., 1999). Disruption of its normal
expression patterns causes deregulations of cell growth and differentiation. For example,
hmga2 knock-out mice developed the pygmy phenotype (Zhou et al., 1995). These
mutant mice were severely deficient in fat cells and other mesenchymal tissues. Breaking
of the hmga2 gene caused a dramatic reduction in obesity of leptin-deficient mice
(Lepob/Lepo) in a gene dosage dependent manner (Anand et al., 2000). These results
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suggest that HMGA2 plays an important role in fat cell proliferation and is a potential
target for the treatment of obesity (Anand et al., 2000).
HMGA2 is a member of the HMGA family, which also includes another two
proteins, HMGAla and lb. HMGAla and lb are splice variants of the same gene, the
HMGA1 gene (Friedmann et al., 1993). HMGA2 is the product of a separate gene, the
HMGA2 gene (Chau et al., 1995). One unique feature of HMGA proteins is that all have
three "AT-hook" DNA binding domains. These DNA binding domains contain a
consensus sequence, PRGRP, flanked on each side by one or two positively charged
amino acids (arginine or lysine). The "AT-hook" DNA binding domain, in the absence of
DNA, is "unstructured" (Lehn et al., 1988; Huth et al, 1997). However, when it binds to
the minor groove of AT-rich sequences, this domain adopts a defined conformation
(Huth et al., 1997). The central core, RGR, deeply penetrates into the minor groove of
AT base pairs with two arginine residues, forming extensive electrostatic and
hydrophobic contacts with the floor of the minor groove (Huth et al., 1997). Two
prolines on each side of the RGR core direct the protein away from the floor of the minor
groove and position the positively charged arginine or lysine near the negatively charged
phosphate backbone, thereby making further contacts. This disordered-to-ordered
conformational change significantly increases HMGA proteins' adaptability and allows
them to participate in a variety of nuclear activities such as gene transcription, DNA
replication, chromatin remodeling, and DNA repair (Goodwin, 1998; Reeves, 2003).
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Since their discovery, HMGA proteins were shown to preferentially bind to AT-
rich DNA sequences in the promoter regions. The early qualitative footprinting studies
showed that they could bind to any run of five to six AT base pairs with similar DNA
binding affinity (Solomon et al., 1986). These studies also suggested that HMGA
proteins only recognize the minor groove configuration of AT base pairs rather than
specific sequences. However, more recent studies showed that HMGA proteins should
have sequence specificity. For example, the high affinity binding of HMGA proteins
requires two to three appropriately spaced AT-rich sequences as a single multivalent
binding site (Maher et al., 1996). The DNA binding affinity of this multivalent binding is
much higher than that of the single valent binding (Maher et al., 1996). More
significantly, each HMGA protein always simultaneously binds to two to three runs of
AT base pairs in the regulatory transcription regions, such as the human interferon f
enhancer (Thanos & Maniatis, 1992; Du et al., 1993), the promoter regions of
interleukin-2 gene (Baldassarre et al., 2001) and interleukin-2 receptor a-chain gene
(John et al., 1995), and the promoter region of interleukin-15 gene (Reeves &
Beckerbauer, 2001). These results suggest that HMGA proteins bind to specific DNA
sequences as transcriptional factors. More evidence for sequence-specific DNA binding
of HMGA proteins comes from the NMR structural studies (Huth et al., 1997). The
structure of an HMGA la-DNA complex showed that the "AT-hook" DNA binding
domain binds to the 5'-AAATT-3' sequence in a fixed orientation with the N-terminal
arginine of the core RGR sequence located near the 3'-end of the sequence, and the C-
terminal arginine located near the 5'-end of the sequence. This binding orientation
resulted from hydrophobic interactions of the arginine side chains of the RGR core with
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the adenine bases of the DNA sequence, and hydrogen bonding between the "AT-hook"
DNA binding domains and the bases of the binding site. These results suggest that
HMGA proteins do not randomly bind to any AT-rich DNA sequences. In this study, we
used an in vitro systematic evolution of ligands by exponential enrichment (SELEX)
experiment to further investigate the DNA binding specificity of HMGA2. Our results
showed that HMGA2 specifically recognizes a type of 15 bp AT-rich DNA sequence: the
first 5 base pairs are AT-rich, the middle 4 or 5 base pairs are GC-rich, and the last 5 or 6
base pairs are AT-rich. Interestingly, all three segments are critical for high affinity
binding of HMGA2 to DNA.
5.3 Materials and Methods
5.3.1 Preparation of 3H-HMGA2 (3H-labeled HMGA2)
E coli strain BLR(DE3), which has plasmid pMGM1, was grown in 200 ml of a
supplemented M9 medium containing 1 x M9 salts, 0.4% glucose, 2 mM MgSO 4 , 0.1
mM CaCl 2 , 0.1 pg/ml thiamine, 40 pg/ml L-leucine, 150 tg/ml L-proline, 50 pg/ml each
of the other 18 L-amino acids, and 50 pg/ml kanamycin. The cell growth was monitored
by measuring OD5 9 5. At OD595 N 1, cells were harvested by centrifugation at 4,000 rpm
and 4 0C, and re-suspended in 100 ml of the supplemented M9 medium in the absence of
L-lysine. After 40 mi incubation at 37 *C, another 100 ml of the supplemented M9
medium (prewarmed to 37 *C) containing 10 mCi of 3H-L-lysine (10 pg/ml) was added
into the cell culture. When the 0D 595 reached ~0.8, HMGA2 expression was induced by
addition of 1 mM of IPTG into the cell culture. After an additional three-hour incubation,
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the cells were harvested by centrifugation at 4,000 rpm for 25 minutes at 4 C. 3H-
HMGA2 was purified as described previously (Cui et al, 2007). The specific activity of
3H-HMGA2 was determined to be 375 cpm/pmol.
5.3.2 Systematic evolution of ligands by exponential enrichment (SELEX)
experiment
SELEX experiments started with a 61 bp DNA library that contains 15 random
nucleotides. This DNA library was constructed through amplification of a 61 base
synthetic oligodeoxynucleotide FL-250, 5'-
CATGGTACCTCTAGAGGCTCGAG(N) 15GCTAGCTGGCATGCAAGCTTCAC-
3'(N1 5 represents the 15 random nucleotides and underlined sequences are cleavage sites
for Kpn I and Hind III, respectively), using two primers, FL-248 (5'-
CATGGTACCTCTAGAGGC-3') and FL-249 (5'-GTGAAGCTTGCATGCCAG-3'),
which correspond to the first 18 bases (top strand) and the last 18 bases (bottom strand).
For the first round of selection, 80 nM of DNA was incubated with increasing amount of
HMGA2 in 12 pl of 1 x DNA binding buffer containing 20 mM Tris-HCl (pH 8.0), 0.5
mM EDTA, 1 mM DTT, 0.5 mM MgCl 2, 50 mM NaCl, and 5% glycerol. After 30 min
incubation at 22 0C, the DNA samples were loaded on a 12% native polyacrylamide gel
to separate the bound and free species. Band shifts were detected by SYBR Gold
staining. The bound DNA was excised and elated in an elution buffer containing 10 mM
Tris-HCl (pH 8.0), 1 mM EDTA, and 100 mM NaCl, and purified by phenol extraction
and ethanol precipitation. The purified DNA was dissolved in water and PCR amplified
for the next round of SELEX selection. 20 cycles of PCR amplification were performed
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for 1 min each at 95, 55, and 72 *C with an additional step of 3 mm at 72 C for the final
cycle of the PCR reaction. The PCR products were purified by phenol extraction and
ethanol precipitation. A total of 10 rounds of SELEX selection were performed. After the
8th round, the concentration of NaCl was increased to 200 mM, and 30 pM (bp) of
poly(dG-dC)2 was added to the binding reactions as a competitor to promote selection
towards a high affinity and specificity pool of DNA fragments. After the 10th round of
selection, the PCR-amplified products were cloned into Hind III-Kpn I sites of pUC 18,
which were used to transform E coli strain DH5cc. The plasmid DNA of each
transformed colony was purified and sequenced. DNA sequences, corresponding to the
15 random nucleotides, were analyzed using programs ClustalX 1.81 (Thompson et al.,
1997) and MEME 3.5.3 (Bailey et al., 2006).
5.3.3 Electrophoretic mobility shift assay (EMSA)
EMSA experiments were used to determine the apparent DNA binding constant
of HMGA2. DNA oligomers containing AT-rich DNA sequences were labeled with 32P
at 5' termini by T4 polynucleotide kinase in the presence of y- 32P-ATP. The protein-
DNA complexes were formed by addition of appropriate amounts of the protein to a
solution containing 1 nM of 32P-labeled DNA in the 1 x DNA-binding buffer containing
20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1.5 pM (bp) poly(dG-dC)2, 0.5 mM EDTA, 1
mM DTT, 0.5 mM MgCl 2, and 5% glycerol. After equilibration for 60 min at 22 'C, the
samples were loaded on a 12% native polyacryamide gel in 0.5 x TBE buffer (0.045 M
Tris-Borate (pH 8.3) and 1 mM EDTA) to separate free and bound DNA. The gels were
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subsequently dried and visualized by autoradiography or quantitated using a Fuji FLA
3000 image analyzer. The radioactivity of the free and bound DNA was determined and
used to calculate the binding ratio (R), which is equal to the ratio of the radioactivity of
the bound DNA divided by the sum of the radioactivity of the bound and free DNA. The
apparent DNA binding constant (Kapp) was obtained by nonlinear-least-squares fitting the
following equation using the program Scientist.
(a+x+1/KPP)- (a+x +1/Kapp) - 4ax
R2= (1)2a
where a and x represent the total DNA and the total protein concentration, respectively.
EMSA experiments were also used to determine binding stoichiometries of
HMGA2 binding to DNA using 32P-labeled ologonucleotides and 3H-HMGA2. In these
experiments, 200 nM of 32P-labeled AT-rich DNA oligomers with a specific activity of
-700 cpm/pmol were mixed with 0.5 pM of 3H-HMGA2 in 50 pl in the 1 x DNA
binding buffer as described above. After incubation at 22 *C for 1 hour, the samples were
loaded on a 12% native polyacryamide gel in 0.5 x TBE buffer to separate free and
bound DNA. The gels were subsequently stained by SYBR Gold. DNA bands
corresponding to the HMGA2-DNA complexes were excised and electro-eluted into a
dialysis bag (8000 MWCO, BioDesign, NY) in 1 x TBE containing 0.1% SDS. The
eluents in the dialysis bag were mixed with 15 ml of Aquasol 2 (PerkinElmer, MA), and
counted in 32P and 3H channels in a liquid scintillation spectrometer to determine the
molar ratio of HMGA2 to DNA oligomers. Alternatively, a method as previously
described by Carey (Carey, 1988) was also used to determine the binding
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stoichiometries. After EMSA experiments, the DNA bands were located by
autoradiography and excised. Gel slices containing the HMGA2-DNA complex were
solubilized by oxidation in 1 ml of 21% H202/17% HCl 4 in a tightly sealed scintillation
vial at 65 "C for 24 hours. Vials were cooled to 22 'C, mixed with 15 ml of Aquasol 2,
and then stored at 4 *C for 48 hours in dark. Radioactivities of 3H and 32 P were counted
in 3H and 32P channels using the method as described above. Background was
determined by counting the control gel slices excised from the unused regions.
5.4 Results and Discussion
5.4.1 Determining the binding stoichiometries of HMGA2 binding to AT-rich DNA
oligonucleotides
Mouse HMGA2 is a small basic protein containing 108 amino acid residues. One
unique feature of HMGA2 is the asymmetric charge distribution of its primary structure
(Figure 3). The positive charges are mainly concentrated in the three "AT hooks" and the
negative charges at the C-terminus. In solution, HMGA2 may self-associate into
homodimers or homo-oligomers through electrostatic interactions and may bind to AT-
rich DNA as a homodimer. Thanos and colleagues showed that HMGA1a, another
member of the HMGA family with similar physical properties, interacts with itself in a
glutathione S-transferase (GST)-pull down experiment (Yie et al., 1999). Our
preliminary results showed that free HMGA2 in solution may be a homodimer (data not
shown). We therefore decided to determine whether HMGA2 binds to AT-rich DNA as a
monomer or as a homodimer.
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As demonstrated in our previous publication (Cui et al., 2005), each HMGA2
(monomer) binds to 15 AT base pairs in aqueous buffer solution. In this study, we used
two DNA oligomers, FL-AT15 (5'-
CATGGTACCTTCAGAGGCTCGAGAAAAAAAAAAAAAAAGCTGACTGGCATG
CAAGCTG-3') and FL-AT30 (5'-
CATGGTACCTTCAGAGGCTCGAGAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAGCTGACTGGCATGCAAGCTG-3'), to determine the stoichiometries of HMGA2
binding to AT-rich DNA sequences. FL-AT15 contains a 15 bp A-track (one HMGA2-
binding site) and FL-AT30 contains a 30 bp A-track (two HMGA2-binding sites). As an
initial step, the apparent DNA binding constants of HMGA2 (Kapp) were determined
using electrophoretic mobility shift assay (EMSA). Figure S3A shows the results of
HMGA2 titrating into a solution containing FL-AT15. In this EMSA experiment, only
one shift band was observed (the bands at the top, Figure S3A). The apparent DNA
binding constant of HMGA2 binding to FL-AT15 was estimated to be 2.2 x 106 M-
according to the method as described under "Materials and Methods." Since we used 200
mM of NaCl and 1.5 pM (bp) of poly(dG-dC) 2 (as a competitor) to reduce the non-
specific binding between HMGA2 and the oligomers (see Figure S3 legend for details),
the relatively low value of Kapp may represent specific binding of HMGA2 to the AT-
rich region of FL-AT15. Figure S3B shows results of HMGA2 titrating into a solution
containing FL-AT30 in which two shift bands were generated. Because FL-AT30
contains two HMGA2-binding sites, it is reasonable to assume that these two shift bands
represent HMGA2 occupying one and two sites on FL-AT30, respectively. Interestingly,
the apparent binding constant of HMGA2 binding to the first site of FL-AT30 was
126
estimated to be 2.0x107 M-, 10-fold higher than Kapp of FL-AT15. These results indicate
that HMGA2 may cooperatively bind to DNA containing multiple AT-rich sites.
The binding stoichiometries of HMGA2-DNA complexes were measured directly
in EMSA experiments using 3H-HMGA2 and 3 2P-labeled FL-AT15 or FL-AT30 (the
double-label experiments). In these experiments, high concentrations of HMGA2 and
DNA oligomers were used for stoichiometric binding (Figure 18). In addition, 200 mM
of NaCl (physiologically relevant salt concentration) and 30 pM (bp) of poly(dG-dC) 2
(as a competitor for non-specific binding) were added to the binding reactions. The
shifted bands were excised; the radioactivities of 3H and 32P in the protein-DNA
complexes were determined by scintillation counting. As described under "Material and
Methods," two methods were used to elute 3H-HMGA2 and 3 2P-labeled oligomers into
solutions. We either electro-eluted 3H-HMGA2 and the 3 2P-oligomers into 1 xTBE
containing 0.1% SDS or dissolved the gel slices into a solution containing 21% H202 and
17% HClO 4 by oxidization. No difference was found between these two methods. Our
results are summarized in Table 4. For the HMGA2-FL-AT15 complex, the shifted band
gave a 1:1 molar ratio of HMGA2 per FL-AT15 molecule. For the HMGA2-FL-AT30
complex, the first shifted band yielded a 1:1 molar ratio of HMGA2 per FL-AT30
molecule and the second shifted band produced a 2:1 molar ratio of HMGA2 per FL-
AT30 molecule. These results indicate that HMGA2 binds to AT-rich sites as a monomer
under physiologically relevant salt conditions. Similar results were also obtained by
using DNA oligomers containing one or two HMGA2 DNA binding sites determined by
SELEX experiments (data not shown; see below for the SELEX experiments).
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Figure 18. Determination of DNA-binding stoichiometries of the HMGA2-
DNA complexes by double-label experiments. EMSA experiments using 32P-
labeled FL-AT15 (A) or FL-AT30 (B) and 3H-HMGA2 were performed as
detailed under "Materials and Methods." The autoradiograms of the 3 2P-
labeled DNA oligomers were shown and used to excise the DNA bands for
scintillation counting. Lane 1 is the free DNA. Lanes 2 and 3 contained 32P-
labeled DNA oligomers and 3H-HMGA2. F is the free DNA; C represents
the HMGA2-FL-AT 15 complex; Cl and C2 represent the first and second
shifted bands of HMGA2-FL-AT30 complexes, respectively.
5.4.2 In vitro selection of DNA oligomers that bind to HMGA2 with high affinity
We next used systematic evolution of ligands by exponential enrichment
(SELEX; (Robertson & Joyce, 1990; Tuerk & Gold, 1990; Ellington & Szostak, 1990;
Cui et al., 1995)) experiments to determine the consensus DNA binding sequences for
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Table 4. The DNA binding stiochiometries of HMGA2 binding to two AT-rich NA
oligomers determined by the double-label experiments
HMGA2-FL-AT3O complex
HMGA2-FL-AT15 complex 1st shift 2nd shift
Method I a 0.92 0.17 0.98 0.05 1.97 0.23
Method II b 0.93 0.05 0.92 0.05 1.88 0.13
aHMGA2-DNA complexes were excised from the polyacrylamide gels after EMSA experiments
as described under "Materials and Methods.". The 32 P-labeled DNA and 3H-HMGA2 were
eluted from the gel in 1 x TBE containing 0.1% SDS at 50 mA for 4 hours. The binding
stoichiometris were calculated from the radioactivities of 32P and 3HI, determined by scintillation
counting.
bThe gel slices containing 3 H-HMGA2 and 32P-labeled DNA oligomers were dissolved in 1 ml
of a solution containing 21% H202 and 17% HClO 4 at 65 C for 24 hours. The binding
stoichiometris were calculated from the radioactivities of 32P and 3H, determined by scintillation
counting.
HMGA2 (Figure 19A). In these experiments, we utilized a library of DNA
oligonucleotides containing a central randomized region of 15 bp, flanked by two 23 bp
regions with defined sequences in each end (total 61 bp; Figure 19A). 15 bp randomized
sequences were chosen because each HMGA2 molecule binds to 15 AT base pairs (Cui
et al., 2005). For the first round of the SELEX experiments, 9.6x10-1 mol of DNA
oligonucleotides (~5.8x 1011 molecules) were used to ensure a completely random
population for selection (approximately 500 copies of each of the 415 possible sequences
on average). This library of oligonucleotides was mixed with increasing amounts of
HMGA2, incubated at 22 0C for 60 min, and loaded on a 12% polyacrylamide gel to
separate free and bound DNA. FL-AT 15 was used as a control to define the position to
which the HMGA2-DNA complex was migrated. The gel containing the HMGA2-DNA
complexes was excised; DNA was eluted from the gel and amplified by PCR according
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to methods as described under "Materials and Methods." The PCR products were
purified and subjected to the next round of selection. After the 8th round, the
concentration of NaCl was increased to 200 mM, and 30 pM (bp) of poly(dG-dC) 2 was
added to the binding reactions to increase the binding specificity. The progress of the
enrichment of DNA molecules recognized by HMGA2 was assessed by an EMSA
experiment in which no HMGA2-DNA complex of the original DNA library and the
DNA pool of the first round of selection was visible in the presence of 200 nM of
HMGA2 (lanes 1 and 2, Figure 19B). In contrast, the DNA pools of rounds 3, 5, and 10
gave approximately 7.1%, 17.5%, and 35.2% of HMGA2-DNA complexes under the
same conditions (lanes 3-5, Figure 19B).
After the 10 round of selection, the purified PCR products were cloned into
Hind III-Kpn I sites of pUC18 and sequenced. We repeated this experiment twice and
sequenced 102 individual clones in which 71 sequences are unique. Figures 20A and S4
show our sequencing results. To our surprise, all sequences have a common unique
feature: the first five base pairs are AT-rich, the middle four to five base pairs are GC-
rich, and the last five to six base pairs are AT-rich. These results suggest that our
conditions for selection were optimal and that enrichment of the highest-affinity
oligonucleutodes was successful. The 71 unique sequences were further analyzed by two
multiple-sequence-alignment programs, ClustalX 1.81 (Thompson et al., 1997) and
MEME 3.5.3 (Bailey et al., 2006), and two consensus sequences, 5'-
ATATTCGCGAWWATT-3' and 5'-ATATTGCGCAWWATT-3' where W represents
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5'-CATGGTACCTCTAGAGGCTCGAGNNN NNNNNNNNNGCTAGCTGGCATGCAAGCTTCAC-
3
'
Reverse Primer
Primer extension
Forward Primer
5'-CATGGTACCTCTAGAGGCTCGAGNNNNNNNNNNNNNNNGCTAGCTGGCATGCAAGCTTCAC-3'
3'-GTACCATGGAGATCTCCGAGCTCNNNNNNNNNNNNNNNCGATCGACCGTACGTTCGAAGTG-5'
HMGA2 Reverse Primer
Isolate Protein-DNA complex by EMSA
Amplify DNA by PCR
Repeat EMSA, DNA isolation and PCR for 10 cycles
Cloning, sequencing, and analysis
1 5 10 Cycle
12 34 5
Figure 19. The SELEX experiments. (A) Strategy for SELEX analysis of HMGA2
DNA binding sites. (B) Representative EMSA analysis used to monitor the progress
of enrichment for HMGA2 binding sites. About 80 nM of the DNA samples isolated
after the first (lane 2), third (lane 3), fifth (lane 4), and tenth (lane 5) rounds of the
selection were incubated with 200 nM of HMGA2 in an EMSA buffer containing 20
mM Tris-HCi (pH 8.0), 200 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 0.5 mM MgCl2
and 5 % glycerol. EMSA experiments were performed as described under "Materials
and Methods." Following electrophoresis, the PAGE gels were stained with SYBR
Gold, destained, and photographed under UV light. Lane 1 is the free DNA library
before the selection. The HMGA2-DNA complex and the free DNA were designated
as C and F, respectively.
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A or T, were identified. These two consensus sequences are identical to those obtained
from manual alignment of the SELEX sequences (Table 5). Another striking feature of
these sequences is that, although each clone is unique, certain sequences appeared
multiple times. For example, a 5 bp AT-rich sequence, 5'-ATATT-3', occurred 58 times;
two GC-rich sequences, 5'-CGCG-3' and 5'-GCGC-3', appeared 22 and 13 times,
respectively (Figures 20A and S4). This finding further suggests that we have identified
HMGA2 binding sites with high affinity. We also sequenced 20 clones of the original
library to confirm that the starting library was generated randomly. These sequences are
shown in Figure 20B. As expected, they look random and none of these sequences
contains the consensus motifs, such as 5'-ATATT-3' and 5'-CGCG-3'. Our SELEX
results are summarized in Figure 20C as a sequence logo.
5.4.3 Quantitative analysis of HMGA2-DNA interactions by EMSA
We previously demonstrated that HMGA2 binds with very high affinity to
poly(dA-dT)2 and poly(dA)poly(dT) under low-salt buffer conditions, and the DNA-
binding constant of HMGA2 is strongly dependent on the salt concentration (Cui et al.,
2005). At physiologically relevant salt conditions, i.e. 200 mM NaCl, it binds to AT-rich
DNA with a binding constant of 106 to 107 M- (Cui et al., 2005). In the present study,
we employed quantitative EMSA to measure the DNA binding constants of HMGA2 to
different DNA oligomers in a buffer containing 200 mM NaCl. We also included 1.5 pM
(bp) of poly(dG-dC) 2 (about 25-fold over 1 nM of 32P-labeled oligonucleotides) as a
competitor to reduce non-specific binding. In this case, the DNA-binding constant should
reflect specific recognition of different DNA sequences by HMGA2. Figure 21A shows a
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ATATT CGCGG ATATT GCTGT TGCGT GTAGC
ATATT CGCGT TAATT TGCTG CCCTG TCGGT
ATATT CGCGC TAATT AGCTA GGCCG TGAGC
ATATT CGCGG TAAAT GGGAG CCTCG TACCG
ATATT CGCGC AATTT CAGTA TCTGT TTGTG
ATATT CGCGT TAAAT CGGTG GGCGT GTGCC
ATATT CGCGT AATAT GTCGT TGCCT TTGGT
ATATT CGCGA TAATT CATGG CTTTG TCCCG
ATATT CGCGG TAATT CGCAT ACGAT AGTTT
ATATT CGCGA ATATT CGGCT GGAAA TGGAA
ATATT GCGCG TAATT GCTGC CTTTG CAATT
ATATT GCGCA TTATT TTCGT GGAGT GGTCT
ATATT GCGCC ATATT TCCTG GTCGG CGTTT
ATATT GCGCG ATATT GCGTT TTGTA CCTAG
ATATT GCGCA ATATT TTTGT TGCGC GCCAT
ATATT GCGCA TAATT GTTGT GTATC CTATT
ATATT GCGCG ATTAT CAGGA TGGGC GGTTC
AAATA CGCGA TAATT TGTTG TGCGG GGCCG
AAAAT CGCGA TTAAT CTAAG TCTTG TGTGC
TTAAT CGCGA TTATT TGCCG TGCGT GTGTG
C
Figure 20. Sequence analysis of the SELEX experiments for HMGA2. (A)
HMGA2 binding sequences identified after 10 rounds of the SELEX
experiments. 20 sequences are shown here. The other 51 sequences are shown
in Figure S4. (B) DNA sequences from the randomized oligonucleotide library
before selection. (C) Sequence logo of the 71 SELEX sequences shown in
Figures 20A and S4. Sequence conservation, measured in bits of information
(2 bits is the highest), is illustrated by the height of stacking of the four letters
for each position in the binding sites. The relative heights are proportional to
their frequencies shown in the 71 SELEX sequences. The sequence logo is
generated by WebLogo (available at www.bio.cam.ac.uk/cgi-
bin/seqlogo/logo.cgi).
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typical EMSA experiment in which HMGA2 was titrated into 1 nM of 32P-labeled FL-
SELEX1, a consensus sequence obtained from our SELEX experiments. The binding
constants were obtained by fitting the binding data to equation 1 as described under
"Materials and Methods." Our binding curves and binding constants are summarized in
Figure 21B and Table 6, respectively. As expected, HMGA2 binds to FL-SELEX1 with
the highest affinity. Intriguingly, when the middle GC-rich sequence was mutated to an
AT-rich sequence (either 5'-TATA-3' or 5'-AAAA-3'), the DNA binding affinity was
reduced 5-fold. These results indicate that the middle GC-rich sequence is required for
high-affinity binding. Our results also demonstrated that one 5 or 6 bp AT-rich sequence
is not sufficient for high affinity binding of HMGA2 to DNA. Mutation of either AT-rich
sequence of FL-SELEX1 to a non-AT-rich sequence significantly decreases the apparent
DNA binding constant. These results suggest that all three segments in FL-SELEX1 are
critical to high affinity binding. Consistent with our previous results (Cui et al., 2005),
HMGA2 also tightly binds to 15 bp A-track and alternate AT sequence although the
binding affinity is three-fold lower than that of FL-SELEX1; it does not bind to GC-rich
sequences.
5.4.4 Biological implication
The identification of the consensus sequences for HMGA2 is an important step
towards characterization of its biological functions in vivo. As demonstrated previously,
HMGA2 is a transcriptional factor involved in adipocytic proliferation and
differentiation during embryogenesis (Zhou et al., 1995; Kools et al., 1995; Li et al.,
2006). However, the mechanism by which HMGA2 regulates fat cell proliferation and
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differentiation is still unknown. Knowing the DNA binding specificity of HMGA2, it is
possible to locate its binding sites within the genome and map its regulatory network in
the cell. Furthermore, the discovery of the preferred binding sites of HMGA2 may
provide essential information for designing new anti-cancer or anti-obesity drugs. It has
been shown that HMGA2 is an oncoprotein associated with many benign and malignant
tumors (Young & Narita, 2007); it is also involved in obesity (Anand et al., 2000). These
studies suggest that HMGA2 is a potential target for treatment of cancers and obesity.
We showed here that HMGA2 strongly and specifically binds to the minor groove of the
two AT sites in the SELEX sequences, suggesting that the minor groove binding agents
are good inhibitors of HMGA2-DNA interactions. Indeed, we have recently
demonstrated that netropsin, a well-known minor groove binder, competitively inhibited
HMGA2 binding to the SELEX sequences (Miao et al, 2007). It is possible to design
new minor groove binders to alleviate tumor development and progression through
inhibition of the important HMGA2-DNA interactions.
5.5 Conclusion
Our results, presented in this article, represent a systematic and unbiased analysis
of HMGA2 DNA binding sites under physiologically relevant conditions (200 mM NaCl
and 30 pM (bp) of poly(dG-dC) 2). Using a SELEX procedure, we have demonstrated
that HMGA2 preferentially binds to a type of 15 bp AT-rich DNA sequence: the first 5
bp are AT-rich, the middle 4 to 5 bp are GC-rich, and the last 5 to 6 bp are AT-rich.
Alignment of 71 unique SELEX sequences revealed two consensus sequences for
HMGA2: 5'-ATATTCGCGAWWATT-3' or 5'-ATATTGCGCAWWATT-3' where W
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= A or T. Our quantitative EMSA assays showed that the three segments in the
consensus sequences (two AT-rich segments and one GC-rich segment) are required for
high affinity binding; mutations of these sequences significantly reduced the DNA-
binding affinity of HMGA2. These results indicate that HMGA2 does not randomly
recognize any AT-rich sequences. In contrast, it binds to specific AT-rich DNA
sequences. We also showed that HMGA2 binds to AT-rich sites as a monomer under
physiologically relevant salt conditions.
Table 6. DNA binding constants for HMGA2 binding to different DNA oligomers
DNA oligomers Sequence (top strand) Kapp (M-)
FL-SELEX1 5' -ATATTCGCGATTATT-3' 7.45 0.77 x 106
FL-304 5' -TATATATATATATAT-3' 2.16 0.14 x 106
FL-AT15 5' -AAAAAAAAAAAAAAA-3' 2.19 0.24 x 106
FL-308 5' -ATATTTATATTTATT-3' 1.44 0.27 x 106
FL-306 5' -ATATTAAAAATTATT-3' 1.46 0.40 x 106
FL-315 5' -ATATTCGCGACTGTC-3' <<1.0 x 105
FL-317 5' -GTGTCCGCGATTATT-3' <<1.0 x 101
FL-GC 5' -GGGGGGGGGGGGGGG-3' 0
aAll DNA oligomers are 59 bp double strand DNA oligonucleotides with the following
sequence,
5'-CATGGTACCTTCAGAGGCTCGAGN 15GCTGACTGGCATGCAAGCTG-3', where N,5
represents the 15 bp DNA sequence listed in the table. Only top strands are shown.
bThe apparent DNA-binding constants of -IMGA2 were measured as decribed under
"Materials and Methods." The values are the average of at least three independent
determinations.
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with increasing concentrations of HMGA2 in 50 d of I x EMSA binding buffer
containing 20 mM Tris-HCI (pH 8.0), 200 mM NaCl, 0.5 mM ETA, 1 mM DTT,
0.5 m Mg1l2, 5 % glycerol and 1.5 pM (bp) poly(dG-dC)2. EMSA experiments
were performed as described under "Materials and Methods." The autoradiogram of
the 32p-labeled FL-SELEXI was shown. The radioactivities were quantified with a
Phosporlmager. Lane 1 is the free FL-SELEXI. In addition to FL-SELEXI, lanes 2
to 14 also contain 10, 20, 40, 80, 100, 200, 300, 400, 500, 1000, 2000, 5000, and
10000 nM of HMGA2, respectively. (B) Quantification analysis of the binding data
from the EMSA experiments. The bound ratio of DNA was plotted against the
protein concentration. The curves are generated from fitting the data to Equation I as
described under "Materials and Methods." Symbols: @, FL-SELEXI; L, FL 300;
Q, FL 304; 0, FL 306; V, FL 308; x, FL 315; +, FL317.
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Appendix 1
Al. Supplemental Materials:
AL. Energetics of Binding the Mammalian High Mobility Group Protein HMGA2
to poly(dA-dT) 2 and poly(dA)poly(dT)
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Figure Si. Fits of poly(dA-dT)2 DNA melting curves in the presence of
various amounts of HMGA2 to McGhee's theory. The dotted lines are
experimental data, and the solid lines are theoretical curves with the
parameters listed in Table Si.
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Figure S2. Fits of poly(dA)poly(dT) DNA melting curves in the presence
of various amounts of HMGA2 to McGhee's theory. The dotted lines are
experimental data, and the solid lines are theoretical curves with the
parameters listed in Table S2.
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A1.2 Specific Recognition of AT-Rich DNA Sequences by the Mammalian High
mobility Group Protein AT-hook 2: A SELEX study
A [H MGA2]
Figure S3. EMSA experiments of HMGA2 binding to FL-AT15 and FL-AT30. 
1
nM of 32P-labeled FL-AT15 (A) or FL-AT30 (B) was incubated with increasing
concentrations of HMGA2 in 50 pl of 1 x EMSA binding buffer containing 20 mM
Tris-HCl (pH 8.0), 200 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 0.5 mM MgC12, 5 %
glycerol and 1.5 pM (bp) poly(dG-dC)2. EMSA experiments were performed as
described under "Materials and Methods." The autoradiograrns of the 32P-labeled
oligonucelotides were shown. The radioactivities were quantified with a
Phosporlmager. Lane 1 is the free DNA oligonucleotides FL-AT15 or FL-AT30. 
In
addition to DNA oligonucleotides, lanes 2to 14 also contain 10, 20, 40, 80, 100,
200, 300, 400, 500, 1000, 2000, 5000, and 10000 nMof HGA2, respectively.
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ATATT GCCGA TTATT AAATC GCGGA ATAAT
ATATT CGCCA ATATT TATTT CGCGT ATTTT
ATATT GCCGA TAATT AATTT GCGCA TTATT
ATATT CGCCG GAAAT AAATT CGCGT AAATT
ATATT GCCCC ATATT ATAAT CGCCA TAATT
ATATT CGCCA TATTT ATAAT CGGCG TTATT
ATATT GGCGG AAATT AATGT CGTGA ATATT
ATATT GGCGG AAATT AAATT GCTCG AAAAT
ATATT CGGCG ATAAT AAATT CGGGA ATAAT
ATATT GTGGA ATATC AAAAT GCCGG TTAAT
ATATT CCGCA TTATT ATAAT GGCCG ATTTT
ATATT GCCGA TATTT ATAAT GCCGA ATATT
ATATT GGCGA TAAAT AAATT GACGC TAAAT
ATATT GCGGA TTATT TATTA CGGCA TTATT
ATATT CCCGG ATATT AAAAT CCGCC ATATT
ATATT CCGCT TAATT ATAAT GGCGA TTATT
ATATT CCGCC ATATT AAATT GCCGT AAATT
ATATT CCCCA TATTT AAATT GCGGT ATATT
ATATT CCCGA TTATT TAATC GCATT TATTC
ATATT GGCGC ATTTT ATAAT GGCGC ATAAT
ATATT CGCCG TTAAT AAATC GGGGT TTATT
ATATT CGCCG ATATT AAATT GCGGT TTATT
ATATT CCGCA TAAAT ATAAT CGCCG ATAAT
ATATT GCCGA ATATT ATAAA CCGCG ATTAT
TATTT GCGCA TTAAT
Figure S4. HMGA2 binding sequences identified after 10 cycles of the
SELEX experiments. 51 sequences are shown here. See text for details.
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Appendix 2
A2. Study the DNA-binding specificity of the AT-hook motif by competition dialysis
assay
A2.1 Introduction
In the NMR structure, an individual AT-hook motif of HMGA proteins has been
shown to specifically bind to 5 bp AT rich sequence in the DNA minor groove.
However, the binding specificity has not been systemically studied. Here, we show how
the sequence specificity of AT-hook binding to DNA was explored using competition
dialysis assay. Our hypothesis is that if some DNA bind to the AT-hook motif with
higher affinities, concentrations of the AT-hook peptide in these DNA samples after
dialysis will be higher than those in DNA samples with lower affinities.
A2.2 Materials and Methods
A2.2.1 AT DNA duplexes
Total 16 AT DNA duplexes were used in study of the binding specificity of the
AT-hook peptide. Each duplex was prepared by annealing two complementary single-
stranded oligonucleotides, which contains a sequence of 5'-GGGGGC(A/T) 5CGGGGG-
3'. The sequences of the AT region on the top strands were listed in Table S3.
Theoretically, all 32 AT sequences with a length of 5 base pairs have been included in
the AT region on both top and bottom strands of the 16 AT DNA duplexes.
Concentrations of the oligonucleotide were determined using their molar extinction
coefficient at 260 nm. In preparation of the duplex, equal amount of each oligonucleotide
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was mixed in 1 x BPE plus 34 mM Na+, heated at 950 C for 15 min, and gradually cooled
down to room temperature.
Table 53. The sequences of the 5 bp AT region in the DNA used for studying the
binding specificity of the AT-hook peptide
Sequence Sequences Sequence Sequences
number (5' to 3', top strand) number (5' to 3', top strand)
1 AAAAA ATTAA
2 AAAAT 10 TTAAA
3 AAATA 11 ATTTA
4 AATAA 12 AATAT
5 ATAAA 13 ATAAT
6 TAAAA 14 T AATA
7 AAATT 15 TATAA
8 AATTA 16 TATAT
A2.2.2 AT-hook peptide (ATHP)
A peptide, N 2Lys-Arg-Pro-Arg-Gly-Arg-Pro-Arg-Lys-Tr-COOH, containing
the same amino acid sequence as the third DNA-binding domain of the HMGA proteins
was synthesized from Advanced ChemTech and used without further purification.
A2.2.3 Nucleic acids
Clostridium perfringens (CP), Micrococcus lysodeikticus (ML), and calf thymus
(CT) DNA were purchased from Sigma. The DNA was dissolved in 1 x BPE plus 34 mM
Na+ and sonicated on ice 10 times at 200 W each time with 10s intervals. The sonicated
sample was further treated by phenol extraction, followed by dialyzing the sample in lx
BPE plus 34 mM Na' overnight. The DNA concentration after dialysis was then
determined using their molar extinction coefficient at the maximal UV absorbance.
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Poly(dA), poly(dT), poly(dA-dT) 2, poly(dA)poly(dT), poly(dG-dC) 2, and poly(dI-dC) 2
were obtained from Amersham Biosciences and used without further purification. The
poly(A)poly(U) were purchased from Sigma. The poly(A)poly(dT) DNA-RNA hybrid
was prepared by mixing poly(A) with poly(dT) in a 1:1 molar ratio, heating to 95*C for
15 min, and slowly cooling down to room temperature. All DNA polymers were
dissolved in 1 x BEP plus 34 mM Na+, and RNA samples were dissolved in the same
buffer made by DEPC water. The purity and conformation of all purchased or self-
prepared nucleic acids were routinely checked by their UV spectra and melting profile.
A2.2.4 Competition dialysis assay
The competition dialysis assay was schematized as in Figure S5. In the
experiment, 0.5 ml of 75 pM (bp) DNA was placed in either a dialysis cassette of 7000
MWCO (Pierce) or a regular dialysis tubing of 8000 MWCO (Spectrum Laboratories
Inc.). Couple of DNA with different conformations and sequences was then equilibrated
with 200 ml of 1 pM AT-hook peptide solution in 1 x BPE plus 34 mM Na* for 7 days.
After dialysis, ATHP concentration in each sample was determined using its intrinsic
fluorescence from the tryptophan residue. Alternatively, the sample was mixed with 50
pl of fluorescamine solution (0.5 mg/ml in acetone) under vortexing, and the
fluorescence intensity from the fluorescamine derivative was used for calculating the
ATHP concentration. In the first method for measuring the ATHP concentration, the
excitation and emission wavelength was set to 295 nm and 360 nm, respectively. The slit
is 2 nm for excitation and 1.8 nm for emission. The ATHP concentration in the sample
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was calculated using a standard curve generated from solutions containing known
amount of ATHP under the same instrumental conditions. Similarly, in the second
method using the fluorescamine derivative, the excitation and emission are 390 nm and
465 nm, respectively.
Figure 55. The competition dialysis experiment. Couple of DNA of
distinct conformations and sequences were kept in individual dialysis
units, respectively; and dialyzed against 200 ml of 1 pM AT-hook
peptide in 1 x BPE plus 34 mM Na+. The system was equilibrated at
room temperature with stirring for 7 days. After equilibrium, the
sample was taken out of the dialysis unit, and the amount of the DNA-
bounded AT-hook peptide was determined.
A2.3 Results
A2.3.1 Comparison of the binding affinities of the ATHP to 32 AT sequences
From NMR study, it is known that each AT-hook motif of HMGA proteins bind
to 5 bp of AT sequence in the DNA minor groove. In order to further reveal the sequence
specificity of this binding, the binding affinities of the ATHP to 32 AT sequences were
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evaluated using competition dialysis assay. In the experiment, the 32 AT sequences were
designed in both top and bottom strands of 16 duplexes, which are generated by
annealing two complementary oligonucleotides. The full sequence of each
oligonucleotide has been described in Materials and Methods, and the sequences of the 5
bp AT region on the top strands of each duplex were listed in Table S3. In the
competition dialysis assay, 0.5 ml of 15 pM DNA samples were injected into a dialysis
cassette with MWCO of 7000, and total 16 DNA samples were subsequently dialyzed
against 200 ml of 1 piM ATHP solution in 1x BPE plus 34 mM Na+. The dialysis was
performed under continuous stirring for 7 days at room temperature. Samples after
dialysis were taken out of the cassette and the ATHP concentrations in the samples were
determined. The final results from two trials of the dialysis experiments are shown in
Figure S6. The blanked bars represent the data from the first trial, while the bars with
stripes represent the result of the second trial. Obviously, the binding affinities of the
ATHP to the 16 AT DNA determined in the two trials are not consistent. Besides, it was
found that approximate 90% of the AT-hook peptide was lost during dialysis without
known reason. A similar competition dialysis experiment was also performed using
regular dialysis tubing of MWCO 8000. Instead of determining the ATHP concentration
by its intrinsic fluorescence property, the sample in individual dialysis unit was mixed
with 50 pl of fluorescamine solution (0.5 mg/ml in acetone), and the fluorescence
intensity of the derivative produced from the reaction was measured at 390 nm excitation
and 465 n emission. The determined ATHP concentrations in 16 DNA samples were
shown in Figure S7. Compared to the results obtained from the two trials described
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above, the peptide concentrations determined here using the fluorescamine derivative are
much higher. However, the binding specificity derived here does not match to any result
obtained using the dialysis cassette. Due to the inconsistent results from different trials of
the competition dialysis assays, the sequence specificity of the AT-hook peptide binding
to DNA cannot be concluded.
2.22
D /
Figure S6. The competition dialysis assay result of the 16 AT DNA using
dialysis cassette of MWCO 7000. The blanked and striped bars are data
frorn the first and second experiment, respectively. For each experiment,
0.5 m1 of 15 ptM AT DNA was placed in an individual dialysis cassette of
MWCO 7000, and total 16 samples were equilibrated with 200 m1 of 1 pM
AT HP solution in 1 x BPE plus 34 mM Na+ for 7 days. After equilibrium,
the ATH concentration in each cassette was determined as described in
Materials and Methods.
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Figure S7. The competition dialysis assay result of the 16 AT DNA
using regular dialysis tubing of 8000 M CO. The dialysis conditions
used are same as those described in Figure A2. However, the ATHP
concentrations after dialysis were determined from the fluorescamine
derivative as described in Materials and Methods.
A2.3.2 Binding affinities of the ATH to 11 different nucleic acids
The binding affinities of the ATHP to 11 different nucleic acids were compared
using the competition dialysis assay. Physical prosperities of these nucleic acids are
listed in Table S4. These 11 nucleic acids were chosen based on their distinct
conformations and nucleotide compositions. Qualities of the nucleic acids were checked
by their UV spectra and the Tm~ obtained in melting studies. In the dialysis experiment,
0.5 ml of 75 pM (bp) each nucleic acid was injected into a dialysis cassette with M CO
of 7000. The 11 samples were then placed in a beaker containing 200 ml of 1 pM AT HP
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in 1 x BPE plus 34 mM Na+. The system was allowed to equilibrate for 7 days at room
temperature with continuous stirring. The amount of ATHP bound to each nucleic acid
was determined spectrophotometrically as described in Materials and Methods. As
shown in Figure 58, the ATHP binds to poly(dA)poly(dT) and poly(dA-dT) 2 with the
highest affinities; whereas, its binding to single-stranded DNA, poly(dA) and poly(dT),
was pretty poor. For three natural double-stranded DNA, CP DNA (31% GC), CT DNA
(42% GC) and ML DNA (72% GC), the amount of the bounded ATHP were found to be
proportional to the AT percentage in the DNA compositions; this is consistent with the
fact that the AT-hook peptide prefers bind to AT rich sequences. The binding specificity
of the ATHP to different nucleic acids revealed here is very similar to that of some minor
groove-binding drugs, such as distamycin A, netropsin and DAP.
Table S4. The physical properties of the 11 nucleic acids used in the competition
dialysis assay
Conformation Nucleic acids (nm) F (1 M' cmI)
Single-stranded DNA poly(dA) 257 8600
poly(dT) 264 8520
Natural double- C. perfringens 260 12476
stranded DNA DNA (31% GC)
Calf thymus DNA 260 12824
(42% GC)
M lysodeikticus 260 13846
DNA (72% GC)
Synthesized double- poly(dA-dT)2 262 13200
stranded DNA poly(dA)poly(dT) 260 12000
poly(dG-dC)2 254 16800
poly(dI-dC)2 251 13800
Double-stranded RNA poly(A)poly(U) 260 14280
DNA-RNA hybrid poly(A)poly(dT) 260 12460
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~1Figure The competition dialysis 
assay result of the 11 nucleic 
acids.
0.5 ml of 75 pM each nucleic acid was placed in a dialysis cassette with
MWCO 7000 and dialyzed against 200 m1 of 1 pM AT HP solution in 1 x
BPE plus 34 mM Na+ for 7 days at room temperature. The bounded ATHP
in each dialysis cassette after equilibrium was measured and plotted here.
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Appendix 3
A3. Pull-down assay for verifying the possible dimmerization of HMGA2
A31 Introduction
There is evidence that two HMGA2 molecules may form a homodimer. In order
to verify this possibility, a pull-down assay using 32P-FL260, Biotin-FL336 and HMGA2
was applied. Principle of the assay is shown in Figure S9. Hairpin DNA FL260 and
FL336, which contains the same sequence, were labeled by 3 2P-ATP and biotin at the 5'
end, respectively. Both hairpin DNA have a 15bp A/T segment in the middle, which
specifically binds to HMGA2. Our hypothesis is that if the HMGA2 can form a
homodimer that binds to both biotin-FL 336 and 32P-FL260 at the same time, the 12P-
FL260 will be detected after co-precipitation with biotin-FL336 during the pull-down
assay.
Figure S9. A carton representing the pull-down assay, in which the
32P-FL260 will co-precipitate with biotin-FL336 if two HMGA2
proteins can form a homodimer that binds simultaneously to both 32p-
FL260 and biotin-FL336.
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A3.2 Materials and Methods
A3.2.1 Materials
DNA: FL260: S'-CAAAAAAAAAAAAAAAGCCCCCGCTTTTTTTTTTTTTTTGG-3'; and
FL 3 6 0:Biotin-5'-CCAAAAAAAAAAAAAAAGCCCCCGCTTTTTTTTTTTTTTTGG-3', were
purchased from MWG-Biotech Inc. and used without further purification. DNA
concentrations were determined using calculated extinction coefficient at 260 nm.
A3.2.2 HMGA2 and 3 1-HMGA2 protein
HMGA2 and 3H-HMGA2 protein was purified from F. coli BLR/DE3 cells as
described previously. Stock solutions of the protein were prepared once and used for all
pull-down assays.
A3.2.3 3 P-labeled FL260
Hairpin DNA FL260 was dissolved in 20 mM Tris-HC1 (pH 8.0) plus 100 mM
NaCl. For 5'-end labeling, 10 pmol of FL260 was incubated with 15 pl of 32P-ATP
(3000Ci/mmol, 10mCi/ml, PerkinElmer) and 20 U of T4 polynucleotide kinase (New
England Biolab) in 20 pl reaction for 1 hr at 37'C. The labeled DNA was subsequently
purified using G-25 size-exclusion column (Amersham).
A3.2.4 Pull-down assay
The streptavidin agarose beads (Cat. 69203-3) were obtained from Novagen. For
each sample in the pull-down assay, 50 d of the streptavidin agarose beads in 50 % v/v
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suspension containing 100 mM sodium phosphate pH 7.5 and 0.02 % sodium azide, was
spun at 13,000 rpm for 5 minutes, followed by washing the pellet twice with 50 pl of the
binding buffer. For the pull-down assay, 100 pi of the binding reaction was equilibrated
at room temperature for 30 mi and added to the prepared streptavidin agarose beads
after that. The mixture was kept at room temperature for 30 min before spinning at 13,
000 rpm for min. The pellet was washed twice with 50 gl of the binding buffer, and
resuspended in 30 gl of denaturing buffer containing 10 mM EDTA (pH 8.0), 95 % (v/v)
formamide, and 0.1 % SDS. Next, the sample was heated in a 65'C water bath for 10
min and spun immediately at 13, 000 rpm for 3 min. 20 pd of the supemant was mixed
with 2.3 pd of the 10 x DNA loading buffer (50 % glycerol, 0.4 % bromphenol blue, and
0.4 % xylene cyanol FF) and 0.5 pl of 5 % SDS. The sample was then heated at 95*C for
10 min, cooled on ice, and loaded to a 15 % urea denaturing polyacrylamide gel. The
electrophoresis was performed at 300 V in 0.5 x TBE for 4 hours. The gel was
subsequently dried and exposed to X-film.
A3.3 Results
A3.3.1 Effect of HMGA2 concentration on the pull-down assay
As more frequent contact between two HMGA2 molecules are expected as a
result of increased HMGA2 concentration, the influence of HMGA2 concentration on
the self association of HMGA2 monomers were studied. In a pull-down assay,
increasing amount of HMGA2 from 0 to 2 pM was incubated with 200 nM 
32 P-FL260
and 200 nM biotin-FL336 in 100 pl binding buffer containing 20 mM Tris-HCl (pH 8.0),
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20 mM NaCl, 0.5 mM EDTA, 1 mM DTT, and 0.5 mM MgCl 2. After 30 min
equilibrium at room temperature, the binding reaction was mixed with 50 pLl pre-
equilibrated streptavidin agarose beads, and the pull-down assay was conducted as
described in the Materials and Methods. As revealed in Figure S10, the amount of co-
precipitated 3 2P-FL260 increased in proportional to the HMGA2 concentration, which
may indicate more stable complexes formed by HMGA2 homodimer, 32 P-FL260 and
biotin-FL336.
STD 123456
Figure 10 The pull-do assay using 200 nM 1 2P
FL260 and 200 nM biotin-FL336 with 0, 200, 400, 800,
1200, and 2000 nM HMGA2 from lane 1 to 6 in 1 x
binding buffer containing 20 mM Tris-HCl (pH 8.0), 20
mM NaCl, 0.5 mM EDTA, 1 mM DTT, and 0.5 mM
MgC 2 . STD is the 
32 P-FL260 used as the molecular
weight standard.
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A3.3.2 Salt-dependence of the pull-down assay
As salt concentration may affect the stability of DNA-HMGA2 complex and
possible homodimer of HMGA2, a pull-down assay using increasing amount of NaCl
was performed. The result was shown in Figure S11. 200 nM 12P-FL-260 and 200 nM
biotin-FL336 were incubated with 800 nM HMGA2 in binding buffer containing
different salt concentrations. Unexpected, the amount of the co-precipitated 32P-FL260
did not change as the salt concentration was increased from 20 mM to 200 mM.
ST-D 12 4
Figure .11 The pull-down assay using 200 nM 3 P-
FL260, 200 nM biotin-FL336 and 800 nM HMGA2 in 1 x
binding buffer of 20 mM Tris-HCl (pH 8.0), 0.5 mM
EDTA, 1 mM DTT 0.5 mM MgCl 2 with 20, 50, 100, 200,
and 400 mM NaCl, respectively, from lane 1 to 5. STD is
the 32P-FL260 used as the molecular weight standard.
A3.3.3 Effect of poly(dG-dC)2 on the pull-down assay
Effect of poly(dG-dC) 2 on the pull-down assay was evaluated by introducing
increasing amount of poly(dG-dC)2 as non-competing DNA in 1 x binding buffer
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containing 20 mM Tris-HCl (pH 8.0), 20 mM NaCl, 0.5 mM EDTA, 1 mM DTT, and 0.5
mM MgC1 2. In the binding reactions, the concentration of 32P-FL260, biotin-FL336, and
HMGA2 were fixed at 200, 200 and 800 nM, respectively. Stock poly(dG-dC) 2 was
added to the binding reaction so that the poly(dG-dC) 2 final concentration (bp) is 1-5 x
of the total A/T base pair concentration including that from 32P-FL260 and biotin-FL336.
As shown in the lane I to 3 in Figure S12, addition of 1 x to 2 x of poly(dG-dC) 2 in the
binding reaction obviously reduced the amount of the pull-down 32P-FL260; However,
further increase of the poly(dG-dC) 2 concentration from 3 x to 5 x as shown in lane 4 to
6 has no significant effect on the pull-down result.
Figure S12. The pull-down assay using 200 M2P_
FL260, 200 nM biotin-FL336 and 800 nM HMGA2 in 1 x
binding buffer containing 20 mM Tris-HCI (pH 8.0), 20
mM NaCl, 0.5 mM EDTA, 1 mM DTT, and 0.5 mM
MgCl 2. The poly(dG-dC)2 concentrations are 0, 6, 12, 18,
24 and 30 pM (bp), respectively, from lane I to 6.
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A3.3.4 The molar ratio of HMGA2 to FL260 in the pull-down complex
To find the molar ratio of HMGA2 to FL260 in the pull-down complex, 0.8 piM
3H-HMGA2 (specificity=375 cpm/pmol) was incubated with 0.2 tM 3 P-FL260
(specificity=4000 cpm/pmol) and 0.2 M biotin-FL336 in 100 pd binding reaction
containing 20 mM Tris-HCl (pH 8.0), 20 mM NaCi, 0.5 mM EDTA, 1 mM DTT, and 0.5
mM MgCl 2. The pull-down assay was performed as described above and the final pellet
that contains the protein-DNA complex was washed once with 50 pl binding buffer and
resuspended in 100 1 binding buffer. The suspension was directly transferred to 15 ml
Aquesol 2 liquid scintillation counter cocktail, and the 3 2P and 3H activities were counted
on a Beckman LS5000TD LSC. Surprisingly, the calculated molar ratio of HMGA2 to
FL260 was abnormally high, which reached around 30:1.
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